WO2023009554A1 - Methods to reduce adverse effects of gene or biologics therapy - Google Patents
Methods to reduce adverse effects of gene or biologics therapy Download PDFInfo
- Publication number
- WO2023009554A1 WO2023009554A1 PCT/US2022/038397 US2022038397W WO2023009554A1 WO 2023009554 A1 WO2023009554 A1 WO 2023009554A1 US 2022038397 W US2022038397 W US 2022038397W WO 2023009554 A1 WO2023009554 A1 WO 2023009554A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- linker
- c6alkyl
- formula
- immunoglobulin
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 91
- 108090000623 proteins and genes Proteins 0.000 title claims description 47
- 230000000694 effects Effects 0.000 title claims description 18
- 238000002560 therapeutic procedure Methods 0.000 title description 96
- 230000002411 adverse Effects 0.000 title description 9
- 229960000074 biopharmaceutical Drugs 0.000 title description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 170
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 170
- 239000003446 ligand Substances 0.000 claims abstract description 137
- 150000003839 salts Chemical class 0.000 claims abstract description 71
- 230000008685 targeting Effects 0.000 claims abstract description 58
- 230000027455 binding Effects 0.000 claims abstract description 38
- 230000028993 immune response Effects 0.000 claims abstract description 38
- 238000001415 gene therapy Methods 0.000 claims abstract description 32
- 150000001875 compounds Chemical class 0.000 claims description 76
- 239000003814 drug Substances 0.000 claims description 74
- 125000000623 heterocyclic group Chemical group 0.000 claims description 60
- 239000013598 vector Substances 0.000 claims description 60
- 125000003118 aryl group Chemical group 0.000 claims description 56
- 125000001072 heteroaryl group Chemical group 0.000 claims description 56
- 125000000217 alkyl group Chemical group 0.000 claims description 51
- 125000001188 haloalkyl group Chemical group 0.000 claims description 45
- -1 C0-C6alkyl-cyano Chemical group 0.000 claims description 44
- 125000003342 alkenyl group Chemical group 0.000 claims description 41
- 125000000304 alkynyl group Chemical group 0.000 claims description 39
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 37
- 229910052739 hydrogen Inorganic materials 0.000 claims description 32
- 239000001257 hydrogen Substances 0.000 claims description 32
- 125000001424 substituent group Chemical group 0.000 claims description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- 102000004169 proteins and genes Human genes 0.000 claims description 28
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 26
- 208000035475 disorder Diseases 0.000 claims description 26
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 26
- 239000013603 viral vector Substances 0.000 claims description 23
- 229940124597 therapeutic agent Drugs 0.000 claims description 21
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 20
- 229910052794 bromium Inorganic materials 0.000 claims description 18
- 229910052801 chlorine Inorganic materials 0.000 claims description 18
- 229910052740 iodine Inorganic materials 0.000 claims description 18
- 229910052731 fluorine Inorganic materials 0.000 claims description 17
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 14
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 14
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 12
- 241000701161 unidentified adenovirus Species 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 241000282414 Homo sapiens Species 0.000 claims description 10
- 241000700584 Simplexvirus Species 0.000 claims description 10
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 9
- 239000013607 AAV vector Substances 0.000 claims description 8
- 150000001408 amides Chemical class 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 125000003636 chemical group Chemical group 0.000 claims description 8
- 230000035772 mutation Effects 0.000 claims description 8
- 101150075175 Asgr1 gene Proteins 0.000 claims description 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 7
- 241000700605 Viruses Species 0.000 claims description 7
- 230000002950 deficient Effects 0.000 claims description 7
- 150000001540 azides Chemical class 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 5
- 241000713666 Lentivirus Species 0.000 claims description 5
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 241000700618 Vaccinia virus Species 0.000 claims description 4
- 229960000598 infliximab Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims description 3
- 108010008165 Etanercept Proteins 0.000 claims description 3
- 108010054218 Factor VIII Proteins 0.000 claims description 3
- 102000001690 Factor VIII Human genes 0.000 claims description 3
- 102000004877 Insulin Human genes 0.000 claims description 3
- 108090001061 Insulin Proteins 0.000 claims description 3
- 229960003697 abatacept Drugs 0.000 claims description 3
- 229960000446 abciximab Drugs 0.000 claims description 3
- 229960002964 adalimumab Drugs 0.000 claims description 3
- 229960000548 alemtuzumab Drugs 0.000 claims description 3
- 229950005725 arcitumomab Drugs 0.000 claims description 3
- 229960004669 basiliximab Drugs 0.000 claims description 3
- 229960000397 bevacizumab Drugs 0.000 claims description 3
- 229950001178 capromab Drugs 0.000 claims description 3
- 229960003115 certolizumab pegol Drugs 0.000 claims description 3
- 229960005395 cetuximab Drugs 0.000 claims description 3
- 229960002806 daclizumab Drugs 0.000 claims description 3
- 229960001251 denosumab Drugs 0.000 claims description 3
- 229960002224 eculizumab Drugs 0.000 claims description 3
- 229960000284 efalizumab Drugs 0.000 claims description 3
- 229960000403 etanercept Drugs 0.000 claims description 3
- 229940093443 fanolesomab Drugs 0.000 claims description 3
- 229960000578 gemtuzumab Drugs 0.000 claims description 3
- 229960001743 golimumab Drugs 0.000 claims description 3
- 229950007354 imciromab Drugs 0.000 claims description 3
- 229940125396 insulin Drugs 0.000 claims description 3
- 229960002450 ofatumumab Drugs 0.000 claims description 3
- 229960000470 omalizumab Drugs 0.000 claims description 3
- 229960000402 palivizumab Drugs 0.000 claims description 3
- 229960001972 panitumumab Drugs 0.000 claims description 3
- 229960003876 ranibizumab Drugs 0.000 claims description 3
- 229960004641 rituximab Drugs 0.000 claims description 3
- 229950006348 sarilumab Drugs 0.000 claims description 3
- 229960004540 secukinumab Drugs 0.000 claims description 3
- 229960003989 tocilizumab Drugs 0.000 claims description 3
- 229960005267 tositumomab Drugs 0.000 claims description 3
- 230000001988 toxicity Effects 0.000 claims description 3
- 231100000419 toxicity Toxicity 0.000 claims description 3
- 229960000575 trastuzumab Drugs 0.000 claims description 3
- 229960003824 ustekinumab Drugs 0.000 claims description 3
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 claims description 2
- 208000002485 Adiposis dolorosa Diseases 0.000 claims description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 2
- 101710081722 Antitrypsin Proteins 0.000 claims description 2
- 208000010061 Autosomal Dominant Polycystic Kidney Diseases 0.000 claims description 2
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 claims description 2
- 206010008723 Chondrodystrophy Diseases 0.000 claims description 2
- 206010010099 Combined immunodeficiency Diseases 0.000 claims description 2
- 102000012437 Copper-Transporting ATPases Human genes 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 201000000913 Duane retraction syndrome Diseases 0.000 claims description 2
- 208000020129 Duane syndrome Diseases 0.000 claims description 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 2
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims description 2
- 208000001914 Fragile X syndrome Diseases 0.000 claims description 2
- 208000015872 Gaucher disease Diseases 0.000 claims description 2
- 208000018565 Hemochromatosis Diseases 0.000 claims description 2
- 208000031220 Hemophilia Diseases 0.000 claims description 2
- 208000009292 Hemophilia A Diseases 0.000 claims description 2
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000025500 Hutchinson-Gilford progeria syndrome Diseases 0.000 claims description 2
- 206010020608 Hypercoagulation Diseases 0.000 claims description 2
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims description 2
- 208000032578 Inherited retinal disease Diseases 0.000 claims description 2
- 208000017924 Klinefelter Syndrome Diseases 0.000 claims description 2
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims description 2
- 208000001826 Marfan syndrome Diseases 0.000 claims description 2
- 208000024556 Mendelian disease Diseases 0.000 claims description 2
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 2
- 208000009905 Neurofibromatoses Diseases 0.000 claims description 2
- 206010029748 Noonan syndrome Diseases 0.000 claims description 2
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims description 2
- 101000989950 Otolemur crassicaudatus Hemoglobin subunit alpha-A Proteins 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 201000011252 Phenylketonuria Diseases 0.000 claims description 2
- 208000019222 Poland syndrome Diseases 0.000 claims description 2
- 241000097929 Porphyria Species 0.000 claims description 2
- 208000010642 Porphyrias Diseases 0.000 claims description 2
- 208000007932 Progeria Diseases 0.000 claims description 2
- 208000032430 Retinal dystrophy Diseases 0.000 claims description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 2
- 208000022292 Tay-Sachs disease Diseases 0.000 claims description 2
- 208000002903 Thalassemia Diseases 0.000 claims description 2
- 206010068233 Trimethylaminuria Diseases 0.000 claims description 2
- 208000026928 Turner syndrome Diseases 0.000 claims description 2
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims description 2
- 201000007960 WAGR syndrome Diseases 0.000 claims description 2
- 208000018839 Wilson disease Diseases 0.000 claims description 2
- 208000008919 achondroplasia Diseases 0.000 claims description 2
- 230000001475 anti-trypsic effect Effects 0.000 claims description 2
- 208000022185 autosomal dominant polycystic kidney disease Diseases 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 108010091897 factor V Leiden Proteins 0.000 claims description 2
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims description 2
- 201000006321 fundus dystrophy Diseases 0.000 claims description 2
- 208000009624 holoprosencephaly Diseases 0.000 claims description 2
- 208000017532 inherited retinal dystrophy Diseases 0.000 claims description 2
- 230000004777 loss-of-function mutation Effects 0.000 claims description 2
- 201000004931 neurofibromatosis Diseases 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 201000005665 thrombophilia Diseases 0.000 claims description 2
- 239000002753 trypsin inhibitor Substances 0.000 claims description 2
- 201000000866 velocardiofacial syndrome Diseases 0.000 claims description 2
- 238000002659 cell therapy Methods 0.000 claims 6
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 3
- 101001045440 Homo sapiens Beta-hexosaminidase subunit alpha Proteins 0.000 claims 1
- 230000000593 degrading effect Effects 0.000 abstract description 93
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 abstract description 58
- 108010006523 asialoglycoprotein receptor Proteins 0.000 abstract description 58
- 230000001225 therapeutic effect Effects 0.000 abstract description 31
- 235000002639 sodium chloride Nutrition 0.000 description 60
- 229940027941 immunoglobulin g Drugs 0.000 description 54
- 210000004027 cell Anatomy 0.000 description 36
- 150000007523 nucleic acids Chemical class 0.000 description 33
- 239000000203 mixture Substances 0.000 description 31
- 108090000765 processed proteins & peptides Proteins 0.000 description 29
- 210000000234 capsid Anatomy 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 27
- 229940099472 immunoglobulin a Drugs 0.000 description 23
- 102000039446 nucleic acids Human genes 0.000 description 22
- 108020004707 nucleic acids Proteins 0.000 description 22
- 150000001413 amino acids Chemical class 0.000 description 21
- 239000001064 degrader Substances 0.000 description 21
- 150000002632 lipids Chemical group 0.000 description 20
- 102000004196 processed proteins & peptides Human genes 0.000 description 20
- 125000000753 cycloalkyl group Chemical group 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 17
- 229920001184 polypeptide Polymers 0.000 description 16
- 125000005647 linker group Chemical group 0.000 description 15
- 238000012384 transportation and delivery Methods 0.000 description 15
- 239000013543 active substance Substances 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 150000002431 hydrogen Chemical class 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- 230000000155 isotopic effect Effects 0.000 description 11
- 238000006467 substitution reaction Methods 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 230000015556 catabolic process Effects 0.000 description 10
- 238000006731 degradation reaction Methods 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 229910052736 halogen Inorganic materials 0.000 description 10
- 150000002367 halogens Chemical class 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 235000019698 starch Nutrition 0.000 description 9
- 206010006187 Breast cancer Diseases 0.000 description 8
- 208000026310 Breast neoplasm Diseases 0.000 description 8
- 210000003494 hepatocyte Anatomy 0.000 description 8
- 239000002502 liposome Substances 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 229940032147 starch Drugs 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 206010025323 Lymphomas Diseases 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 150000008574 D-amino acids Chemical class 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 229920002125 Sokalan® Polymers 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000008366 buffered solution Substances 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 230000012202 endocytosis Effects 0.000 description 6
- 238000011269 treatment regimen Methods 0.000 description 6
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 5
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 5
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 5
- 108010002913 Asialoglycoproteins Proteins 0.000 description 5
- 206010003571 Astrocytoma Diseases 0.000 description 5
- 208000003950 B-cell lymphoma Diseases 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 229920002401 polyacrylamide Polymers 0.000 description 5
- 239000013608 rAAV vector Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- BITHHVVYSMSWAG-KTKRTIGZSA-N (11Z)-icos-11-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCC(O)=O BITHHVVYSMSWAG-KTKRTIGZSA-N 0.000 description 4
- YWWVWXASSLXJHU-AATRIKPKSA-N (9E)-tetradecenoic acid Chemical compound CCCC\C=C\CCCCCCCC(O)=O YWWVWXASSLXJHU-AATRIKPKSA-N 0.000 description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 229930182830 galactose Natural products 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 229940125974 heterobifunctional degrader Drugs 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 210000003712 lysosome Anatomy 0.000 description 4
- 230000001868 lysosomic effect Effects 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 241000702421 Dependoparvovirus Species 0.000 description 3
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 description 3
- 208000006168 Ewing Sarcoma Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000031814 IgA Vasculitis Diseases 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical group CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 3
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Chemical group CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 229910004749 OS(O)2 Inorganic materials 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 108700013125 Zolgensma Proteins 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 3
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 3
- 230000001588 bifunctional effect Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 150000001991 dicarboxylic acids Chemical class 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 230000008105 immune reaction Effects 0.000 description 3
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 3
- 201000002313 intestinal cancer Diseases 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 230000000116 mitigating effect Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 229960003424 phenylacetic acid Drugs 0.000 description 3
- 239000003279 phenylacetic acid Substances 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 229940117392 provisc Drugs 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 206010046766 uterine cancer Diseases 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GWHCXVQVJPWHRF-KTKRTIGZSA-N (15Z)-tetracosenoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-KTKRTIGZSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 2
- URXZXNYJPAJJOQ-FPLPWBNLSA-N (Z)-icos-13-enoic acid Chemical compound CCCCCC\C=C/CCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-FPLPWBNLSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- YWWVWXASSLXJHU-UHFFFAOYSA-N 9E-tetradecenoic acid Natural products CCCCC=CCCCCCCCC(O)=O YWWVWXASSLXJHU-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 2
- 102100036664 Adenosine deaminase Human genes 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 206010014967 Ependymoma Diseases 0.000 description 2
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 108050001049 Extracellular proteins Proteins 0.000 description 2
- 201000001342 Fallopian tube cancer Diseases 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 2
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 2
- 206010021263 IgA nephropathy Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 208000009388 Job Syndrome Diseases 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 201000003791 MALT lymphoma Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 208000000172 Medulloblastoma Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 206010060880 Monoclonal gammopathy Diseases 0.000 description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 description 2
- 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- XJXROGWVRIJYMO-SJDLZYGOSA-N Nervonic acid Natural products O=C(O)[C@@H](/C=C/CCCCCCCC)CCCCCCCCCCCC XJXROGWVRIJYMO-SJDLZYGOSA-N 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 201000010133 Oligodendroglioma Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 235000021319 Palmitoleic acid Nutrition 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 208000002774 Paraproteinemias Diseases 0.000 description 2
- 206010034277 Pemphigoid Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 229910019999 S(O)2O Inorganic materials 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- UWHZIFQPPBDJPM-FPLPWBNLSA-M Vaccenic acid Natural products CCCCCC\C=C/CCCCCCCCCC([O-])=O UWHZIFQPPBDJPM-FPLPWBNLSA-M 0.000 description 2
- 235000021322 Vaccenic acid Nutrition 0.000 description 2
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 2
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 2
- GWHCXVQVJPWHRF-UHFFFAOYSA-N cis-tetracosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-UHFFFAOYSA-N 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229940108623 eicosenoic acid Drugs 0.000 description 2
- BITHHVVYSMSWAG-UHFFFAOYSA-N eicosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCC(O)=O BITHHVVYSMSWAG-UHFFFAOYSA-N 0.000 description 2
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- LQJBNNIYVWPHFW-QXMHVHEDSA-N gadoleic acid Chemical compound CCCCCCCCCC\C=C/CCCCCCCC(O)=O LQJBNNIYVWPHFW-QXMHVHEDSA-N 0.000 description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 235000021299 gondoic acid Nutrition 0.000 description 2
- 239000003979 granulating agent Substances 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 206010051040 hyper-IgE syndrome Diseases 0.000 description 2
- 230000007233 immunological mechanism Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 208000030776 invasive breast carcinoma Diseases 0.000 description 2
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 2
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 2
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 206010024627 liposarcoma Diseases 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 201000011519 neuroendocrine tumor Diseases 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 238000005935 nucleophilic addition reaction Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 201000008106 ocular cancer Diseases 0.000 description 2
- 229950009805 onasemnogene abeparvovec Drugs 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 210000004214 philadelphia chromosome Anatomy 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229940068984 polyvinyl alcohol Drugs 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000009163 protein therapy Methods 0.000 description 2
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000011078 sorbitan tristearate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 201000011096 spinal cancer Diseases 0.000 description 2
- 208000014618 spinal cord cancer Diseases 0.000 description 2
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 206010042863 synovial sarcoma Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 208000008732 thymoma Diseases 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- UWHZIFQPPBDJPM-BQYQJAHWSA-N trans-vaccenic acid Chemical compound CCCCCC\C=C\CCCCCCCCCC(O)=O UWHZIFQPPBDJPM-BQYQJAHWSA-N 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FPRKGXIOSIUDSE-SYACGTDESA-N (2z,4z,6z,8z)-docosa-2,4,6,8-tetraenoic acid Chemical compound CCCCCCCCCCCCC\C=C/C=C\C=C/C=C\C(O)=O FPRKGXIOSIUDSE-SYACGTDESA-N 0.000 description 1
- UNSRRHDPHVZAHH-YOILPLPUSA-N (5Z,8Z,11Z)-icosatrienoic acid Chemical compound CCCCCCCC\C=C/C\C=C/C\C=C/CCCC(O)=O UNSRRHDPHVZAHH-YOILPLPUSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- UBLAMKHIFZBBSS-UHFFFAOYSA-N 3-Methylbutyl pentanoate Chemical compound CCCCC(=O)OCCC(C)C UBLAMKHIFZBBSS-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
- UNSRRHDPHVZAHH-UHFFFAOYSA-N 6beta,11alpha-Dihydroxy-3alpha,5alpha-cyclopregnan-20-on Natural products CCCCCCCCC=CCC=CCC=CCCCC(O)=O UNSRRHDPHVZAHH-UHFFFAOYSA-N 0.000 description 1
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 1
- 101150106774 9 gene Proteins 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000017726 ALK-positive large B-cell lymphoma Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 1
- 241000649045 Adeno-associated virus 10 Species 0.000 description 1
- 241000300529 Adeno-associated virus 13 Species 0.000 description 1
- 241000958487 Adeno-associated virus 3B Species 0.000 description 1
- 241000649044 Adeno-associated virus 9 Species 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010001742 Allergy to animal Diseases 0.000 description 1
- 208000012791 Alpha-heavy chain disease Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 206010002412 Angiocentric lymphomas Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 206010073360 Appendix cancer Diseases 0.000 description 1
- 206010069002 Autoimmune pancreatitis Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000010566 B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma Diseases 0.000 description 1
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 description 1
- 206010003908 B-cell small lymphocytic lymphoma Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 101100189913 Caenorhabditis elegans pept-1 gene Proteins 0.000 description 1
- 101100243399 Caenorhabditis elegans pept-2 gene Proteins 0.000 description 1
- 101100243401 Caenorhabditis elegans pept-3 gene Proteins 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 208000005024 Castleman disease Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108010028773 Complement C5 Proteins 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- WQZGKKKJIJFFOK-WHZQZERISA-N D-aldose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-WHZQZERISA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000021994 Diffuse astrocytoma Diseases 0.000 description 1
- 235000021292 Docosatetraenoic acid Nutrition 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010065563 Eosinophilic bronchitis Diseases 0.000 description 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 description 1
- 201000005231 Epithelioid sarcoma Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 208000012841 Gamma-heavy chain disease Diseases 0.000 description 1
- 201000004066 Ganglioglioma Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000021309 Germ cell tumor Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000002125 Hemangioendothelioma Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 101000729271 Homo sapiens Retinoid isomerohydrolase Proteins 0.000 description 1
- 101000617738 Homo sapiens Survival motor neuron protein Proteins 0.000 description 1
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- 208000015865 IgA pemphigus Diseases 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 208000009147 Jaw Neoplasms Diseases 0.000 description 1
- 206010023256 Juvenile melanoma benign Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 1
- 241000218652 Larix Species 0.000 description 1
- 235000005590 Larix decidua Nutrition 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 235000021353 Lignoceric acid Nutrition 0.000 description 1
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 description 1
- 208000001244 Linear IgA Bullous Dermatosis Diseases 0.000 description 1
- 208000012309 Linear IgA disease Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 206010062038 Lip neoplasm Diseases 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 1
- 241001491663 Lycia Species 0.000 description 1
- 208000004059 Male Breast Neoplasms Diseases 0.000 description 1
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 1
- 208000033724 Malignant tumor of fallopian tubes Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 201000009574 Mesenchymal Chondrosarcoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010051696 Metastases to meninges Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000012799 Mu-heavy chain disease Diseases 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 102000001621 Mucoproteins Human genes 0.000 description 1
- 108010093825 Mucoproteins Proteins 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 208000005927 Myosarcoma Diseases 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical class CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010028729 Nasal cavity cancer Diseases 0.000 description 1
- 206010028767 Nasal sinus cancer Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 208000003937 Paranasal Sinus Neoplasms Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 206010061336 Pelvic neoplasm Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 201000007286 Pilocytic astrocytoma Diseases 0.000 description 1
- 206010050487 Pinealoblastoma Diseases 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 241000243142 Porifera Species 0.000 description 1
- 208000008691 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 description 1
- 208000024588 Primary cutaneous follicle center lymphoma Diseases 0.000 description 1
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 description 1
- 208000037276 Primitive Peripheral Neuroectodermal Tumors Diseases 0.000 description 1
- 206010057846 Primitive neuroectodermal tumour Diseases 0.000 description 1
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 description 1
- 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010037127 Pseudolymphoma Diseases 0.000 description 1
- 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 208000011783 Splenic diffuse red pulp small B-cell lymphoma Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 102100021947 Survival motor neuron protein Human genes 0.000 description 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
- 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- WPMWEFXCIYCJSA-UHFFFAOYSA-N Tetraethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCO WPMWEFXCIYCJSA-UHFFFAOYSA-N 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 206010044002 Tonsil cancer Diseases 0.000 description 1
- 208000006842 Tonsillar Neoplasms Diseases 0.000 description 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 101150114976 US21 gene Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046392 Ureteric cancer Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010052568 Urticaria chronic Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XGKPLOKHSA-N [2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XGKPLOKHSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 201000001256 adenosarcoma Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 201000010435 allergic urticaria Diseases 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical class O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000000420 anogeissus latifolia wall. gum Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 208000021780 appendiceal neoplasm Diseases 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000004982 autoimmune uveitis Diseases 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 229940125385 biologic drug Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 206010006007 bone sarcoma Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000005389 breast carcinoma in situ Diseases 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 229940096529 carboxypolymethylene Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 229960000800 cetrimonium bromide Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 description 1
- 208000019097 eosinophilic gastrointestinal disease Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 201000007280 estrogen-receptor negative breast cancer Diseases 0.000 description 1
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 description 1
- FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 1
- 201000006569 extramedullary plasmacytoma Diseases 0.000 description 1
- 208000024711 extrinsic asthma Diseases 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 201000001169 fibrillary astrocytoma Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 201000008361 ganglioneuroma Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000019314 gum ghatti Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 208000025750 heavy chain disease Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 208000014796 hyper-IgE recurrent infection syndrome 1 Diseases 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical group C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 208000014899 intrahepatic bile duct cancer Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- YAQXGBBDJYBXKL-UHFFFAOYSA-N iron(2+);1,10-phenanthroline;dicyanide Chemical compound [Fe+2].N#[C-].N#[C-].C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1 YAQXGBBDJYBXKL-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000001837 jaw cancer Diseases 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 201000011059 lobular neoplasia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 208000022080 low-grade astrocytoma Diseases 0.000 description 1
- 208000026535 luminal A breast carcinoma Diseases 0.000 description 1
- 208000026534 luminal B breast carcinoma Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 201000010453 lymph node cancer Diseases 0.000 description 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
- 208000006116 lymphomatoid granulomatosis Diseases 0.000 description 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 201000003175 male breast cancer Diseases 0.000 description 1
- 208000010907 male breast carcinoma Diseases 0.000 description 1
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 208000010943 meningeal sarcoma Diseases 0.000 description 1
- 201000003776 meninges sarcoma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 208000037970 metastatic squamous neck cancer Diseases 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 201000004058 mixed glioma Diseases 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 150000002762 monocarboxylic acid derivatives Chemical class 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- 201000002335 monodermal teratoma Diseases 0.000 description 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
- 201000003731 mucosal melanoma Diseases 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 208000021284 ovarian germ cell tumor Diseases 0.000 description 1
- 208000025207 ovarian monodermal teratoma Diseases 0.000 description 1
- 201000006842 ovarian sex-cord stromal tumor Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 201000007052 paranasal sinus cancer Diseases 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 208000016802 peripheral primitive neuroectodermal tumor Diseases 0.000 description 1
- 201000002524 peritoneal carcinoma Diseases 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000003113 pineoblastoma Diseases 0.000 description 1
- 201000002511 pituitary cancer Diseases 0.000 description 1
- 208000007525 plasmablastic lymphoma Diseases 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 1
- 229940043349 potassium metabisulfite Drugs 0.000 description 1
- 235000010263 potassium metabisulphite Nutrition 0.000 description 1
- 229940096992 potassium oleate Drugs 0.000 description 1
- MLICVSDCCDDWMD-KVVVOXFISA-M potassium;(z)-octadec-9-enoate Chemical compound [K+].CCCCCCCC\C=C/CCCCCCCC([O-])=O MLICVSDCCDDWMD-KVVVOXFISA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 201000007282 progesterone-receptor negative breast cancer Diseases 0.000 description 1
- 201000007283 progesterone-receptor positive breast cancer Diseases 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229940045847 receptor mimetic Drugs 0.000 description 1
- 229960000160 recombinant therapeutic protein Drugs 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000790 retinal pigment Substances 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 208000017022 seasonal allergic rhinitis Diseases 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000012890 simulated body fluid Substances 0.000 description 1
- 208000037968 sinus cancer Diseases 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 201000006576 solitary osseous plasmacytoma Diseases 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 239000003634 thrombocyte concentrate Substances 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 201000007423 tubular adenocarcinoma Diseases 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- This invention provides methods to modulate an immune response to a therapeutic, for example gene therapy, by administering an immunoglobulin degrading molecule that has an asialoglycoprotein receptor (ASGPR) Binding Ligand bound to an Immunoglobulin Targeting Ligand or a pharmaceutically acceptable salt thereof.
- ASGPR asialoglycoprotein receptor
- Elevated immune responses to treatments has been most prevalent in gene therapies and recombinant therapeutic protein treatments, mitigating a promising area of medical advancement for a number of disorders.
- gene therapies rely on viral vectors, such as adenovirus vectors and adeno-associated virus vectors (AAV), for delivering gene therapy targets to cells.
- viral vectors such as adenovirus vectors and adeno-associated virus vectors (AAV)
- AAV adeno-associated virus vectors
- Many patients have pre-existing immunity to the adenovirus or AAV vector which can be further triggered by administration of the vector.
- the increasing immune response from the patient results in the escalated removal of the vector before they can reach their target cells.
- ongoing therapy requires either increasingly larger doses of the vector being delivered, risking damage to the patient's liver, or discontinuation of the therapy due to inefficacy.
- many patients suffering from disorders, such as genetic disorders or cancers are unable to receive ongoing or repeat treatments using such viral vectors that might
- Factors influencing immunogenicity include recombinant protein dependent factors such as the primary amino acid sequence, and glycosylation patterns (Hermeling et al. (2004) Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res. 21, 897-903).
- Other factors influencing immunogenicity include treatment dependent factors such as the dose of the protein, the route of administration, and the duration of treatment, patient HLA alleles, underlying genetic defects, and product dependent factors such as the mechanical processing, manufacture, and contaminants contained in the therapeutic protein formulation (see Ross et al. (2000) Immunogenicity of interferon -beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann. Neurol.
- Novel methods of mitigating a subject’s immune response to therapy comprising administering an effective amount of an heterobifunctional extracellular immunoglobulin degrader or a pharmaceutically acceptable salt thereof in combination with, in advance of, or following the therapy.
- the immunoglobulin degraders described herein can sequester and inactivate or degrade antibodies, including anti -drug antibodies (AD As), such as immunoglobulin G (IgG), immunoglobulin A (IgA), immunoglobulin E (IgE), or immunoglobulin M (IgM) antibodies which would otherwise impede the desired therapy and cause unwanted adverse effects.
- AD As anti -drug antibodies
- IgG immunoglobulin G
- IgA immunoglobulin A
- IgE immunoglobulin E
- IgM immunoglobulin M
- the immunoglobulin heterobifunctional degrader comprises a noncovalent ligand for IgG optionally linked to an asialoglycoprotein receptor (ASGPR) ligand.
- ASGPR asialoglycoprotein receptor
- This heterobifunctional immunoglobulin degrader binds an immunoglobulin protein, such as IgG, that is in extracellular circulation and then ASGPR mediates endocytosis and degradation of the antibody, for example by cellular lysosomes in the liver.
- a method described herein results in a mitigated effect of the immune response to therapy. In other embodiments, a method described herein completely inhibits the effects of the immune response to therapy.
- the asialoglycoprotein receptor is a Ca 2+ - dependent lectin that is primarily expressed in parenchymal hepatocyte cells.
- the main role of ASGPR is to help regulate serum glycoprotein levels by mediating endocytosis of desialylated glycoproteins.
- the receptor binds ligands with a terminal galactose or N-acetylgalactosamine.
- Asialoglycoproteins bind to ASGPRs and are then cleared by receptor-mediated endocytosis.
- Avilar Therapeutics has described a series of heterobifunctional degraders of extracellular proteins using the ASGPR-mediated degradation mechanism as described above (WO 2021/155317).
- Other publications describing various utilizations of the ASGPR mechanism include: U.S. Patent Nos. 9,340,553; 9,617,293; 10,039,778; 10,376,531, and 10,813,942 assigned to Pfizer Inc.; Sanhueza et al. ( JACS , 2017, 139, 3528); Petrov et al.
- the immunoglobulin degrading compound is of Formula I, Formula II, or Formula III is provided: wherein ASPGR Binding Ligand is a compound selected from: one of R 1 or R 5 is a bond to Linker A ; the other of R 1 and R 5 is independently selected from hydrogen, heteroalkyl, C0-C6alkyl-cyano, alkyl, alkenyl, alkynyl, haloalkyl, F, Cl, Br, I, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, heterocycloalkyl, haloalkoxy, C0-C6alkyl-OR 6 , C0-C6alkyl-SR 6 , C 0 -C 6 alkyl-NR 6 R 7 , C 0 -C 6 alkyl-C(O)R 3 , C 0 -C 6 alkyl-S(O)R 3 , C 0 -C 6 alkyl-C(S)R
- a compound when “optionally substituted” it may be substituted as allowed by valence with one or more groups selected from alkyl (including C1-C4alkyl), alkenyl (including C 2 -C 4 alkenyl), alkynyl (including C 2 -C 4 alkynyl), haloalkyl (including C 1 -C 4 haloalkyl), -OR 6 , F, Cl, Br, I, -NR 6 R 7 , heteroalkyl, heterocycle, heteroaryl, aryl, cyano, nitro, hydroxyl, azide, amide, -SR 3 , -S(O)(NR 6 )R 3 , -NR 8 C(O)R 3 , -C(O)NR 6 R 7 , -C(O)OR 3 , -C(O)R 3 , -SF , and , wherein the optional substituent is selected such that a stable compound results.
- alkyl including C1-C4
- an immunoglobulin degrading compound of Formula I-A, Formula II-A, or Formula III-A is provided: or a pharmaceutically acceptable salt thereof.
- ASGPR Binding Ligand is a compound selected from: or a pharmaceutically acceptable salt thereof.
- the heterobifunctional extracellular immunoglobulin degrader is provided as an isotopically enriched immunoglobulin degrader, for example an immunoglobulin degrader with at least one desired isotopic substitution of an atom, at an amount above the natural abundance of the isotope.
- deuterium can replace one or more hydrogens in the immunoglobulin degrader and 13 C can replace one or more carbon atoms.
- the isotopic substitution is in one or more positions of the ASGPR Ligand.
- the isotopic substitution is in one or more positions of the Linker portion of the molecule.
- the isotopic substitution is in one or more positions of the Immunoglobulin Targeting Ligand portion of the molecule.
- the immunoglobulin heterobifunctional degrader can be administered to a patient suffering from an immune response due to the administration of a therapeutic according to the severity of the response.
- the response may be severe and life threatening and the patient can be administered the immunoglobulin heterobifunctional degrader one or more time a day, for example, once a day, twice a day, three times a day, or four time a day.
- the immunoglobulin heterobifunctional degrader can be administered one or more times a day for multiple days, for example at least 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days or more until the immune response subsides.
- the methods of the invention may be used with any gene or biologies therapy that generates or implicates an undesirable immune response.
- Methods of the invention may be used, in particular, with a gene therapy, for example a gene therapy comprising a vector delivery including, for example CRISPR-based gene therapy.
- the gene therapy can be a somatic-cell-targeting gene therapy.
- the gene therapy can be a germline-cell-targeting cell gene therapy.
- the therapy can be a chimeric antigen receptor T-cell (CAR T- cell) therapy.
- the vector may be a viral vector, for example but not limited to an adenovirus- associated virus (AAV) vector, lentivirus vector, adenovirus vector, respiratory syncytial virus (RSV) vector, herpes simplex virus (HSV) vector, poxvirus, or vaccinia virus.
- AAV adenovirus- associated virus
- RSV respiratory syncytial virus
- HSV herpes simplex virus
- poxvirus poxvirus
- vaccinia virus vaccinia virus.
- the viral vector is AAV.
- the vector is a lipid nanoparticle (LNP).
- the replacement of a defective gene expressing a mutated or non-functional protein with a normal or wild-type gene expressing a functional protein may result in the induction of an immune reaction to the normal protein in the host.
- the heterobifunctional extracellular immunoglobulin degrader is administered to a subject receiving gene therapy to replace a defective protein in order to reduce the effects of an immune response to a normal, functionalized or wild-type protein.
- the heterobifunctional extracellular immunoglobulin degrader is administered once a week, once every two weeks, once every three weeks, or once a month.
- the therapy can be a recombinant protein therapy.
- the recombinant protein is a recombinant Factor VIII protein.
- the recombinant protein is insulin.
- the therapy is an anti-tumor necrosis factor a (TNFa) monoclonal antibody therapy.
- TNFa anti-tumor necrosis factor a
- the monoclonal antibody is adalimumab, infliximab, or golimumab.
- the therapy is the anti-TNFa therapy etanercept, a soluble TNF receptor IgG Fc fusion protein.
- the therapy is the anti-TNFa therapy certolizumab, a pegylated anti-TNFa antibody fragment.
- the therapy is a cytokine inhibitor therapy.
- the therapy is an anti-IL-12/IL-23 therapy, for example, ustekinumab.
- the therapy is an anti-IL-17 therapy, for example, secukinumab.
- the therapy is an anti-IL-6 therapy, for example tocilizumab or sarilumab.
- the therapy is an anti-IL2 receptor therapy, for example, daclizumab or basiliximab.
- the therapy is an anti-IIb therapy, for example cankinumab.
- the therapy is an anti-CD20 therapy, for example, rituximab, tositumomab, ofatumumab, or ibritumomab.
- the therapy is an anti-CD28 therapy, for example, abatacept.
- the therapy is an anti-CD3 therapy, for example muromanab.
- the therapy is an anti-CDl la therapy, for example, efalizumab.
- the therapy is an anti-CD52 therapy, for example alemtuzumab.
- the therapy is an anti-CD33 therapy, for example gemtuzumab.
- the therapy is an anti-human C5 complement therapy, for example eculizumab or ultomiris.
- the therapy is an anti-IgE therapy, for example omalizumab.
- the therapy is an RSV prophylaxis therapy, for example palivizumab.
- the therapy is a PTCA adjunct therapy, for example, abciximab.
- the therapy is a diagnostic therapy, for example, nofetumumab. capromab, fanolesomab, arcitumomab, or imciromab.
- the therapy is a cancer therapy, for example, trastuzumab, cetuximab, bevacizumab, or panitumumab.
- the therapy is a macular degeneration therapy, for example ranibizumab.
- the therapy is a rheumatoid arthritis or Crohn’s disease therapy, for example cetolizumab pegol.
- the therapy is a bone loss therapy, for example denosumab.
- a heterobifunctional immunoglobulin degrader may be provided simultaneous with, prior to, or following the therapy administration of an effective amount to the subject.
- the heterobifunctional extracellular immunoglobulin degrader is provided to the subject along with the first administration of the therapy to the subject.
- the immunoglobulin degrader is provided during subsequent administrations of the therapy to the subject.
- the immunoglobulin degrader may be administered prior to the therapy being readministered to the subject or the immunoglobulin degrader may be conducted after the subject has been administered the therapy at least once.
- the immunoglobulin degrader may be administered 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 days following administration of the therapy.
- the immunoglobulin degrader may be administered once a week, once every two weeks, once every three weeks, or once a month following administration of the therapy.
- aspects of the invention include a method for administering an effective amount of an extracellular immunoglobulin degrader (a heterobifunctional compound) comprising a first ligand configured to bind IgG and a second ligand configured to bind an asialoglycoprotein receptor (ASGPR), optimally connected with a linker, to thereby sequester and degrade immunoglobulin G (IgG), immunoglobulin A (IgA), immunoglobulin E (IgE), or immunoglobulin M (IgM) in the subject in a manner that a therapy can be re-administered to the subject and produce a therapeutic effect in the subject that would not otherwise be achieved due to IgG adversely affecting the therapy.
- an extracellular immunoglobulin degrader a heterobifunctional compound
- A immunoglobulin A
- IgE immunoglobulin E
- IgM immunoglobulin M
- the Immunoglobulin Targeting Ligand is covalently bound to Linker in the immunoglobulin degrader compound through the Anchor Bond (which is the chemical bond between the Immunoglobulin Targeting Ligand and either Linker B, Linker C or Linker D). This bond can be placed at any location on the ligand that does not unacceptably disrupt the ability of the Immunoglobulin Targeting Ligand to bind to the Target Immunoglobulin.
- the Anchor Bond is depicted on the nonlimiting examples of Immunoglobulin Targeting Ligands in the figures as:
- FIG. 1A provides a non-limiting list of Immunoglobulin Targeting Ligands that target Immunoglobulin A (IgA).
- FIG. IB provides a non-limiting list of Immunoglobulin Targeting Ligands that target Immunoglobulin G (IgG).
- FIG. 1C-1G provides a non-limiting list of Immunoglobulin Targeting Ligands that target Immunoglobulin E (IgE).
- FIG. 2 provides non-limiting examples of IgG protein degrading compounds for use in the present invention.
- the present invention provides methods for administering a cell, gene, or biologies therapy in combination with a method for mitigating a subject's immune response to produce a therapeutic effect in the subject that would not otherwise be achieved due to the subject's immune response to the cell, gene, or biologies therapy.
- the subject is generally a human, but can also be a non-human mammal. Methods of the invention can be used to modulate the immune response to any therapy that triggers an immune response.
- the invention may use a bifunctional compound comprising a first ligand configured to bind to the antibody, for example an IgG, and a second ligand configured to bind an asialoglycoprotein receptor (ASGPR) optimally connected with a linker.
- ASGPR asialoglycoprotein receptor
- the bifunctional compound sequesters the antibody of interest and then ASGPR mediates endocytosis and degradation of the antibody, for example by cellular lysosomes, thereby mediating a subject's immune response.
- one or more additional therapeutically active agents is administered in addition to the heterobifunctional extracellular immunoglobulin degrading compound and the cell, gene, or biologies therapy.
- the therapeutics and/or immunoglobulin degrading compound or composition can be administered concurrently with, prior to, or after, administration of the cell, gene, or biologies therapy.
- each agent will be administered at a dose and/or on a time schedule determined for that agent.
- the additional therapeutically active agent used in this combination can be administered together in a single composition or administered separately in different compositions.
- the particular combination used in a regimen will take into account compatibility of the inventive therapeutics and/or immunoglobulin degrading molecule with the additional therapeutically active agent and/or the desired therapeutic effect to be achieved.
- additional therapeutically active agents used in combination be used at levels that do not exceed the levels at which they are used individually. In some embodiments, the levels used in combination will be lower than those used individually.
- the present invention may be used in the delivery of any cell, gene, or biologies therapy, for example a recombinant protein or antibody therapy, that triggers an immune response.
- the present invention may be used together with gene therapies.
- Gene therapies are therapeutics which focus on the genetic modification of cells to produce a therapeutic effect.
- the gene therapy is delivered via a vector, for example a viral vector, capable of inducing an immune response in the host, which can reduce the effectiveness or ability to readminister the viral vector in the host.
- the viral vector is a AAV vector, lentivirus vector, adenovirus vector, respiratory syncytial virus (RSV) vector, herpes simplex virus (HSV) vector, poxvirus, or vaccinia virus.
- the replacement of a defective gene expressing a mutated or non-functional protein with a normal or wild-type gene expressing a functional protein may result in the induction of an immune reaction to the normal protein in the host.
- the heterobifunctional extracellular immunoglobulin degrader is administered to a subject receiving gene therapy to replace a defective protein in order to reduce the effects of an immune response to a normal, functionalized or wild-type protein.
- the heterobifunctional extracellular immunoglobulin degrader is administered once a week, once every two weeks, once every three weeks, or once a month.
- an effective amount of an immunoglobulin degrading compound described herein, for example and IgG degrading compound is administered before, concurrently with, or after administration of gene therapy.
- Gene therapies may be provided according to the invention to treat a number of disorders, for example Achondroplasia, Alpha-I Antitrypsin Deficiency, Antiphospholipid Syndrome, Autosomal Dominant Polycystic Kidney Disease, Charcot-Marie-Tooth, cancer, Cri du chat, Crohn's Disease, Cystic fibrosis, Dercum Disease, Duane Syndrome, Duchenne Muscular Dystrophy, Factor V Leiden Thrombophilia, Familial Hypercholesterolemia, Familial Mediterranean Fever, Fragile X Syndrome, Gaucher Disease, Hemochromatosis, Hemophilia, Holoprosencephaly, Huntington's disease, Klinefelter syndrome, Marfan syndrome, Myotonic Dystrophy, Neurofibromatosis, Noonan Syndrome, Osteogenesis Imperfecta, Parkinson's disease, Phenylketonuria, Tru Anomaly, Porphyria, Progeria, Retinitis Pigmentosa, Se
- the disorder to be treated is caused by a loss-of-function mutation disorder. In certain embodiments, the disorder to be treated is a monogenic disorder. In certain embodiments, the disorder to be treated is caused by a gain-of- toxicity mutation. In certain embodiments, the disorder to be treated is caused by recessive compound heterozygous mutations.
- the disorder is a cancer.
- cancer include squamous-cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinomas, and renal cell carcinomas, cancer of the bladder, bowel, breast, cervix, colon, esophagus, head, kidney, liver, lung, neck, ovary, pancreas, prostate, and stomach; leukemias; benign and malignant lymphomas, particularly Burkitfs lymphoma and Non-Hodgkin's lymphoma; benign and malignant melanomas; myeloproliferative diseases; sarcomas, including Ewing's sarcoma, hemangiosarcoma, Kaposi's sarcoma, liposarcoma, myosarcomas, peripheral neuroepithelioma, synovial sarcoma, gliomas, astrocytomas, oligodendrogliomas, ependymomas
- Additional cancers which may be treated using the disclosed compounds according to the present invention include, for example, acute granulocytic leukemia, acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), adenocarcinoma, adenosarcoma, adrenal cancer, adrenocortical carcinoma, anal cancer, anaplastic astrocytoma, angiosarcoma, appendix cancer, astrocytoma, Basal cell carcinoma, B-Cell lymphoma, bile duct cancer, bladder cancer, bone cancer, bone marrow cancer, bowel cancer, brain cancer, brain stem glioma, breast cancer, triple (estrogen, progesterone and HER-2) negative breast cancer, double negative breast cancer (two of estrogen, progesterone and HER-2 are negative), single negative (one of estrogen, progesterone and HER-2 is negative), estrogen-receptor positive, HER2negative breast cancer, estrogen receptor-negative breast cancer, estrogen receptor positive breast
- the methods of the present invention may mediate an immune response to vectors used for the delivery of therapeutics, for example by sequestering IgG's reactive to a given vector.
- Vectors are particularly useful in delivering nucleic acid molecules to cells, for example for gene therapies and vaccines.
- an effective amount of a heterobifunctional immunoglobulin degrading compound described herein, for example an IgG degrading compound is administered before, concurrently with, or after administration of a delivery vector.
- Vectors may be divided broadly into viral vectors and non-viral vectors.
- viral vectors or virus-associated vectors are known in the art. Such vectors can be used as carriers of a nucleic acid construct into the cell. Constructs may be integrated and packaged into non-replicating, defective viral genomes like Adenovirus, Adeno-associated virus (AAV), or Herpes simplex virus (HSV) or others, including retroviral and lentiviral vectors, for infection or transduction into cells.
- Adenovirus Adeno-associated virus
- HSV Herpes simplex virus
- retroviral and lentiviral vectors for infection or transduction into cells.
- retroviral and lentiviral vectors for infection or transduction into cells.
- retroviral and lentiviral vectors for infection or transduction into cells.
- retroviral and lentiviral vectors for infection or transduction into cells.
- retroviral and lentiviral vectors for infection or transduction into cells.
- retroviral and lentiviral vectors for infection or transduction into cells.
- retroviruses such as
- Adeno-associated viral vectors are a family of medium-sized, non- enveloped viruses used as vectors. More than 30 naturally occurring serotypes of AAV are available. Many natural variants in the AAV capsid exist.
- AAV serotypes include, but are not limited to, AAV serotypes AAVI, AAV2, AAV3, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV7M8, AAV8, AAV8bp, AAV9, AAV10, AAVI 1, AAV 12, AAV13, AAVAnc80, AAVrhlO, AAVPHP.B, and variants of the known or mentioned AAVs or AAVs yet to be discovered or variants or mixtures thereof (see, e.g., WO 2005/033321, which is incorporated herein by reference).
- LUXTURNA ® voretigene neparvovec-rzyl
- ZOLGENSMA ® ona shogene abeparvovec-xioi
- LUXTURNA ® is an AAV serotype 2 gene therapy for the treatment of patients having biallelic RPE65 mutation-associated retinal dystrophy
- ZOLGENSMA ® is an AAV serotype 9 gene therapy for the treatment of pediatric patients less than 2 years of age having bi-all elic SMN1 mutation-associated spinal muscular atrophy (SMA).
- SMA spinal muscular atrophy
- the AAV capsid is selected from AAVI capsid, AAV8 capsid, or AAV9 capsid, or variants thereof.
- the AAV comprises an AAV capsid having one or substitutions of the amino acid tyrosine (Y) to the amino acid phenylalanine (F) on the surface of the capsid protein.
- the AAV capsid comprises an AAV capsid having one or more substitutions of the amino acid tyrosine (Y) to the amino acid phenylalanine (F) on the surface of the AAV capsid protein.
- AAV capsid having tyrosine to phenylalanine mutations are known in the art, as described for example in US 8445267, US 8802440, US 9157098, US 9611302, US 9775918, US 9920097, US 10011640, US 10294281, US 10723768, US 10815279, and US 10934327, each of which is incorporated by refence.
- the AAV capsid is an AAV capsid having substitutions selected from Y272F, Y444F, Y447F, T491 V, T494F, Y500F, Y730F, Y733F or a combination thereof.
- present invention comprises a method that mediates an immune response to the administration of a recombinant adeno-associated virus (rAAV) containing a nucleic acid encoding a therapeutic polypeptide, thereby increasing the efficacy and/or reducing the needed dosage of therapies that use vector deliveries.
- the rAAV comprises an AAV capsid and the nucleic acid sequence encoding the therapeutic polypeptide in the AAV capsid, wherein the nucleic acid sequence encoding the therapeutic polypeptide is operably linked to a promoter as described herein and AAV inverted terminal repeats (ITRs) required for packaging a nucleic acid into the capsid.
- ITRs AAV inverted terminal repeats
- the nucleic acid to be packaged comprises therapeutic polypeptide encoding nucleic acid sequences, promoter sequences, and optionally other regulatory sequences as described herein, which are flanked by packaging signals of the AAV genome to facilitate efficient packaging of the nucleic acid into the AAV capsid for delivery and expression in the target cell and/or organ.
- the nucleic acid sequence encoding the therapeutic polypeptide is flanked at the 5’ and 3’ ends by AAV ITRs.
- a 5’ AAV ITR, the nucleic acid sequence encoding the therapeutic polypeptide, and a 3’ AAV ITR comprise the nucleic acid that is packaged into the AAV capsid.
- the term “ITR” is defined as a cis genetic element responsible for facilitating the replication and packaging of a nucleic acid during AAV vector production necessary for rAAV generation.
- the ITRs are derived from a different AAV variant than the AAV capsid variant.
- the source of the ITRs are of one AAV variant and the AAV capsid is from another AAV variant, the resulting vector is defined as pseudotyped.
- the ITRs are derived from the AAV2 variant.
- the ITRs are derived from deleted, or shortened, version of the AAV2 variant (AITR).
- an AAV vector genome comprises an AAV 5’ ITR, a nucleic acid encoding a polypeptide operably linked to a promoter and optionally linked to one or more regulatory sequences, and an AAV 3’ ITR.
- scAAV selfcomplementary AAV
- the term “Self-complementary AAV” refers to a construct in which a coding nucleic acid sequence carried by an rAAV has been designed to form an intra-molecular double-stranded DNA template.
- the two complementary regions of scAAV Upon infection, rather than waiting for cell-mediated second strand synthesis, the two complementary regions of scAAV will associate to form one double stranded DNA (dsDNA) unit that is amenable to immediate replication and transcription.
- the ITRs to be used are selected from wild- type, full-length, engineered, shortened, deleted, or a combination thereof.
- An engineered AAV may be, without limitation, a pseudotyped AAV, a chimeric AAV capsid, a recombinant AAV capsid, or a “humanized” AAV capsid.
- a deleted, or shortened, version of the 5’ ITR termed 5’ AITR, has been described in which the D-sequence and terminal resolution sites (TRs) are deleted.
- the ITR comprises a shortened ITR of the AAV2 variant comprises 130 base pairs (bps), wherein the external “a” element is deleted.
- the shorted AAV2 ITR is lengthened during vector DNA amplification using the internal “a” element as a template.
- full-length AAV 5’ and 3’ ITRs are used.
- wild-type AAV 5’ and 3’ ITRs are used.
- engineered ITRs are used. Suitable AAV ITR sequences are known in the art (see, e.g., Yan et al., J Virol. 79(1):364- 379(2005), incorporated herein by reference).
- the nucleic acid to be packaged comprises one or more regulatory elements such that the total rAAV vector genome is about 2.0 to about 5.5 kilobases (kb) in size.
- the one or more regulatory sequences are selected such that the total rAAV vector genome is about 2.1, 2.3, 2.8, 3.1, 3.2, 3.3, 4.0 kb, 4.7 kb, or 5.2 kb in size.
- the rAAV vector genome approximates the size of a native AAV genome.
- the one or more regulatory sequences are selected such that the total rAAV vector genome is about 4.7 kb in size.
- the one or more regulatory sequences are selected such that the total rAAV vector genome is about 5.2 kb in size.
- the nucleic acid to be packaged comprises one or more regulatory elements selected from a promoter, a Woodchuck Hepatitis virus (WHP) posttranscriptional regulatory element (WPRE), a polyadenylation (poly A) signal, an intron, or a combination thereof.
- WP Woodchuck Hepatitis virus
- WPRE Woodchuck Hepatitis virus
- poly A polyadenylation
- the one or more regulatory elements are operably linked to the nucleic acid encoding a therapeutic polypeptide.
- a packaging cell line is used for production of a vector (e.g., a recombinant AAV).
- a host cell may be a prokaryotic or eukaryotic cell (e.g., human, insect, or yeast) that contains exogenous or heterologous DNA that has been introduced into the cell by any means, e.g., electroporation, calcium phosphate precipitation, microinjection, transformation, viral infection, transfection, liposome delivery, membrane fusion techniques, high velocity DNA- coated pellets, viral infection, and protoplast fusion.
- Examples of host cells may include, but are not limited to an isolated cell, a cell culture, an Escherichia coli cell, a yeast cell, a human cell, a non-human cell, a mammalian cell, a non-mammalian cell, an insect cell, a HEK-293 cell, a liver cell, a kidney cell, a cell of the central nervous system, a neuron, a glial cell, or a stem cell.
- the nucleic acid encoding a therapeutic polypeptide is optimized for expression in the desirable subject species, for example, in humans. Codon-optimized coding nucleic acid sequences can be designed by various different methods known to those skilled in the art.
- the entire length of the open reading frame (ORF) of the nucleic acid encoding a therapeutic polypeptide is modified.
- a fragment of the open reading frame (ORF) of the nucleic acid encoding a therapeutic polypeptide is modified.
- the nucleic acid encoding a therapeutic polypeptide is optimized for tropism towards the desirable target organ.
- the target organ is selected from muscle, eye, liver, brain, or a combination thereof.
- the nucleic acid encoding a therapeutic polypeptide is optimized for tropism towards the desirable target cell-type.
- target cell refers to any cell in which the expression of the therapeutic polypeptide is desired.
- the term “target cell” is intended to reference the cells of the subject being treated.
- the target cell-type is selected from neurons, glia, photoreceptors, retinal pigment epithelial (RPE) cells, hepatocytes, myocytes, skeletal muscle cells, heart cells, or a combination thereof.
- the AAV vector is formulated in a buffer/carrier suitable for infusion in a subject, for example a human subject.
- the viral vector e.g, rAAV
- the rAAV is delivered systemically.
- the rAAV is delivered intravenously, intraperitoneally, intranasally, or via inhalation.
- the buffer/carrier comprises a component that prevents the AAV from attaching to the infusion tube.
- the dosage of the vector is about 1 x 10 9 GC to about 1 x 10 13 genome copies (GC) per dose.
- the dose of the vector administered to a patient is at least about 1.0 x 10 9 GC/kg , about 1.5 x 10 9 GC/kg , about 2.0 x 10 9 GC/g, about 2.5 x 10 9 GC/kg , about 3.0 x 10 9 GC/kg , about 3.5 x 10 9 GC/kg , about 4.0 x 10 9 GC/kg , about 4.5 x 10 9 GC/kg , about 5.0 x 10 9 GC/kg , about 5.5 x 10 9 GC/kg , about 6.0 x 10 9 GC/kg , about 6.5 x 10 9 GC/kg , about 7.0 x 10 9 GC/kg , about 7.5 x 10 9 GC
- the AAV capsid includes variants which may include up to about 10% variation from any described or known AAV capsid sequence.
- the AAV capsid shares about 90% identity to about 99.9 % identity, about 95% to about 99% identity, or about 97% to about 98% identity to an AAV capsid provided herein and/or known in the art.
- the AAV capsid shares at least 95% identity with an AAV capsid.
- the comparison may be made over any of the variable proteins (e.g., vpl, vp2, or vp3).
- percent (%) identity in the context of nucleic acid sequences or amino acid sequences refers to the residues in the two sequences which are the same when aligned for correspondence. Unless otherwise specified, it is to be understood that a percentage of identity is a minimum level of identity and encompasses all higher levels of identity up to 100% identity to the reference sequence. For example, “95% identity” and “at least 95% identity” may be used interchangeably and include 95, 96, 97, 98, 99 up to 100% identity to the referenced sequence, and all fractions therebetween.
- the length of sequence identity comparison may be over the full-length of the genome, the full-length of a gene coding sequence, a fragment of a gene coding sequence, a fragment of at least about 500 to about 5000 nucleotides, the full-length of an amino acid sequence, a fragment of an amino acid sequence, a fragment of at least about 8 to about 200 amino acids, is desired.
- identity refers to “identity”, “homology”, or “similarity” between two different sequences, “identity”, “homology” or “similarity” is determined in reference to “aligned” sequences.
- Aligned sequences or “alignments” refer to more than one nucleic acid sequences or amino acid sequences, often containing corrections for missing or additional bases or amino acids as compared to a reference sequence.
- Multiple sequence alignment programs are also available for nucleic acid sequences and amino acid sequences. Examples of such programs include, “Clustal Omega”, “Clustal W”, “CAP Sequence Assembly”, “BLAST”, “MAP”, and “MEME”, which are accessible through Web Servers on the internet. Other sources for such programs are known to those skilled in the art.
- Non-viral delivery systems may also be used together with the present invention, for example a liposome, lipid nanoparticle, or other lipid formulations.
- a nucleic acid for delivery may be associated with a lipid.
- the nucleic acid associated with a lipid may be encapsulated in the aqueous interior of a liposome, interspersed within the lipid bilayer of a liposome, attached to a liposome via a linking molecule that is associated with both the liposome and the oligonucleotide, entrapped in a liposome, complexed with a liposome, dispersed in a solution containing a lipid, mixed with a lipid, combined with a lipid, contained as a suspension in a lipid, contained or complexed with a micelle, or otherwise associated with a lipid.
- the nucleic acid for delivery may be encapsulated in a lipid nanoparticle.
- Lipid nanoparticles can be comprised of a cationic lipid, an anionic lipid, a polyethylene glycol functionalized lipid, and steroids.
- Lipid, lipid/DNA or lipid/expression vector associated compositions are not limited to any particular structure in solution. For example, they may be present in a bilayer structure, as micelles, or with collapsed structure. They may also simply be interspersed in a solution, possibly forming aggregates that are not uniform in size or shape. Lipids are fatty substances which may be naturally occurring or synthetic lipids.
- lipids include the fatty droplets that naturally occur in the cytoplasm as well as the class of compounds which contain long-chain aliphatic hydrocarbons and their derivatives, such as fatty acids, alcohols, amines, amino alcohols, and aldehydes.
- the methods of the present invention mediate an immune response to any vector used for the delivery of therapeutics, thereby increasing the efficacy and/or reducing the needed dosage of therapies that use vector deliveries.
- the present invention comprises the use of an effective amount of an immunoglobulin degrading compound described herein, for example and IgG degrading compound, which is to be administered before, concurrently with, or after a vector for the delivery of a therapeutic polypeptide.
- Immunoglobulin G is the main type of antibody found in all body fluids (for example, blood and extracellular fluid) and protects against bacterial and viral infections. It represents approximately 75% of serum antibodies in humans and is thus the most common type of antibody found in circulation. IgG antibodies are generated following class switching and maturation of the antibody response, thus they participate predominantly in the secondary immune response.
- IgG antibodies frequently mediate a subject's response to therapies, diminishing the effectiveness of those therapies.
- IgG can be divided into 4 distinct subclasses: IgGl, IgG2, IgG3, & IgG4.
- the evolution of IgG subclass switches is regulated by interaction with T cells and follows a I-way direction: IgG3 to IgGl to IgG2 to IgG4.
- the differences between subclasses are mainly in their size and the configuration of the hinge region, glycosylation sites, and structures, as well as a few key amino acids that impact the ability to interact with complement and FC receptors.
- IgGl and IgG3 are monomeric, having 2 heavy chains & 2 light chains, and bivalent, having 2 variable regions.
- IgG2 has a disulfide bond pattern which allows for two monomeric IgG2 antibodies to form a dimeric and tetravalent structure through unique inter-molecule disulfide bonds.
- IgG4 has two intrachain disulfide bonds that can be reduced, which generates a monovalent structure.
- the monovalent structures can reform the disulfide bonds, but may not be the same IgG4 monovalent chain, meaning the resulting IgG4 will be a bivalent monomer but will have two different variable regions. Binding of IgG can be accomplished through the use of an IgG-specific ligand.
- the ligand may bind to the FC region of IgG.
- the IgG-specific ligand may be a Fc-binding peptide, such as a Fc-BP2.
- the IgG-specific ligand may be Fc-111. or a pharmaceutically acceptable salt thereof.
- the Protein Data Bank website provides the crystal structure of IgG searchable by 1H3X (Krapp, S., et al., J. Mol. Biol., 2003, 325: 979); and 5V43 (Lee, C.H., et al., Nat. Immunol., 2017, 18: 889-898); as well as the crystal structure of IgG bound to various compounds searchable by 5YC5 (Kiyoshi M., et al., Sci. Rep., 2018, 8: 3955-3955); 5XJE (Sakae Y., et al., Sci. Rep., 2017, 7: 13780-13780); 5GSQ (Chen, C. L., et al., ACS Chem.
- Kiyoshi, M., et al. provides insight into the structural basis for binding of human IgGl to its high-affinity human receptor FcyRI. (Kiyosi M., et al., Nat Commun., 2015, 6, 6866).
- IgG Targeting Ligands are provided in Fig. IB. Additional representative IgG Targeting Ligands include: wherein X R is O, S, NH, or N-C 1 -C 3 alkyl; and X M is O, S, NH, or N-C 1 -C 3 alkyl. In other embodiments the IgG Targeting Ligand is selected from: , In some embodiments, the IgG Targeting Ligand is a group according to the chemical structure: wherein R N02 is a dinitrophenyl group optionally linked through CH2, S(O), S(O)2, - S(O)2O, - OS(O)2, or OS(O)2O.
- the IgG Targeting Ligand is selected from: ted from O, CH2, NH, N-C1-C3 alkyl, NC(O)C1-C3 alkyl, S(O), S(O)2, -S(O) 2 O, - OS(O) 2 , or OS(O) 2 O.
- the IgG Targeting Ligand is a 3-indoleacetic acid group according to the chemical structure: where k”” is 1-4 (preferably 2-3, most often 3) or a group.
- the IgG Targeting Ligand is a peptide.
- Nonlimiting examples of IgG Targeting Ligand peptides include:
- PAM (RTY)4K2KG (Fassina, et al, J. Mol. Recognit. 1996, 9, 564-569) comprising SEQ ID NO: 1 RTYK and SEQ ID NO:2 RTYKKG
- D-PAM wherein the amino acids of the PAM sequence are all D-amino acids (Verdoliva, et al, J. Immunol. Methods, 2002, 271, 77-88) SEQ ID NO:3 RTYK (D-amino acids) and SEQ ID NO:4 RTYKKG (D-amino acids).
- D-RAM-F wherein the amino acids of the PAM sequence are all D-amino acids with further modifications wherein the four N-terminal arginines are acetylated with phenylacetic acid (Dinon, et al J. Mol. Recognit. 2011, 24, 1087-1094) SEQ ID NO:5 RTYK (D-amino acids, N- terminal arginine acetylated with phenylacetic acid) and SEQ ID NO: 6 RTYKKG (D-amino acids, N-terminal arginine acetylated with phenylacetic acid).
- SEQ ID NO:30 HWRGWV (Yang, et al., J Peptide Res. 2006, 66, 1 1 0-137)
- SEQ ID NO:31 HYFKFD (Yang, et al, J. Chromatogr. A 2009, 1216, 910-918)
- SEQ ID NO:32 HFRRHL (Menegatti, et al, J. Chromatogr. A 2016, 1445, 93-104)
- SEQ ID NO:33 HWCitGWV (Menegatti, et al, J. Chromatogr. A 2016, 1445, 93-
- SEQ ID NO:36 DAAG Mall Synthetic peptide ligand, Lund, et al, J. Chromatogr. A 2012, 1225, 158- 167;
- SEQ ID NO:37 cyclo[(Na-Ac) S(A)-RWHYFK-Lact-E] (Menegatti, et al, Anal. Chem. 2013, 85, 9229-9237);
- SEQ ID NO:38 cyclo[(Na-Ac)-Dap(A)-RWHYFK-Lact-E] (Menegatti, et al, Anal. Chem. 2013, 85, 9229-9237);
- SEQ ID NO:40 NKFRGKYK (Sugita, et al, Biochem. Eng. J. 2013, 79, 33-40); SEQ ID NO:41 NARKFYKG (Sugita, et al, Biochem. Eng. J. 2013, 79, 33-40); SEQ ID NO:42 FYWHCLDE (Zhao, et al, Biochem. Eng. J. 2014, 88, 1-11); SEQ ID NO:43 FYCHWALE (Zhao, et al, J Chromatogr. A 2014, 1355, 107-114); SEQ ID NO:44 FYCHTIDE (Zhao, et al., Z Chromatogr.
- the IgG Targeting Ligand is specific for IgG4.
- the IgG4 specific Targeting Ligand is described in Gunnarsson et al. Biomolecular Engineering 2006, 23, 111-117.
- the IgG4 specific targeting ligand is selected from SEQ ID NO : 55 FDLLEHFY and SEQ ID NO:56 DLLHHFDYF.
- Additional IgG Targeting Ligands include
- the immunoglobulin degrading compound is selected from: or a pharmaceutically acceptable salt thereof; or a pharmaceutically acceptable salt thereof;
- IgG degrading compounds include:
- a hydroxyl, amine, amide, or carboxylic acid group in an Immunoglobulin Targeting Ligand drawn herein is capped with a protecting group.
- a protecting group for example in this embodiment:
- an Immunoglobulin Targeting Ligand drawn herein is used as the attachment point to Linker instead of the drawn attachment point.
- the immunoglobulin degrading compound is selected from:
- the immunoglobulin degrading compound is selected from:
- the Immunoglobulin Targeting Ligand is: In certain embodiments the Immunoglobulin Targeting Ligand is:
- Immunoglobulin E (IgE)
- Immunoglobulin E is a strong mediator of allergic disease, including but not limited to, atopic asthma, allergic rhinitis, atopic dermatitis, cutaneous contact hypersensitivity, IgE- mediated food allergy, IgE-mediated animal allergies, allergic conjunctivitis, allergic urticaria, anaphylactic shock, nasal polyposis, keratoconjunctivitis, mastocytosis, eosinophilic gastrointestinal disease, bullous pemphigoid, chemotherapy induced hypersensitivity reaction, seasonal allergic rhinitis, interstitial cystitis, eosinophilic esophagitis, angioedema, acute interstitial nephritis, atopic eczema, eosinophilic bronchitis, chronic obstructive pulmonary disease, gastroenteritis, hyper-IgE syndrome (Job's Syndrome), IgE monoclonal gammopathy, monoclonal gammopathy, mono
- the immunoglobulin degrading compound is: or a pharmaceutically acceptable salt thereof.
- the immunoglobulin degrading compound is: or a pharmaceutically acceptable salt thereof. In certain embodiments the immunoglobulin degrading compound is: or a pharmaceutically acceptable salt thereof.
- the immunoglobulin degrading compound is: or a pharmaceutically acceptable salt thereof.
- the immunoglobulin degrading compound is: or a pharmaceutically acceptable salt thereof.
- the Immunoglobulin Targeting Ligand is:
- IgE degrading compounds include:
- Immunoglobulin A (IgA)
- IgA immunoglobulin A
- IgA nephropathy also known as Berger’s disease
- celiac disease also known as Berger’s disease
- HSP Henoch-Schonlein purpura
- IgA pemphigus IgA pemphigus
- dermatitis herpetiformis IgA herpetiformis
- IBD inflammatory bowel disease
- Sjogren's syndrome ankylosing spondylitis
- IgA multiple myeloma a-chain disease
- IgA monoclonal gammopathy monoclonal gammopathy of undetermined significance (MGUS)
- MGUS monoclonal gammopathy of undetermined significance
- IgA-specific Immunoglobulin Targeting Ligand used is an Opt peptide. Variations and derivatives of the IgA-specific Opt peptide suitable for use as IgA-specific Immunoglobulin Targeting Ligands are described in Hatanaka et al. Journal of Biological Chemistry , 287(57) 43126-43136. In certain embodiments, the IgA-specific Immunoglobulin Targeting Ligand is Opt-1. In certain embodiments, the IgA-specific
- Immunoglobulin Targeting Ligand is Opt-2.
- Immunoglobulin Targeting Ligand is Opt-3.
- the immunoglobulin degrading compound is: or a pharmaceutically acceptable salt thereof. In certain embodiments the immunoglobulin degrading compound is: or a pharmaceutically acceptable salt thereof.
- the immunoglobulin degrading compound is: or a pharmaceutically acceptable salt thereof.
- the Immunoglobulin Targeting Ligand is: .
- Linkers In non-limiting embodiments, Linker A and Linker B are independently selected from: ; wherein: R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , and R 20 are independently at each occurrence selected from the group consisting of a bond, alkyl, -C(O)-, -C(O)O-, -OC(O)-, -SO 2 -, -S(O)-, -C(S)-, -C(O)NR 6 -, -NR 6 C(O)-, -O-, -S-, -NR 6 -, -C(R 21 R 21 )-, -P(O)(R 3 )O-, -P(O)(R 3 )-, a divalent residue of a natural or unnatural amino acid, alkenyl, alkynyl,
- a divalent residue of an amino acid is selected from
- amino acid can be oriented in either direction and wherein the amino acid can be in the L- or D-form.
- a divalent residue of a dicarboxylic acid is generated from a nucleophilic addition reaction:
- xx is independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, and 25.
- yy is independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, and 25.
- a divalent residue of a dicarboxylic acid is generated from a condensation reaction:
- Non-limiting embodiments of a divalent residue of a saturated monocarboxylic acid is selected from butyric acid (-0C(0)(CH2)2CH2-), caproic acid (-0C(0)(CH2)4CH2-), caprylic acid (-0C(0)(CH2)5CH2-), capric acid (-0C(0)(CH2)8CH2-), lauric acid (-OC(0)(CH2)IOCH2-), myristic acid (-0C(0)(CH2)i2CH2-), pentadecanoic acid (-OC(O)(CH 2 ) 13 CH 2 -), palmitic acid (-OC(O)(CH 2 ) 14 CH 2 -), stearic acid (-OC(O)(CH 2 ) 16 CH 2 -), behenic acid (-OC(O)(CH2)20CH2-), and lignoceric acid (-OC(O)(CH2)22CH2-);
- Non-limiting embodiments of a divalent residue of a fatty acid include residues selected from linoleic
- Linker C is selected from: . wherein: R 22 is independently at each occurrence selected from the group consisting of alkyl, -C(O)N-, -NC(O)-, -N-, -C(R 21 )-, -P(O)O-, -P(O)-, -P(O)(NR 6 R 7 )N-, alkenyl, haloalkyl, aryl, heterocycle, and heteroaryl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 21 ; and the remaining variables are as defined herein.
- Linker D is selected from: ; wherein: R 32 is independently at each occurrence selected from the group consisting of alkyl, N + X " , -C-, alkenyl, haloalkyl, aryl, heterocycle, and heteroaryl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 21 ;
- X- is an anionic group, for example Br- or Cl -; and all other variables are as defined herein.
- Linker A is selected from: each of which is optionally substituted with 1, 2, 3, or 4 optional substituents as defined herein.
- Linker A is selected from: each of which is optionally substituted with 1, 2, 3, or 4 optional substituents as defined herein. In certain embodiments Linker A is selected from: each of which is optionally substituted with 1, 2, 3, or 4 optional substituents as defined herein.
- Linker A is selected from: each of which is optionally substituted with 1, 2, 3, or 4 optional substituents as defined herein.
- Linker A is selected from: each of which is optionally substituted with 1, 2, 3, or 4 optional substituents as defined herein.
- Linker A is selected from: each of which is optionally substituted with 1, 2, 3, or 4 optional substituents as defined herein.
- Linker A is selected from: wherein each heteroaryl, heterocycle, cycloalkyl, and aryl can optionally be substituted with 1, 2, 3, or 4 of any combination of halogen, alkyl, haloalkyl, aryl, heteroaryl, heterocycle, or cycloalkyl, as allowed by valence.
- Linker A is selected from: wherein each heteroaryl, heterocycle, cycloalkyl, and aryl can optionally be substituted with 1, 2, 3, or 4 of any combination of halogen, alkyl, haloalkyl, aryl, heteroaryl, heterocycle, or cycloalkyl, as allowed by valence.
- Linker A is selected from: wherein each heteroaryl, heterocycle, cycloalkyl, and aryl can optionally be substituted with 1, 2, 3, or 4 of any combination of halogen, alkyl, haloalkyl, aryl, heteroaryl, heterocycle, or cycloalkyl, as allowed by valence.
- Linker B , Linker C , or Linker D is selected from: wherein tt is independently selected from 1, 2, or 3 and ss is 3 minus tt. In certain embodiments Linker B , Linker C , or Linker B is selected from: wherein tt and ss are as defined herein.
- Linker B is selected from:
- each heteroaryl, heterocycle, cycloalkyl, and aryl can optionally be substituted with 1, 2, 3, or 4 of any combination of halogen, alkyl, haloalkyl, aryl, heteroaryl, heterocycle, or cycloalkyl, as allowed by valence; and tt and ss are as defined herein.
- Linker B is selected from: wo 2023/009554
- each heteroaryl, heterocycle, cycloalkyl, and aryl can optionally be substituted with 1, 2, 3, or 4 of any combination of halogen, alkyl, haloalkyl, aryl, heteroaryl, heterocycle, or cycloalkyl, as allowed by valence; and tt and ss are as defined herein.
- Linker B is selected from: wherein each heteroaryl and aryl can optionally be substituted with 1, 2, 3, or 4 of any combination of halogen, alkyl, haloalkyl, aryl, heteroaryl, heterocycle, or cycloalkyl, as allowed by valence; and tt and ss are as defined herein.
- Linker A is selected from: In certain embodiments Linker B is selected from:
- the Linker A is selected from
- Linker A is selected from wherein each is optionally substituted with 1, 2, 3, or 4 substituents substituent selected from R 21 . In certain embodiments Linker A is selected from:
- Linker A is selected from: In certain embodiments Linker A is selected from:
- Linker A is selected from: In certain embodiments Linker A is selected from:
- the Linker B is selected from
- the Linker B is selected from
- the Linker B is selected from wherein each is optionally substituted with 1, 2, 3, or 4 substituents substituent selected from R 21 .
- Linker B is selected from: In certain embodiments Linker B is selected from:
- Linker B -Linker A is selected from: In certain embodiments Linker B -Linker A is selected from:
- the Linker C is selected from
- the Linker C is selected from In certain embodiments, the Linker C is selected from
- Linker c -(Linker A ) 2 is selected from: In certain embodiments Linker c -(Linker A ) 2 is selected from: In certain embodiments Linker c -(Linker A ) 2 is selected from:
- the Linker D is selected from
- the Linker D is selected from In certain embodiments, the Linker D is selected from wherein each is optionally substituted with 1, 2, 3, or 4 substituents are selected from R 21 . In certain embodiments, Linker B -(Linker A ) is selected from In certain embodiments, Linker°-(Linker A ) is selected from
- Linker B is selected from: wherein each heteroaryl, heterocycle, cycloalkyl, and aryl can optionally be substituted with 1, 2, 3, or 4 of any combination of halogen, alkyl, haloalkyl, aryl, heteroaryl, heterocycle, or cycloalkyl, as allowed by valence. In certain embodiments Linker B is selected from: wherein each heteroaryl, heterocycle, cycloalkyl, and aryl can optionally be substituted with 1, 2, 3, or 4 of any combination of halogen, alkyl, haloalkyl, aryl, heteroaryl, heterocycle, or cycloalkyl, as allowed by valence.
- Linker B is selected from: wherein each heteroaryl, heterocycle, cycloalkyl, and aryl can optionally be substituted with 1, 2, 3, or 4 of any combination of halogen, alkyl, haloalkyl, aryl, heteroaryl, heterocycle, or cycloalkyl, as allowed by valence.
- Linker B is selected from:
- each heteroaryl, heterocycle, cycloalkyl, and aryl can optionally be substituted with 1, 2, 3, or 4 of any combination of halogen, alkyl, haloalkyl, aryl, heteroaryl, heterocycle, or cycloalkyl, as allowed by valence.
- Linker A is selected from: each of which is substituted with 1 or 2 optional substituents .
- Linker A is bond
- Linker A is attached to the ASGPR Binding Ligand and the right side is attached to Linker B , Linker C , or Linker D .
- the right side of Linker A is attached to the ASGPR Binding Ligand and the right side is attached to Linker B , Linker C , or Linker D .
- the left side of Linker B is attached to the Extracellular Targeting Ligand and the right side is attached to Linker A .
- the right side of Linker B is attached to the Extracellular Targeting Ligand and the left side is attached to Linker A .
- Linker B is bond
- a linker is provided as described above wherein a , replaced with a for example where Linker B is drawn as it is in this embodiment.
- a linker is provided as described above wherein a is replaced with a , for example where Linker B is drawn as this embodiment.
- a linker is provided as described above wherein a is replaced with a
- the asialoglycoprotein receptor is a Ca 2 +-dependent receptor.
- the primary endogenous role of ASGPRs is to help regulate serum glycoprotein levels by mediating endocytosis of glycoproteins.
- the receptor binds ligands with a terminal galactose or N- acetylgalactosamine.
- the C 3 - and C 4 - hydroxyl groups bind to Ca 2 +, with the N-acetyl position also been considered important to binding activity.
- Asialoglycoproteins bind to ASGPRs and are then cleared by receptor-mediated endocytosis.
- the receptor and the protein are dissociated in the acidic endosomal compartment and the protein is eventually degraded by lysosomes.
- the receptor is endocytosed and recycled constitutively from the endosome back to the plasma membrane about every 1 5 minutes regardless of whether or not a glycoprotein is bound. Internalization rate of the receptor may be altered by presence of a bound ligand.
- the ligand of the immunoglobulin degrading compound that binds to ASGPR may be an asialoglycoprotein or a derivative thereof.
- the ASGPR is comprised of two homologous subunits known as HI and H2. Various ratios of HI and H2 form functional homo- and hetero-oligomers with different conformations, but the most abundant conformation is a trimer composed of two HI and one H2 subunits.
- the ASGPR is composed of a cytoplasmic domain, a transmembrane domain, a stalk region, and a carbohydrate recognition domain (CRD). Both the HI and H2 subunit form the CRD, and expression of both subunits mediates endocytosis of asialoglycoproteins.
- ASGPRs are primarily expressed on hepatocytes, and hepatocytes exhibit a high exposition of ASGPR binding cites (approximately 100,000 — 500,000 binding sites per cell).
- any ligand of ASGPR may be used in immunoglobulin degrading compounds of the invention.
- ligands that may be used with the invention are described in Stokmaier, Bioorg. Med. Chem., 2009, 17, 7254, which describes the synthesis of a series of D-GalNAc derivatives where the anomeric OH group is removed and the acetamido group is replaced with a 4-substituted 1,2, 3 -triazole moiety, and Mamidyala, JACS, 2012, 134, 1978, which describes compounds derived from 2-azidogalactosyl analogs where the anomeric position is occupied by either a B-methyl or a B-4-methoxy-phenyl group and the azide group is replaced with an amide or a triazole, the entirety of the contest of each of which are incorporated by reference herein.
- ASGPR ligands that may be used with the invention are described in PCT Application No. PCT/US21/15939, filed January 29, 2021, and U.S. Provisional Application No. 63/183,450, filed May 3, 2021, the entirety of the contents of each of which are incorporated by reference herein.
- the ASGPR ligand may include derivatives of six-carbon pyranose moieties, specifically galactose and talose. These two sugars differ in the stereochemistry of the C 2 substituent.
- the "down" C 2 configuration corresponds to the stereochemistry of galactose, while the C 2 substituent in the "up” configuration corresponds to the stereochemistry oftalose.
- substituents may be at the C 2 position of the two sugars.
- the immunoglobulin degrading compounds may utilize a 2:1 ratio of ASGPR ligands to antibody binding ligands. Multiple ASGPR ligands may bind ASGPR more tightly and have increased degradation efficacy.
- the immunoglobulin degrading compounds may have a 1:1 ratio of ASGPR binding ligands to antibody binding ligands.
- the compounds may utilize a heteroaryl amine substituents at the C 2 position. The substituents may increase efficacy of the ligand, preferable in compounds with a 1:1 ratio of ASGPR ligand to antibody ligand.
- the immunoglobulin degrading molecule is:
- the immunoglobulin degrading molecule is: or a pharmaceutically acceptable salt thereof.
- immunoglobulin degrading compounds may comprise a ligand that binds to IgG, for example an FC binding peptide, for example Fc-111, Fc-BP2, or derivatives thereof that bind the FC portion of the antibody and thus facilitate the selective recruitment of antibody to hepatocytes for degradation
- immunoglobulin degrading compounds may comprise a ligand that binds to IgA, for example an FC binding peptide, for example an Opt class of peptides.
- Opt class peptides are advantageous in that they are highly selective for IgA and thus facilitate the selective recruitment of IgA to hepatocytes for degradation.
- the immunoglobulin degrading molecule may be. or a pharmaceutically acceptable salt thereof.
- the immunoglobulin degrading molecule of the present invention may be provided as an isotopically enriched immunoglobulin degrading molecule with at least one desired isotopic substitution of an atom, at an amount above the natural abundance of the isotope.
- deuterium can replace one or more hydrogens in the bispecific compound and 13 c can replace one or more carbon atoms.
- the isotopic substitution is in one or more positions of the ASGPR ligand.
- the isotopic substitution is in one or more positions of a linker portion of the molecule.
- the isotopic substitution is in the antibody ligand portion of the molecule.
- the ASGPR ligand may be a molecule according to the Formula IV, Formula V, Formula
- R 1 and R 5 are independently selected from hydrogen, heteroalkyl, C0-C6alkyl-cyano, alkyl, alkenyl, alkynyl, haloalkyl, F, Cl, Br, I, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, heterocycloalkyl, haloalkoxy, C 0 -C 6 alkyl-OR 6 , C 0 -C 6 alkyl-SR 6 , C 0 -C 6 alkyl-NR 6 R 7 , C 0 -C 6 alkyl-C(O)R 3 , C 0 -C 6 alkyl-S(O)R 3 , C 0 -C 6 alkyl-C(S)R 3 , C 0 -C 6 alkyl- S(O)2R 3 , C0-C6alkyl-N(R 8 )-C(
- the ASGPR Binding Ligand is of Formula: or a pharmaceutically acceptable salt thereof.
- the ASGPR ligand or ASGPR ligand-Linker- may be a compound according to the Formula:
- ASGPR ligands and ASGPR ligand-Linkers are typically attached to the Immunoglobulin Targeting Ligand through the C6 position.
- the ASGPR ligand or ASGPR ligand-Linker is a compound of Formula:
- the ASGPR ligand is of structure:
- the ASGPR ligand is of structure:
- the ASGPR ligand is of structure:
- the ASGPR ligand is of structure: Compositions and administration
- heterobifunctional extracellular immunoglobulin degrading compound for use in the present invention or a pharmaceutically acceptable salt, solvate or prodrug thereof as disclosed herein can be administered as a pharmaceutical composition that includes an effective amount for a subject in need of such treatment to mediate the subject’s immune response to a therapy.
- the present invention provides a treatment regimen for use in mediating a subject’s immune response to a cell, gene or biologies therapy that includes administration of an effective amount of a pharmaceutical composition comprising an immunoglobulin degrading bifunctional molecule of the present invention or a pharmaceutically acceptable composition, salt, isotopic analog such as a deuterated derivative, or prodrug thereof, and a pharmaceutically acceptable excipient.
- a pharmaceutical composition comprising an immunoglobulin degrading bifunctional molecule of the present invention or a pharmaceutically acceptable composition, salt, isotopic analog such as a deuterated derivative, or prodrug thereof, and a pharmaceutically acceptable excipient.
- the cell, gene, or biologies therapy and heterobifunctional immunoglobulin degrading molecule is present in an effective amount, for example a therapeutically effective amount or a prophylactically effective amount.
- the heterobifunctional immunoglobulin degrading molecule mediates the subject's immune response, the effective amount of the therapeutic to be delivered may be reduced.
- the treatment regimen of the present invention that includes administering an effective amount of therapeutics and/or immunoglobulin degrading molecules can be administered in any manner that allows the immunoglobulin degrading molecule to bind to the immunoglobulin, typically in the blood stream, and carry it to the ASGPR-bearing hepatocyte cells on the liver for endocytosis and degradation.
- Methods to deliver the therapeutics and immunoglobulin degrading molecules of the present invention may include oral, intravenous, sublingual, subcutaneous, parenteral, buccal, rectal, intra-aortal, intracranial, subdermal or transnasal, or by other means, in dosage unit formulations containing one or more conventional pharmaceutically acceptable carriers, as appropriate.
- the treatment regimen of the present invention includes administering an effective amount of therapeutics and/or immunoglobulin degrading molecules which may be administered intravenously.
- the therapeutics and/or immunoglobulin degrading molecule may be formulated in a liquid dosage form for intravenous injection, such as a buffered solution, for example a phosphate buffered solution and saline buffered solution. The solution may be buffered with multiple salts.
- the treatment regimen of the present invention includes administering an effective amount of therapeutics and/or immunoglobulin degrading molecule which may be administered orally.
- the therapeutics and/or immunoglobulin degrading molecule may be formulated in capsules, tablets, and powders, for example a gel containing capsule.
- the treatment regimen of the present invention includes administering an effective amount of therapeutics and/or heterobifunctional immunoglobulin degrading molecule which may be administered subcutaneously.
- the therapeutics and immunoglobulin degrading molecule may be formulated in a liquid dosage form for subcutaneous injection, such as a buffered solution, for example a phosphate buffered solution and saline buffered solution.
- the solution may be buffered with multiple salts.
- a pharmaceutically acceptable salt means a salt of the described therapeutics and/or heterobifunctional immunoglobulin degrading molecule which is suitable for administration to a subject without undue toxicity, irritation, or allergic response, and commensurate with a reasonable benefit to risk ratio, and effective for its intended use.
- a pharmaceutically acceptable salt means a relatively nontoxic, inorganic and organic acid addition salts of the presently disclosed therapeutics and/or immunoglobulin degrading molecules.
- salts can be prepared during the final isolation and purification of the therapeutics and/or immunoglobulin degrading molecules or by separately reacting the purified therapeutics and/or immunoglobulin degrading molecule in its free form with a suitable organic or inorganic acid and then isolating the salt thus formed.
- Acid addition salts of the basic therapeutics and/or immunoglobulin degrading molecules are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner.
- the free base form can be regenerated by contacting the salt form with a base and isolating the free base in the conventional manner.
- the free base forms may differ from their respective salt forms in certain physical properties such as solubility in polar solvents.
- Pharmaceutically acceptable base addition salts may be formed with metals or amines, such as alkali and alkaline earth metal hydroxides, or of organic amines.
- metals used as cations include, but are not limited to, sodium, potassium, magnesium, calcium, and the like.
- suitable amines include, but are not limited to, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine, and procaine.
- the base addition salts of acidic therapeutics and/or immunoglobulin degrading molecules are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner.
- the free acid form can be regenerated by contacting the salt form with an acid and isolating the free acid in a conventional manner.
- the free acid forms may differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents.
- Salts can be prepared from inorganic acids sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, phosphorus, and the like.
- Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate mesylate, glucoheptonate, lactobionate, laurylsulphonate and isethionate salts, and the like.
- Salts can also be prepared from organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl -substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. and the like.
- organic acids such as aliphatic mono- and dicarboxylic acids, phenyl -substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. and the like.
- Representative salts include acetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenyl acetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like.
- Pharmaceutically acceptable salts can include cations based on the alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium and the like, as well as non-toxic ammonium, quaternary ammonium, and amine cations including, but not limited to, ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. Also contemplated are the salts of amino acids such as arginate, gluconate, galacturonate, and the like. See, for example, Berge et ah, J. Pharm. Sci., 1977, 66, 1-19, which is incorporated herein by reference.
- compositions include inert diluents, dispersing and/or granulating agents, surface active agents and/or emulsifiers, disintegrating agents, binding agents, preservatives, buffering agents, lubricating agents, and/or oils. Additional acceptable excipients include cocoa butter and suppository waxes, coloring agents, coating agents, sweetening, flavoring, perfuming agents, etc., and combinations thereof.
- Diluents may include calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, etc., and combinations thereof.
- Granulating and/or dispersing agents may include potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponge, cation — exchange resins, calcium carbonate, silicates, sodium carbonate, cross — linked poly(vinyl — pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross — linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (Veegum), sodium lauryl sulfate, quaternary ammonium compounds, etc., and combinations thereof.
- Surface active agents and/or emulsifiers may include natural emulsifiers (e.g. acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g. bentonite [aluminum silicate] and Veegum [magnesium aluminum silicate]), long chain amino acid derivatives, high molecular weight alcohols (e.g.
- natural emulsifiers e.g. acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin
- colloidal clays e.g. bentonite [aluminum silicate] and Veegum [magnes
- stearyl alcohol cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g. carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxyvinyl polymer), carrageenan, cellulosic derivatives (e.g. carboxymethylcellulose sodium, powdered cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose), sorbitan fatty acid esters (e.g.
- polyoxyethylene monostearate [Myij 45], polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and Solutol), sucrose fatty acid esters, polyethylene glycol fatty acid esters (e.g., Cremophor), polyoxyethylene ethers, (e.g .
- Binding agents may include starch (e.g. cornstarch and starch paste), gelatin, sugars (e.g.
- natural and synthetic gums e.g. acacia, sodium alginate, extract of Irish moss,
- Preservatives may include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives, etc., and/or combinations thereof.
- Antioxidants may include alpha tocopherol, ascorbic acid, acorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabi sulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabi sulfite, and sodium sulfite.
- the pharmaceutical composition is in a dosage form that contains from about 0.1 mg to about 1500 mg, from about 10 mg to about 1000 mg, from about 100 mg to about 800 mg, or from about 200 mg to about 600 mg of the active immunoglobulin degrading molecule and optionally from about 0.1 mg to about 1500 mg, from about 10 mg to about 1000 mg, from about 100 mg to about 800 mg, or from about 200 mg to about 600 mg of an additional active agent in a unit dosage form.
- Examples are dosage forms with at least about 0.1, 1, 5, 10, 25, 50, 100, 200, 250, 300, 400, 500, 600, 700, 750, 800, 850, 900, 950, or 1,000 mg of active immunoglobulin degrading molecule, or its salt.
- the dosage form has at most about 0.1, 1, 5, 10, 25, 50, 100, 200, 250, 300, 400, 500, 600, 700, 750, 800, 850, 900, 950, or 1,000 mg of active immunoglobulin degrading molecule, or its salt.
- the dose ranges from about 0.01-100 mg/kg of patient bodyweight, for example about 0.01 mg/kg, about 0.05 mg/kg, about 0. 1 mg/kg, about 0.5 mg/kg, about 1 mg/kg, about 1.5 mg/kg, about 2 mg/kg, about 2.5 mg/kg, about 3 mg/kg, about 3.5 mg/kg, about 4 mg/kg, about 4.5 mg/kg, about 5 mg/kg, about 110 mg/kg, about 115 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65 mg/kg, about 70 mg/kg, about 75 mg/kg, about 80 mg/kg, about 85 mg/kg, about 90 mg/kg, about 95 mg/kg, or about 100 mg/kg.
- heterobifunctional immunoglobulin degrading molecules disclosed herein are used as described are administered once a day (QD), twice a day (BID), or three times a day (TID).
- immunoglobulin degrading molecules disclosed herein are used as described are administered at least once a day for at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, at least 14 days, at least
- the heterobifunctional immunoglobulin degrading molecule is administered once a day, twice a day, three times a day, or four times a day.
- the pharmaceutical composition may be formulated as any pharmaceutically useful form, for example, a pill, capsule, tablet, an injection or infusion solution, a syrup, an inhalation formulation, a suppository, a buccal or sublingual formulation, a parenteral formulation, or in a medical device.
- Some dosage forms, such as tablets and capsules, can be subdivided into suitably sized unit doses containing appropriate quantities of the active components, e.g., an effective amount to achieve the desired purpose.
- Carriers include excipients and diluents and must be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the patient being treated.
- the carrier can be inert, or it can possess pharmaceutical benefits of its own.
- the amount of carrier employed in conjunction with the therapeutics and/or immunoglobulin degrading molecule is sufficient to provide a practical quantity of material for administration per unit dose of the therapeutics and/or immunoglobulin degrading molecule. If provided as in a liquid, it can be a solution or a suspension.
- Representative carriers include phosphate buffered saline, water, solvent(s), diluents, pH modifying agents, preservatives, antioxidants, suspending agents, wetting agent, viscosity agents, tonicity agents, stabilizing agents, and combinations thereof.
- the carrier is an aqueous carrier.
- aqueous carries include, but are not limited to, an aqueous solution or suspension, such as saline, plasma, bone marrow aspirate, buffers, such as Hank's Buffered Salt Solution (HBSS), HEPES (4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid), Ringers buffer, ProVisc@, diluted ProVisc@, Provisc@ diluted with PBS, Krebs buffer, Dulbecco's PBS, normal PBS, sodium hyaluronate solution (HA, 5 mg/mL in PBS), citrate buffer, simulated body fluids, plasma platelet concentrate and tissue culture medium or an aqueous solution or suspension comprising an organic solvent.
- HBSS Hank's Buffered Salt Solution
- HEPES 4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid
- Ringers buffer such as Hank's Buffered Salt Solution (HBSS), HEPES (4-(2-
- Acceptable solutions include, for example, water, Ringer' s solution and isotonic sodium chloride solutions.
- the formulation may also be a sterile solution, suspension, or emulsion in a non-toxic diluent or solvent such as 1,3-butanediol.
- Viscosity agents may be added to the pharmaceutical composition to increase the viscosity of the composition as desired.
- useful viscosity agents include, but are not limited to, hyaluronic acid, sodium hyaluronate, carbomers, polyacrylic acid, cellulosic derivatives, polycarbophil, polyvinylpyrrolidone, gelatin, dextin, polysaccharides, polyacrylamide, polyvinyl alcohol (including partially hydrolyzed polyvinyl acetate), polyvinyl acetate, derivatives thereof and mixtures thereof.
- Solutions, suspensions, or emulsions for administration may be buffered with an effective amount necessary to maintain a pH suitable for the selected administration.
- Suitable buffers are well known by those skilled in the art. Some examples of useful buffers are acetate, borate, carbonate, citrate, and phosphate buffers.
- Solutions, suspensions, or emulsions for topical, for example, ocular administration may also contain one or more tonicity agents to adjust the isotonic range of the formulation. Suitable tonicity agents are well known in the art. Some examples include glycerin, mannitol, sorbitol, sodium chloride, and other electrolytes.
- Classes of carriers include, but are not limited to binders, buffering agents, coloring agents, diluents, disintegrants, emulsifiers, flavorants, glidants, lubricants, preservatives, stabilizers, surfactants, tableting agents, and wetting agents.
- Some carriers may be listed in more than one class, for example vegetable oil may be used as a lubricant in some formulations and a diluent in others.
- Exemplary pharmaceutically acceptable carriers include sugars, starches, celluloses, powdered tragacanth, malt, gelatin, talc, and vegetable oils.
- Optional active agents may be included in a pharmaceutical composition, which do not substantially interfere with the activity of the therapeutics and/or immunoglobulin degrading molecule of the present invention.
- the pharmaceutical compositions/combinations can be formulated for oral administration. These compositions can contain any amount of active therapeutics and/or immunoglobulin degrading molecule that achieves the desired result, for example between 0.1 and 99 weight % (wt.%) of the therapeutics and/or immunoglobulin degrading molecule and usually at least about 5 wt.% of the therapeutics and/or immunoglobulin degrading molecule. Some embodiments contain from about 25 wt. % to about 50 wt. % or from about 5 wt. % to about 75 wt. % of the therapeutics and/or immunoglobulin degrading molecule. Enteric coated oral tablets may also be used to enhance bioavailability of the therapeutics and/or immunoglobulin degrading molecules for an oral route of administration.
- Formulations suitable for rectal administration are typically presented as unit dose suppositories. These may be prepared by admixing the active therapeutics and/or immunoglobulin degrading molecule with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.
- conventional solid carriers for example, cocoa butter
- Therapeutics and/or immunoglobulin degrading molecules and pharmaceutically acceptable composition, salts, isotopic analogs, or prodrugs thereof may be formulated in dosage unit form for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of the compositions comprising a therapeutics and/or immunoglobulin degrading molecule as described herein will be decided by the attending physician within the scope of sound medical judgment.
- the specific therapeutically effective dose level for any particular subject or organism will depend upon a variety of factors including the disease, disorder, or condition being treated and the severity of the disorder; the activity of the specific therapeutics and/or immunoglobulin degrading molecule employed; the specific composition employed; the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific therapeutics and/or immunoglobulin degrading molecule employed; the duration of the treatment; drugs used in combination or coincidental with the specific therapeutics and/or immunoglobulin degrading molecule employed; and like factors well known in the medical arts.
- the therapeutics and/or immunoglobulin degrading molecules and compositions provided herein can be administered by any route, including enteral (e.g., oral), parenteral, intravenous, intramuscular, intra — arterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal, topical (as by powders, ointments, creams, and/or drops), mucosal, nasal, buccal, sublingual; by intratracheal instillation, bronchial instillation, and/or inhalation; and/or as an oral spray, nasal spray, and/or aerosol.
- enteral e.g., oral
- parenteral intravenous, intramuscular, intra — arterial, intramedullary
- intrathecal subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal
- topical as by powders, ointments, creams, and/
- Specifically contemplated routes are oral administration, intravenous administration (e.g., systemic intravenous injection), regional administration via blood and/or lymph supply, and/or direct administration to an affected site.
- intravenous administration e.g., systemic intravenous injection
- regional administration via blood and/or lymph supply
- direct administration to an affected site.
- the most appropriate route of administration will depend upon a variety of factors including the nature of the agent (e.g., its stability in the environment of the gastrointestinal tract), the condition of the subject (e.g., whether the subject is able to tolerate oral administration).
- the exact amount of the therapeutic and/or immunoglobulin degrading molecule required to achieve an effective amount will vary from subject to subject, depending, for example, on species, age, and general condition of a subject, severity of the side effects or disorder, identity of the particular therapeutics and/or immunoglobulin degrading molecule(s), mode of administration, and the like.
- the desired dosage can be delivered using any frequency determined to be useful by the health care provider, including three times a day, two times a day, once a day, every other day, every third day, every week, every two weeks, every three weeks, or every four weeks.
- the desired dosage can be delivered using multiple administrations (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more administrations).
- therapeutics and/or immunoglobulin degrading molecules or compositions can be administered in combination with one or more additional therapeutically active agents.
- the therapeutics and/or immunoglobulin degrading molecules or compositions can be administered in combination with additional therapeutically active agents that improve their bioavailability, reduce and/or modify their metabolism, inhibit their excretion, and/or modify their distribution within the body.
- the therapy employed may achieve a desired effect for the same disorder (for example, a therapeutic and/or immunoglobulin degrading molecule can be administered in combination with an anti — inflammatory agent, anti — cancer agent, immunosuppressant, etc.), and/or it may achieve different effects (e.g., control of adverse side — effects, e.g., emesis controlled by an antiemetic).
- the therapeutics and/or immunoglobulin degrading molecule or composition can be administered concurrently with, prior to, or subsequent to, one or more additional therapeutically active agents.
- each agent will be administered at a dose and/or on a time schedule determined for that agent.
- the additional therapeutically active agent utilized in this combination can be administered together in a single composition or administered separately in different compositions.
- the particular combination to employ in a regimen will take into account compatibility of the inventive therapeutics and/or immunoglobulin degrading molecule with the additional therapeutically active agent and/or the desired therapeutic effect to be achieved.
- additional therapeutically active agents utilized in combination be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination will be lower than those utilized individually.
- Additional therapeutically active agents may include, but are not limited to, small organic molecules such as drug compounds (e.g., compounds approved by the Food and Drugs Administration as provided in the Code of Federal Regulations (CFR)), peptides, proteins, carbohydrates, monosaccharides, oligosaccharides, polysaccharides, nucleoproteins, mucoproteins, lipoproteins, synthetic polypeptides or proteins, small molecules linked to proteins, glycoproteins, steroids, nucleic acids, DNAs, RNAs, nucleotides, nucleosides, oligonucleotides, antisense oligonucleotides, lipids, hormones, vitamins and cells.
- the additional therapeutically active agent is an anti -cancer agent, e.g., radiation therapy and/or one or more chemotherapeutic agents.
- a treatment regimen comprising the administration of a therapeutic and/or immunoglobulin degrading molecule of the present invention or a pharmaceutically acceptable composition, salt, isotopic analog (such as a deuterated derivative), or prodrug thereof in combination or in alternation with at least one additional therapeutic agent.
- the combinations and/or alternations can be administered for beneficial, additive, or synergistic effect in the treatment of immunoglobulin-mediated disorders.
- the methods of the present invention mediate an immune response to any additional excipient or combinations used for the delivery of the therapeutics or the immunoglobulin degrading molecule by the action of the immunoglobulin degrading molecule itself.
- a method for administering a therapy comprising: sequestering immunoglobulin G (IgG) in a subject so that a therapy can be initiated and readministered to the subject and produce a therapeutic effect in the subject that would not otherwise be achieved due to IgG interacting with the therapy.
- IgG immunoglobulin G
- a method for administering a therapy comprising: providing to a subject an immunoglobulin degrading compound comprising a first ligand configured to bind IgG, and a second ligand configured to bind an asialoglycoprotein receptor (ASGPR), to thereby sequester and degrade immunoglobulin G (IgG) in the subject so that a therapy can be re-administered to the subject and produce a therapeutic effect in the subject that would not otherwise be achieved due to IgG interacting with the therapy.
- an immunoglobulin degrading compound comprising a first ligand configured to bind IgG, and a second ligand configured to bind an asialoglycoprotein receptor (ASGPR), to thereby sequester and degrade immunoglobulin G (IgG) in the subject so that a therapy can be re-administered to the subject and produce a therapeutic effect in the subject that would not otherwise be achieved due to IgG interacting with the therapy.
- the viral vector is an adenovirus-associated virus (AAV) vector.
- AAV adenovirus-associated virus
Abstract
This invention provides methods to modulate an immune response to a therapeutic, for example gene therapy, by administering an immunoglobulin degrading molecule that has an asialoglycoprotein receptor (ASGPR) Binding Ligand bound to an Immunoglobulin Targeting Ligand or a pharmaceutically acceptable salt thereof.
Description
METHODS TO REDUCE THE ADVERSE EFFECTS OF GENE OR BIOLOGICS THERAPY
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of U.S. Provisional Application No. 63/225,746, filed July 26, 2021, the entirety of which is hereby incorporated by reference for all purposes.
FIELD OF THE INVENTION
This invention provides methods to modulate an immune response to a therapeutic, for example gene therapy, by administering an immunoglobulin degrading molecule that has an asialoglycoprotein receptor (ASGPR) Binding Ligand bound to an Immunoglobulin Targeting Ligand or a pharmaceutically acceptable salt thereof.
INCORPORATION BY REFERENCE
The contents of the text file named “19121-010W01_SequenceListing_ST26” which was created on July 25, 2022 and is 59.2 KB in size, are hereby incorporated by reference in their entirety.
BACKGROUND OF THE INVENTION
Recent medical advances have resulted in novel and improved biological agents useful to treat a host of maladies that affect humans. Biological agents are structurally immunogenic, and therefore usually elicit a minor, subclinical and transient phenomenon (see, e.g., Vande Casteele et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterology 2013; 108: 962-971). While immune responses to drug products such as vaccines may be desirable, when a therapeutic protein or viral vector elicits an unwanted immune response, the safety and efficacy of the biologic drug can be adversely affected.
Occasionaly, complete inhibition of the biological effects of the drug may occur. Additional serious consequences include the development of serious adverse immune reactions (e.g., anaphylaxis), and autoimmune-like outcomes when endogenous human proteins are targeted by anti-drug antibodies (ADAs).
Elevated immune responses to treatments has been most prevalent in gene therapies and recombinant therapeutic protein treatments, mitigating a promising area of medical advancement
for a number of disorders. For example, many gene therapies rely on viral vectors, such as adenovirus vectors and adeno-associated virus vectors (AAV), for delivering gene therapy targets to cells. Many patients have pre-existing immunity to the adenovirus or AAV vector which can be further triggered by administration of the vector. Also, with each delivery of the vector, the increasing immune response from the patient results in the escalated removal of the vector before they can reach their target cells. As a result, ongoing therapy requires either increasingly larger doses of the vector being delivered, risking damage to the patient's liver, or discontinuation of the therapy due to inefficacy. As a consequence, many patients suffering from disorders, such as genetic disorders or cancers, are unable to receive ongoing or repeat treatments using such viral vectors that might otherwise save or improve their lives.
Similarly, the development of an immune response to recombinant protein therapies has been a significant challenge. The development of ADAs can lead to cross-reactivity with the endogenous protein, leading to life-threatening conditions (see, e.g., Macdougall, (2007) Epoetin- induced pure red cell aplasia: diagnosis and treatment. Curr. Opin. Nephrol. Hypertens. 16, 585— 588). Little is known, however, about the immunological mechanisms underlying the unwanted immune response against human homolog protein therapeutics. Sauerbom et ah, Immunological mechanism underlying the immune response to recombinant human protein therapeutics, Trends in Pharmacological Sciences, Vol. 31 (2), 2010, pgs. 53-59). Factors influencing immunogenicity include recombinant protein dependent factors such as the primary amino acid sequence, and glycosylation patterns (Hermeling et al. (2004) Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res. 21, 897-903). Other factors influencing immunogenicity include treatment dependent factors such as the dose of the protein, the route of administration, and the duration of treatment, patient HLA alleles, underlying genetic defects, and product dependent factors such as the mechanical processing, manufacture, and contaminants contained in the therapeutic protein formulation (see Ross et al. (2000) Immunogenicity of interferon -beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann. Neurol. 48, 706-712; Rosenberg, A.S. (2006) Effects of protein aggregates: an immunologic perspective. AAPS J. 8, E501-E507). Nevertheless, the development of ADA responses and ADA-mediated adverse events can hamper the development and widespread use of promising therapeutics.
It is an object of the invention to provide a method to reduce the adverse effects of gene or biologies therapy.
SUMMARY OF THE INVENTION
Novel methods of mitigating a subject’s immune response to therapy, for example cell, gene, or biologies therapy, are provided comprising administering an effective amount of an heterobifunctional extracellular immunoglobulin degrader or a pharmaceutically acceptable salt thereof in combination with, in advance of, or following the therapy. The immunoglobulin degraders described herein can sequester and inactivate or degrade antibodies, including anti -drug antibodies (AD As), such as immunoglobulin G (IgG), immunoglobulin A (IgA), immunoglobulin E (IgE), or immunoglobulin M (IgM) antibodies which would otherwise impede the desired therapy and cause unwanted adverse effects. In certain embodiments, the immunoglobulin heterobifunctional degrader comprises a noncovalent ligand for IgG optionally linked to an asialoglycoprotein receptor (ASGPR) ligand. This heterobifunctional immunoglobulin degrader binds an immunoglobulin protein, such as IgG, that is in extracellular circulation and then ASGPR mediates endocytosis and degradation of the antibody, for example by cellular lysosomes in the liver. In certain embodiments, a method described herein results in a mitigated effect of the immune response to therapy. In other embodiments, a method described herein completely inhibits the effects of the immune response to therapy.
Other heterobifunctional molecules have been described that use the asialoglycoprotein receptor to degrade extracellular proteins. The asialoglycoprotein receptor (ASGPR) is a Ca2+- dependent lectin that is primarily expressed in parenchymal hepatocyte cells. The main role of ASGPR is to help regulate serum glycoprotein levels by mediating endocytosis of desialylated glycoproteins. The receptor binds ligands with a terminal galactose or N-acetylgalactosamine. Asialoglycoproteins bind to ASGPRs and are then cleared by receptor-mediated endocytosis. The receptor and the protein are dissociated in the acidic endosomal compartment and the protein is eventually degraded by lysosomes. Avilar Therapeutics has described a series of heterobifunctional degraders of extracellular proteins using the ASGPR-mediated degradation mechanism as described above (WO 2021/155317). Other publications describing various utilizations of the ASGPR mechanism include: U.S. Patent Nos. 9,340,553; 9,617,293; 10,039,778; 10,376,531, and 10,813,942 assigned to Pfizer Inc.; Sanhueza et al. ( JACS , 2017, 139, 3528); Petrov et al. ( Bioorganic andMedicinal Chemistry Letters, 2018, 28, 382); WO 2018/223073 and WO2018/223081 assigned to Pfizer Inc. and Wave Life Sciences Ltd.; WO 2018/223056 assigned to Wave Sciences Ltd.; Schmidt et al. ( Nucleic Acids Research , 2017, 45, 2294); Huang et al.
(Bioconjugate Chem. 2017, 28, 283); WO 2019/199621, WO 2019/199634, WO 2021/072246, and WO 2021/072269 assigned to Yale University; WO 2020/132100 assigned to The Board of Trustees of the Leland Stanford Junior University; WO 2021/142377, WO 2021/263060, WO 2021/263061, and WO 2022/150721 assigned to Lycia Therapeutics Inc.; Banik et al. (Nature, 2020, 584, 291); and an article from the Bertozzi group titled “LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation” (Ahn, et al. Nat. Chem. Biol. (2021)), published in the journal Nature Chemical Biology.
In certain embodiments the immunoglobulin degrading compound is of Formula I, Formula II, or Formula III is provided:
wherein
ASPGR Binding Ligand is a compound selected from:
one of R1 or R5 is a bond to LinkerA; the other of R1 and R5 is independently selected from hydrogen, heteroalkyl, C0-C6alkyl-cyano, alkyl, alkenyl, alkynyl, haloalkyl, F, Cl, Br, I, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, heterocycloalkyl, haloalkoxy, C0-C6alkyl-OR6, C0-C6alkyl-SR6, C0-C6alkyl-NR6R7, C0-C6alkyl-C(O)R3, C0-C6alkyl-S(O)R3, C0-C6alkyl-C(S)R3, C0-C6alkyl- S(O)2R3, C0-C6alkyl-N(R8)-C(O)R3, C0-C6alkyl-N(R8)-S(O)R3, C0-C6alkyl-N(R8)-C(S)R3, C0-C6alkyl-N(R8)-S(O)2R3 C0-C6alkyl-O-C(O)R3, C0-C6alkyl-O-S(O)R3, C0-C6alkyl-O-C(S)R3, -N=S(O)(R3)2, C0-C6alkylN3, and C0-C6alkyl-O-S(O)2R3, each of which is optionally substituted with 1, 2, 3, or 4 substituents;
R3 at each occurrence is independently selected from hydrogen, alkyl, heteroalkyl, haloalkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle, -OR8, and -NR8R9; R6 and R7 are independently selected at each occurrence from hydrogen, heteroalkyl, alkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, haloalkyl, heteroaryl, heterocycle, -alkyl-OR8, -alkyl-NR8R9, C(O)R3, S(O)R3, C(S)R3, and S(O)2R3; R8 and R9 are independently selected at each occurrence from hydrogen, heteroalkyl, alkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocycle; R10 is selected from hydrogen, alkyl, heteroalkyl, haloalkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle, C(O)R3, S(O)R3, C(S)R3, and S(O)2R3; R65, R66, and R67 are independently selected from hydrogen, heteroalkyl, C0-C6alkyl-cyano, alkyl, alkenyl, alkynyl, haloalkyl, F, Cl, Br, I, heterocycle, heterocycloalkyl, haloalkoxy, C0-C6alkyl-OR6, C0-C6alkyl-SR6, C0-C6alkyl-NR6R7, C0-C6alkyl-C(O)R3, C0-C6alkyl-S(O)R3, C0-C6alkyl-C(S)R3, C0-C6alkyl-S(O)2R3, C0-C6alkyl-N(R8)-C(O)R3, C0-C6alkyl-N(R8)-S(O)R3, C0-C6alkyl-N(R8)-C(S)R3, C0-C6alkyl-N(R8)-S(O)2R3 C0-C6alkyl-O-C(O)R3, C0-C6alkyl-O-S(O)R3, C0-C6alkyl-O-C(S)R3, -N=S(O)(R3)2, C0-C6alkylN3, and C0-C6alkyl-O-S(O)2R3, each of which is optionally substituted with 1, 2, 3, or 4 substituents; LinkerA is a bond or a moiety that covalently links LinkerB, LinkerC, or LinkerD to the ASGPR Binding Ligand; LinkerB is a bond or a moiety that covalently links LinkerA to an Immunoglobulin Targeting Ligand; LinkerC is a chemical group that links each LinkerA to the Immunoglobulin Targeting Ligand; LinkerD is a chemical group that links each LinkerA to the Immunoglobulin Targeting Ligand; Immunoglobulin Targeting Ligand is a Ligand that binds to an immunoglobulin, for example IgG or IgA. and when a compound is “optionally substituted” it may be substituted as allowed by valence with one or more groups selected from alkyl (including C1-C4alkyl), alkenyl (including C2-C4alkenyl), alkynyl (including C2-C4alkynyl), haloalkyl (including C1-C4haloalkyl), -OR6, F,
Cl, Br, I, -NR6R7, heteroalkyl, heterocycle, heteroaryl, aryl, cyano, nitro, hydroxyl, azide, amide, -SR3, -S(O)(NR6)R3, -NR8C(O)R3, -C(O)NR6R7, -C(O)OR3, -C(O)R3, -SF
, and , wherein the optional substituent is selected such that a stable compound results. In certain aspects an immunoglobulin degrading compound of Formula I-A, Formula II-A, or Formula III-A is provided:
or a pharmaceutically acceptable salt thereof.
In certain embodiments ASGPR Binding Ligand is a compound selected from:
or a pharmaceutically acceptable salt thereof.
In certain embodiments the heterobifunctional extracellular immunoglobulin degrader is provided as an isotopically enriched immunoglobulin degrader, for example an immunoglobulin degrader with at least one desired isotopic substitution of an atom, at an amount above the natural abundance of the isotope. For example, deuterium can replace one or more hydrogens in the immunoglobulin degrader and 13C can replace one or more carbon atoms. In one embodiment, the isotopic substitution is in one or more positions of the ASGPR Ligand. In another embodiment, the isotopic substitution is in one or more positions of the Linker portion of the molecule. In another embodiment, the isotopic substitution is in one or more positions of the Immunoglobulin Targeting Ligand portion of the molecule.
In certain aspects, the immunoglobulin heterobifunctional degrader can be administered to a patient suffering from an immune response due to the administration of a therapeutic according to the severity of the response. In some embodiments, the response may be severe and life threatening and the patient can be administered the immunoglobulin heterobifunctional degrader one or more time a day, for example, once a day, twice a day, three times a day, or four
time a day. In some embodiments, the immunoglobulin heterobifunctional degrader can be administered one or more times a day for multiple days, for example at least 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days or more until the immune response subsides.
Advantageously, the methods of the invention may be used with any gene or biologies therapy that generates or implicates an undesirable immune response. Methods of the invention may be used, in particular, with a gene therapy, for example a gene therapy comprising a vector delivery including, for example CRISPR-based gene therapy. In certain non-limiting embodiments, the gene therapy can be a somatic-cell-targeting gene therapy. In certain nonlimiting embodiments, the gene therapy can be a germline-cell-targeting cell gene therapy. In certain non-limiting embodiments, the therapy can be a chimeric antigen receptor T-cell (CAR T- cell) therapy. The vector may be a viral vector, for example but not limited to an adenovirus- associated virus (AAV) vector, lentivirus vector, adenovirus vector, respiratory syncytial virus (RSV) vector, herpes simplex virus (HSV) vector, poxvirus, or vaccinia virus. In some embodiments, the viral vector is AAV. In certain non-limiting embodiments, the vector is a lipid nanoparticle (LNP).
In addition, the replacement of a defective gene expressing a mutated or non-functional protein with a normal or wild-type gene expressing a functional protein may result in the induction of an immune reaction to the normal protein in the host. In certain embodiments, the heterobifunctional extracellular immunoglobulin degrader is administered to a subject receiving gene therapy to replace a defective protein in order to reduce the effects of an immune response to a normal, functionalized or wild-type protein. In some embodiments, the heterobifunctional extracellular immunoglobulin degrader is administered once a week, once every two weeks, once every three weeks, or once a month.
In some embodiments, the therapy can be a recombinant protein therapy.
In some embodiments, the recombinant protein is a recombinant Factor VIII protein.
In some embodiments, the recombinant protein is insulin.
In some embodiments, the therapy is an anti-tumor necrosis factor a (TNFa) monoclonal antibody therapy. In some embodiments, the monoclonal antibody is adalimumab, infliximab, or golimumab.
In some embodiments, the therapy is the anti-TNFa therapy etanercept, a soluble TNF receptor IgG Fc fusion protein. In some embodiments, the therapy is the anti-TNFa therapy certolizumab, a pegylated anti-TNFa antibody fragment.
In some embodiments, the therapy is a cytokine inhibitor therapy. In some embodiments, the therapy is an anti-IL-12/IL-23 therapy, for example, ustekinumab. In some embodiments, the therapy is an anti-IL-17 therapy, for example, secukinumab. In some embodiments, the therapy is an anti-IL-6 therapy, for example tocilizumab or sarilumab. In some embodiments, the therapy is an anti-IL2 receptor therapy, for example, daclizumab or basiliximab. In some embodiments, the therapy is an anti-IIb therapy, for example cankinumab.
In some embodiments, the therapy is an anti-CD20 therapy, for example, rituximab, tositumomab, ofatumumab, or ibritumomab. In some embodiments, the therapy is an anti-CD28 therapy, for example, abatacept. In some embodiment, the therapy is an anti-CD3 therapy, for example muromanab. In some embodiments, the therapy is an anti-CDl la therapy, for example, efalizumab. In some embodiments, the therapy is an anti-CD52 therapy, for example alemtuzumab. In some embodiments, the therapy is an anti-CD33 therapy, for example gemtuzumab.
In some embodiments, the therapy is an anti-human C5 complement therapy, for example eculizumab or ultomiris.
In some embodiments, the therapy is an anti-IgE therapy, for example omalizumab.
In some embodiments, the therapy is an RSV prophylaxis therapy, for example palivizumab.
In some embodiments, the therapy is a PTCA adjunct therapy, for example, abciximab.
In some embodiments, the therapy is a diagnostic therapy, for example, nofetumumab. capromab, fanolesomab, arcitumomab, or imciromab. In some embodiments, the therapy is a cancer therapy, for example, trastuzumab, cetuximab, bevacizumab, or panitumumab.
In some embodiments, the therapy is a macular degeneration therapy, for example ranibizumab.
In some embodiments, the therapy is a rheumatoid arthritis or Crohn’s disease therapy, for example cetolizumab pegol.
In some embodiments, the therapy is a bone loss therapy, for example denosumab.
A heterobifunctional immunoglobulin degrader may be provided simultaneous with, prior to, or following the therapy administration of an effective amount to the subject. In certain embodiments the heterobifunctional extracellular immunoglobulin degrader is provided to the subject along with the first administration of the therapy to the subject. In certain embodiments the immunoglobulin degrader is provided during subsequent administrations of the therapy to the
subject. The immunoglobulin degrader may be administered prior to the therapy being readministered to the subject or the immunoglobulin degrader may be conducted after the subject has been administered the therapy at least once. In some embodiments, the immunoglobulin degrader may be administered 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 days following administration of the therapy. In some embodiments, the immunoglobulin degrader may be administered once a week, once every two weeks, once every three weeks, or once a month following administration of the therapy.
Aspects of the invention include a method for administering an effective amount of an extracellular immunoglobulin degrader (a heterobifunctional compound) comprising a first ligand configured to bind IgG and a second ligand configured to bind an asialoglycoprotein receptor (ASGPR), optimally connected with a linker, to thereby sequester and degrade immunoglobulin G (IgG), immunoglobulin A (IgA), immunoglobulin E (IgE), or immunoglobulin M (IgM) in the subject in a manner that a therapy can be re-administered to the subject and produce a therapeutic effect in the subject that would not otherwise be achieved due to IgG adversely affecting the therapy.
BRIEF DESCRIPTION OF THE FIGURES
The Immunoglobulin Targeting Ligand is covalently bound to Linker in the immunoglobulin degrader compound through the Anchor Bond (which is the chemical bond between the Immunoglobulin Targeting Ligand and either Linker B, Linker C or Linker D). This bond can be placed at any location on the ligand that does not unacceptably disrupt the ability of the Immunoglobulin Targeting Ligand to bind to the Target Immunoglobulin. The Anchor Bond is depicted on the nonlimiting examples of Immunoglobulin Targeting Ligands in the figures as:
FIG. 1A provides a non-limiting list of Immunoglobulin Targeting Ligands that target Immunoglobulin A (IgA).
FIG. IB provides a non-limiting list of Immunoglobulin Targeting Ligands that target Immunoglobulin G (IgG).
FIG. 1C-1G provides a non-limiting list of Immunoglobulin Targeting Ligands that target Immunoglobulin E (IgE).
FIG. 2 provides non-limiting examples of IgG protein degrading compounds for use in the present invention.
DETAILED DESCRIPTION
The present invention provides methods for administering a cell, gene, or biologies therapy in combination with a method for mitigating a subject's immune response to produce a therapeutic effect in the subject that would not otherwise be achieved due to the subject's immune response to the cell, gene, or biologies therapy. As provided herein, the subject is generally a human, but can also be a non-human mammal. Methods of the invention can be used to modulate the immune response to any therapy that triggers an immune response. For example, without being limited to a mechanism of action, the invention may use a bifunctional compound comprising a first ligand configured to bind to the antibody, for example an IgG, and a second ligand configured to bind an asialoglycoprotein receptor (ASGPR) optimally connected with a linker. The bifunctional compound sequesters the antibody of interest and then ASGPR mediates endocytosis and degradation of the antibody, for example by cellular lysosomes, thereby mediating a subject's immune response.
In certain embodiments one or more additional therapeutically active agents is administered in addition to the heterobifunctional extracellular immunoglobulin degrading compound and the cell, gene, or biologies therapy. The therapeutics and/or immunoglobulin degrading compound or composition can be administered concurrently with, prior to, or after, administration of the cell, gene, or biologies therapy. In general, each agent will be administered at a dose and/or on a time schedule determined for that agent. It will further be appreciated that the additional therapeutically active agent used in this combination can be administered together in a single composition or administered separately in different compositions. The particular combination used in a regimen will take into account compatibility of the inventive therapeutics and/or immunoglobulin degrading molecule with the additional therapeutically active agent and/or the desired therapeutic effect to be achieved. In general, it is expected that additional therapeutically active agents used in combination be used at levels that do not exceed the levels at which they are used individually. In some embodiments, the levels used in combination will be lower than those used individually.
Therapies
Advantageously, the present invention may be used in the delivery of any cell, gene, or biologies therapy, for example a recombinant protein or antibody therapy, that triggers an immune response.
For example, the present invention may be used together with gene therapies. Gene therapies are therapeutics which focus on the genetic modification of cells to produce a therapeutic effect. In some embodiments, the gene therapy is delivered via a vector, for example a viral vector, capable of inducing an immune response in the host, which can reduce the effectiveness or ability to readminister the viral vector in the host. In some embodiments, the viral vector is a AAV vector, lentivirus vector, adenovirus vector, respiratory syncytial virus (RSV) vector, herpes simplex virus (HSV) vector, poxvirus, or vaccinia virus. In addition, the replacement of a defective gene expressing a mutated or non-functional protein with a normal or wild-type gene expressing a functional protein may result in the induction of an immune reaction to the normal protein in the host. In certain embodiments, the heterobifunctional extracellular immunoglobulin degrader is administered to a subject receiving gene therapy to replace a defective protein in order to reduce the effects of an immune response to a normal, functionalized or wild-type protein. In some embodiments, the heterobifunctional extracellular immunoglobulin degrader is administered once a week, once every two weeks, once every three weeks, or once a month. In certain aspects an effective amount of an immunoglobulin degrading compound described herein, for example and IgG degrading compound, is administered before, concurrently with, or after administration of gene therapy.
Gene therapies may be provided according to the invention to treat a number of disorders, for example Achondroplasia, Alpha-I Antitrypsin Deficiency, Antiphospholipid Syndrome, Autosomal Dominant Polycystic Kidney Disease, Charcot-Marie-Tooth, cancer, Cri du chat, Crohn's Disease, Cystic fibrosis, Dercum Disease, Duane Syndrome, Duchenne Muscular Dystrophy, Factor V Leiden Thrombophilia, Familial Hypercholesterolemia, Familial Mediterranean Fever, Fragile X Syndrome, Gaucher Disease, Hemochromatosis, Hemophilia, Holoprosencephaly, Huntington's disease, Klinefelter syndrome, Marfan syndrome, Myotonic Dystrophy, Neurofibromatosis, Noonan Syndrome, Osteogenesis Imperfecta, Parkinson's disease, Phenylketonuria, Poland Anomaly, Porphyria, Progeria, Retinitis Pigmentosa, Severe Combined Immunodeficiency (SCID), Sickle cell disease, Spinal Muscular Atrophy, Tay-Sachs disease,
Thalassemia, Trimethylaminuria, Turner Syndrome, Velocardiofacial Syndrome, WAGR Syndrome, or Wilson Disease. In certain embodiments, the disorder to be treated is caused by a loss-of-function mutation disorder. In certain embodiments, the disorder to be treated is a monogenic disorder. In certain embodiments, the disorder to be treated is caused by a gain-of- toxicity mutation. In certain embodiments, the disorder to be treated is caused by recessive compound heterozygous mutations.
In certain embodiments the disorder is a cancer. Non-limiting examples of cancer include squamous-cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinomas, and renal cell carcinomas, cancer of the bladder, bowel, breast, cervix, colon, esophagus, head, kidney, liver, lung, neck, ovary, pancreas, prostate, and stomach; leukemias; benign and malignant lymphomas, particularly Burkitfs lymphoma and Non-Hodgkin's lymphoma; benign and malignant melanomas; myeloproliferative diseases; sarcomas, including Ewing's sarcoma, hemangiosarcoma, Kaposi's sarcoma, liposarcoma, myosarcomas, peripheral neuroepithelioma, synovial sarcoma, gliomas, astrocytomas, oligodendrogliomas, ependymomas, gliobastomas, neuroblastomas, ganglioneuromas, gangliogliomas, medulloblastomas, pineal cell tumors, meningiomas, meningeal sarcomas, neurofibromas, and Schwannomas; bowel cancer, breast cancer, prostate cancer, cervical cancer, uterine cancer, lung cancer, ovarian cancer, testicular cancer, thyroid cancer, astrocytoma, esophageal cancer, pancreatic cancer, stomach cancer, liver cancer, colon cancer, melanoma; carcinosarcoma, Hodgkin's disease, Wilms' tumor and teratocarcinomas. Additional cancers which may be treated using the disclosed compounds according to the present invention include, for example, acute granulocytic leukemia, acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), adenocarcinoma, adenosarcoma, adrenal cancer, adrenocortical carcinoma, anal cancer, anaplastic astrocytoma, angiosarcoma, appendix cancer, astrocytoma, Basal cell carcinoma, B-Cell lymphoma, bile duct cancer, bladder cancer, bone cancer, bone marrow cancer, bowel cancer, brain cancer, brain stem glioma, breast cancer, triple (estrogen, progesterone and HER-2) negative breast cancer, double negative breast cancer (two of estrogen, progesterone and HER-2 are negative), single negative (one of estrogen, progesterone and HER-2 is negative), estrogen-receptor positive, HER2negative breast cancer, estrogen receptor-negative breast cancer, estrogen receptor positive breast cancer, metastatic breast cancer, luminal A breast cancer, luminal B breast cancer, Her2-negative breast cancer, HER2-positive or negative breast cancer, progesterone receptor-negative breast cancer,
progesterone receptor-positive breast cancer, recurrent breast cancer, carcinoid tumors, cervical cancer, cholangiocarcinoma, chondrosarcoma, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), colon cancer, colorectal cancer, craniopharyngioma, cutaneous lymphoma, cutaneous melanoma, diffuse astrocytoma, ductal carcinoma in situ (DCIS), endometrial cancer, ependymoma, epithelioid sarcoma, esophageal cancer, ewing sarcoma, extrahepatic bile duct cancer, eye cancer, fallopian tube cancer, fibrosarcoma, gallbladder cancer, gastric cancer, gastrointestinal cancer, gastrointestinal carcinoid cancer, gastrointestinal stromal tumors (GIST), germ cell tumor glioblastoma multiforme (GBM), glioma, hairy cell leukemia, head and neck cancer, hemangioendothelioma, Hodgkin lymphoma, hypopharyngeal cancer, infiltrating ductal carcinoma (IDC), infiltrating lobular carcinoma (ILC), inflammatory breast cancer (IBC), intestinal Cancer, intrahepatic bile duct cancer, invasive/infiltrating breast cancer, Islet cell cancer, jaw cancer, Kaposi sarcoma, kidney cancer, laryngeal cancer, leiomyosarcoma, leptomeningeal metastases, leukemia, lip cancer, liposarcoma, liver cancer, lobular carcinoma in situ, low-grade astrocytoma, lung cancer, lymph node cancer, lymphoma, male breast cancer, medullary carcinoma, medulloblastoma, melanoma, meningioma, Merkel cell carcinoma, mesenchymal chondrosarcoma, mesenchymous, mesothelioma metastatic breast cancer, metastatic melanoma metastatic squamous neck cancer, mixed gliomas, monodermal teratoma, mouth cancer mucinous carcinoma, mucosal melanoma, multiple myeloma, Mycosis Fungoides, myelodysplastic syndrome, nasal cavity cancer, nasopharyngeal cancer, neck cancer, neuroblastoma, neuroendocrine tumors (NETs), non-Hodgkin's lymphoma, non-small cell lung cancer (NSCLC), oat cell cancer, ocular cancer, ocular melanoma, oligodendroglioma, oral cancer, oral cavity cancer, oropharyngeal cancer, osteogenic sarcoma, osteosarcoma, ovarian cancer, ovarian epithelial cancer ovarian germ cell tumor, ovarian primary peritoneal carcinoma, ovarian sex cord stromal tumor, Paget's disease, pancreatic cancer, papillary carcinoma, paranasal sinus cancer, parathyroid cancer, pelvic cancer, penile cancer, peripheral nerve cancer, peritoneal cancer, pharyngeal cancer, pheochromocytoma, pilocytic astrocytoma, pineal region tumor, pineoblastoma, pituitary gland cancer, primary central nervous system (CNS) lymphoma, prostate cancer, rectal cancer, renal cell carcinoma, renal pelvis cancer, rhabdomyosarcoma, salivary gland cancer, soft tissue sarcoma, bone sarcoma, sarcoma, sinus cancer, skin cancer, small cell lung cancer (SCLC), small intestine cancer, spinal cancer, spinal column cancer, spinal cord cancer, squamous cell carcinoma, stomach cancer, synovial sarcoma, T-cell lymphoma, testicular cancer,
throat cancer, thymoma/thymic carcinoma, thyroid cancer, tongue cancer, tonsil cancer, transitional cell cancer, tubal cancer, tubular carcinoma, undiagnosed cancer, ureteral cancer, urethral cancer, uterine adenocarcinoma, uterine cancer, uterine sarcoma, vaginal cancer, vulvar cancer, T-cell lineage acute lymphoblastic leukemia (T-ALL), T-cell lineage lymphoblastic lymphoma (T-LL), peripheral T-cell lymphoma, Adult T-cell leukemia, Pre-B ALL, Pre-B lymphomas, large B-cell lymphoma, Burkitt's lymphoma, B-cell ALL, Philadelphia chromosome positive ALL, Philadelphia chromosome positive CML, juvenile myelomonocytic leukemia (JMML), acute promyelocytic leukemia (a subtype of AML), large granular lymphocytic leukemia, Adult T-cell chronic leukemia, diffuse large B cell lymphoma, follicular lymphoma; Mucosa-Associated Lymphatic Tissue lymphoma (MALT), small cell lymphocytic lymphoma, mediastinal large B cell lymphoma, nodal marginal zone B cell lymphoma (NMZL); splenic marginal zone lymphoma (SMZL); intravascular large B-cell lymphoma; primary effusion lymphoma; or lymphomatoid granulomatosis;; B-cell prolymphocytic leukemia; splenic lymphoma/leukemia, unclassifiable, splenic diffuse red pulp small B-cell lymphoma; lymphoplasmacytic lymphoma; heavy chain diseases, for example, Alpha heavy chain disease, Gamma heavy chain disease, Mu heavy chain disease, plasma cell myeloma, solitary plasmacytoma of bone; extraosseous plasmacytoma; primary cutaneous follicle center lymphoma, T cell/hi stocyte rich large B-cell lymphoma, DLBCL associated with chronic inflammation; Epstein-Barr virus (EBV)+ DLBCL of the elderly; primary mediastinal (thymic) large B-cell lymphoma, primary cutaneous DLBCL -leg type, ALK+ large B-cell lymphoma, plasmablastic lymphoma; large B-cell lymphoma arising in HHV8 -associated multicentric, Castleman disease; B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma, or B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma.
Advantageously, the methods of the present invention may mediate an immune response to vectors used for the delivery of therapeutics, for example by sequestering IgG's reactive to a given vector. Vectors are particularly useful in delivering nucleic acid molecules to cells, for example for gene therapies and vaccines. In certain aspects an effective amount of a heterobifunctional immunoglobulin degrading compound described herein, for example an IgG degrading compound, is administered before, concurrently with, or after administration of a delivery vector.
Vectors may be divided broadly into viral vectors and non-viral vectors.
Many viral vectors or virus-associated vectors are known in the art. Such vectors can be used as carriers of a nucleic acid construct into the cell. Constructs may be integrated and packaged into non-replicating, defective viral genomes like Adenovirus, Adeno-associated virus (AAV), or Herpes simplex virus (HSV) or others, including retroviral and lentiviral vectors, for infection or transduction into cells. For example, vectors derived from retroviruses, such as the lentivirus, may be used for long-term gene transfer. Lentiviral vectors are particularly advantageous because they can transduce non-proliferating cells, such as hepatocytes. They also have the added advantage of low immunogenicity. Adeno-associated viral vectors (AAVs) are a family of medium-sized, non- enveloped viruses used as vectors. More than 30 naturally occurring serotypes of AAV are available. Many natural variants in the AAV capsid exist. AAV serotypes include, but are not limited to, AAV serotypes AAVI, AAV2, AAV3, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV7M8, AAV8, AAV8bp, AAV9, AAV10, AAVI 1, AAV 12, AAV13, AAVAnc80, AAVrhlO, AAVPHP.B, and variants of the known or mentioned AAVs or AAVs yet to be discovered or variants or mixtures thereof (see, e.g., WO 2005/033321, which is incorporated herein by reference). Currently, two AAV vectors, LUXTURNA® (voretigene neparvovec-rzyl) and ZOLGENSMA® (onasemnogene abeparvovec-xioi), are approved by the US Food and Drug Administration (FDA). LUXTURNA® is an AAV serotype 2 gene therapy for the treatment of patients having biallelic RPE65 mutation-associated retinal dystrophy. ZOLGENSMA® is an AAV serotype 9 gene therapy for the treatment of pediatric patients less than 2 years of age having bi-all elic SMN1 mutation-associated spinal muscular atrophy (SMA). As of July 2022, there were 292 ongoing clinical trials involving the administration of AAVs registered at ClinicalTrials.gov.
In certain embodiments, the AAV capsid is selected from AAVI capsid, AAV8 capsid, or AAV9 capsid, or variants thereof. In certain embodiments the AAV comprises an AAV capsid having one or substitutions of the amino acid tyrosine (Y) to the amino acid phenylalanine (F) on the surface of the capsid protein. In certain embodiments, the AAV capsid comprises an AAV capsid having one or more substitutions of the amino acid tyrosine (Y) to the amino acid phenylalanine (F) on the surface of the AAV capsid protein. AAV capsid having tyrosine to phenylalanine mutations are known in the art, as described for example in US 8445267, US 8802440, US 9157098, US 9611302, US 9775918, US 9920097, US 10011640, US 10294281, US 10723768, US 10815279, and US 10934327, each of which is incorporated by refence. In
certain embodiments, the AAV capsid is an AAV capsid having substitutions selected from Y272F, Y444F, Y447F, T491 V, T494F, Y500F, Y730F, Y733F or a combination thereof.
In certain embodiments, present invention comprises a method that mediates an immune response to the administration of a recombinant adeno-associated virus (rAAV) containing a nucleic acid encoding a therapeutic polypeptide, thereby increasing the efficacy and/or reducing the needed dosage of therapies that use vector deliveries. The rAAV comprises an AAV capsid and the nucleic acid sequence encoding the therapeutic polypeptide in the AAV capsid, wherein the nucleic acid sequence encoding the therapeutic polypeptide is operably linked to a promoter as described herein and AAV inverted terminal repeats (ITRs) required for packaging a nucleic acid into the capsid. The nucleic acid to be packaged comprises therapeutic polypeptide encoding nucleic acid sequences, promoter sequences, and optionally other regulatory sequences as described herein, which are flanked by packaging signals of the AAV genome to facilitate efficient packaging of the nucleic acid into the AAV capsid for delivery and expression in the target cell and/or organ. In certain embodiments, the nucleic acid sequence encoding the therapeutic polypeptide is flanked at the 5’ and 3’ ends by AAV ITRs. For example, a 5’ AAV ITR, the nucleic acid sequence encoding the therapeutic polypeptide, and a 3’ AAV ITR comprise the nucleic acid that is packaged into the AAV capsid. The term “ITR” is defined as a cis genetic element responsible for facilitating the replication and packaging of a nucleic acid during AAV vector production necessary for rAAV generation. In certain embodiments, the ITRs are derived from a different AAV variant than the AAV capsid variant. In those embodiments wherein the source of the ITRs are of one AAV variant and the AAV capsid is from another AAV variant, the resulting vector is defined as pseudotyped. In certain embodiments, the ITRs are derived from the AAV2 variant. In certain embodiments, the ITRs are derived from deleted, or shortened, version of the AAV2 variant (AITR), Typically, an AAV vector genome comprises an AAV 5’ ITR, a nucleic acid encoding a polypeptide operably linked to a promoter and optionally linked to one or more regulatory sequences, and an AAV 3’ ITR. Other arrangements comprising addition of further elements or subtraction of said elements may be suitable. In certain embodiments, a selfcomplementary AAV (scAAV) is provided. As defined herein, the term “Self-complementary AAV” refers to a construct in which a coding nucleic acid sequence carried by an rAAV has been designed to form an intra-molecular double-stranded DNA template. Upon infection, rather than waiting for cell-mediated second strand synthesis, the two complementary regions of scAAV will
associate to form one double stranded DNA (dsDNA) unit that is amenable to immediate replication and transcription. In certain embodiments, the ITRs to be used are selected from wild- type, full-length, engineered, shortened, deleted, or a combination thereof. An engineered AAV may be, without limitation, a pseudotyped AAV, a chimeric AAV capsid, a recombinant AAV capsid, or a “humanized” AAV capsid. A deleted, or shortened, version of the 5’ ITR, termed 5’ AITR, has been described in which the D-sequence and terminal resolution sites (TRs) are deleted. In certain embodiments, the ITR comprises a shortened ITR of the AAV2 variant comprises 130 base pairs (bps), wherein the external “a” element is deleted. In certain embodiments, the shorted AAV2 ITR is lengthened during vector DNA amplification using the internal “a” element as a template. In certain embodiments, full-length AAV 5’ and 3’ ITRs are used. In certain embodiments, wild-type AAV 5’ and 3’ ITRs are used. In certain embodiments, engineered ITRs are used. Suitable AAV ITR sequences are known in the art (see, e.g., Yan et al., J Virol. 79(1):364- 379(2005), incorporated herein by reference).
In certain embodiments, the nucleic acid to be packaged comprises one or more regulatory elements such that the total rAAV vector genome is about 2.0 to about 5.5 kilobases (kb) in size. In certain embodiments, the one or more regulatory sequences are selected such that the total rAAV vector genome is about 2.1, 2.3, 2.8, 3.1, 3.2, 3.3, 4.0 kb, 4.7 kb, or 5.2 kb in size. In certain embodiments, the rAAV vector genome approximates the size of a native AAV genome. In certain embodiments, the one or more regulatory sequences are selected such that the total rAAV vector genome is about 4.7 kb in size. In certain embodiments, the one or more regulatory sequences are selected such that the total rAAV vector genome is about 5.2 kb in size. In certain embodiments, the nucleic acid to be packaged comprises one or more regulatory elements selected from a promoter, a Woodchuck Hepatitis virus (WHP) posttranscriptional regulatory element (WPRE), a polyadenylation (poly A) signal, an intron, or a combination thereof. In certain embodiments, the one or more regulatory elements are operably linked to the nucleic acid encoding a therapeutic polypeptide.
In certain embodiments, a packaging cell line is used for production of a vector (e.g., a recombinant AAV). A host cell may be a prokaryotic or eukaryotic cell (e.g., human, insect, or yeast) that contains exogenous or heterologous DNA that has been introduced into the cell by any means, e.g., electroporation, calcium phosphate precipitation, microinjection, transformation, viral infection, transfection, liposome delivery, membrane fusion techniques, high velocity DNA- coated pellets, viral infection, and protoplast fusion. Examples of host cells may include, but are
not limited to an isolated cell, a cell culture, an Escherichia coli cell, a yeast cell, a human cell, a non-human cell, a mammalian cell, a non-mammalian cell, an insect cell, a HEK-293 cell, a liver cell, a kidney cell, a cell of the central nervous system, a neuron, a glial cell, or a stem cell. In certain embodiments, the nucleic acid encoding a therapeutic polypeptide is optimized for expression in the desirable subject species, for example, in humans. Codon-optimized coding nucleic acid sequences can be designed by various different methods known to those skilled in the art. In certain embodiments, the entire length of the open reading frame (ORF) of the nucleic acid encoding a therapeutic polypeptide is modified. In certain embodiments, a fragment of the open reading frame (ORF) of the nucleic acid encoding a therapeutic polypeptide is modified. In certain embodiments, the nucleic acid encoding a therapeutic polypeptide is optimized for tropism towards the desirable target organ. In certain embodiments, the target organ is selected from muscle, eye, liver, brain, or a combination thereof. In certain embodiments, the nucleic acid encoding a therapeutic polypeptide is optimized for tropism towards the desirable target cell-type. As defined herein, the term “target cell” refers to any cell in which the expression of the therapeutic polypeptide is desired. In certain embodiments, the term “target cell” is intended to reference the cells of the subject being treated. In certain embodiments, the target cell-type is selected from neurons, glia, photoreceptors, retinal pigment epithelial (RPE) cells, hepatocytes, myocytes, skeletal muscle cells, heart cells, or a combination thereof. In certain embodiments, the AAV vector is formulated in a buffer/carrier suitable for infusion in a subject, for example a human subject. In certain embodiments, the viral vector (e.g, rAAV) is delivered systemically. In certain embodiments, the rAAV is delivered intravenously, intraperitoneally, intranasally, or via inhalation. In certain embodiments, the buffer/carrier comprises a component that prevents the AAV from attaching to the infusion tube. In certain embodiments, the dosage of the vector is about 1 x 109 GC to about 1 x 1013 genome copies (GC) per dose. In certain embodiments, the dose of the vector administered to a patient is at least about 1.0 x 109 GC/kg , about 1.5 x 109 GC/kg , about 2.0 x 109 GC/g, about 2.5 x 109 GC/kg , about 3.0 x 109 GC/kg , about 3.5 x 109 GC/kg , about 4.0 x 109 GC/kg , about 4.5 x 109 GC/kg , about 5.0 x 109 GC/kg , about 5.5 x 109 GC/kg , about 6.0 x 109 GC/kg , about 6.5 x 109 GC/kg , about 7.0 x 109 GC/kg , about 7.5 x 109 GC/kg , about 8.0 x 109 GC/kg , about 8.5 x 109 GC/kg , about 9.0 x 109 GC/kg , about 9.5 x 109 GC/kg , about 1.0 x 1010 GC/kg , about 1.5 x 1010 GC/kg , about 2.0 x 1010 GC/kg , about 2.5 x 1010 GC/kg , about 3.0 x 1010 GC/kg , about 3.5 x 1010 GC/kg , about 4.0 x 1010 GC/kg , about 4.5 x 1010 GC/kg , about 5.0 x 1010 GC/kg , about 5.5 x 1010 GC/kg ,
about 6.0 x 1010 GC/kg , about 6.5 x 1010 GC/kg , about 7.0 x 1010 GC/kg , about 7.5 x 1010 GC/kg , about 8.0 x 1010 GC/kg , about 8.5 x 1010 GC/kg , about 9.0 x 1010 GC/kg , about 9.5 x 1010 GC/kg , about 1.0 x 1011 GC/kg , about 1.5 x 1011 GC/kg , about 2.0 x 1011 GC/kg , about 2.5 x 1011 GC/kg , about 3.0 x 1011 GC/kg , about 3.5 x 1011 GC/kg , about 4.0 x 1011 GC/kg , about 4.5 x 1011 GC/kg , about 5.0 x 1011 GC/kg , about 5.5 x 1011 GC/kg , about 6.0 x 1011 GC/kg , about 6.5 x 1011 GC/kg , about 7.0 x 1011 GC/kg , about 7.5 x 1011 GC/kg , about 8.0 x 1011 GC/kg , about 8.5 x 1011 GC/kg , about 9.0 x 1011 GC/kg , about 9.5 x 1011 GC/kg , about 1.0 x 1012 GC/kg , about 1.5 x 1012 GC/kg , about 2.0 x 1012 GC/kg , about 2.5 x 1012 GC/kg , about 3.0 x 1012 GC/kg , about 3.5 x 1012 GC/kg , about 4.0 x 1012 GC/kg , about 4.5 x 1012 GC/kg , 48 about 5.0 x 1012 GC/kg , about 5.5 x 1012 GC/kg , about 6.0 x 1012 GC/kg , about 6.5 x 1012 GC/kg , about 7.0 x 1012 GC/kg , about 7.5 x 1012 GC/kg , about 8.0 x 1012 GC/kg , about 8.5 x 1012 GC/kg , about 9.0 x 1012 GC/kg , about 9.5 x 1012 GC/kg , about 1.0 x 1013 GC/kg , about 1.5 x 1013 GC/kg , about 2.0 x 1013 GC/kg , about 2.5 x 1013 GC/kg , about 3.0 x 1013 GC/kg , about 3.5 x 1013 GC/kg , about 4.0 x 1013 GC/kg , about 4.5 x 1013 GC/kg , about 5.0 x 1013 GC/kg , about 5.5 x 1013 GC/kg , about 6.0 x 1013 GC/kg , about 6.5 x 1013 GC/kg , about 7.0 x 1013 GC/kg , about 7.5 x 1013 GC/kg , about 8.0 x 1013 GC/kg , about 8.5 x 1013 GC/kg , about 9.0 x 1013 GC/kg , about 9.5 x 1013 GC/kg , or about 1.0 x 1014 GC/kg.As used herein, relating to AAV, the term “variant” means any AAV sequence which is derived from a known AAV sequence, including those with a conservative amino acid replacement, and those sharing at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or greater sequence identity over the amino acid or nucleic acid sequence. In certain embodiments, the AAV capsid includes variants which may include up to about 10% variation from any described or known AAV capsid sequence. In certain embodiments, the AAV capsid shares about 90% identity to about 99.9 % identity, about 95% to about 99% identity, or about 97% to about 98% identity to an AAV capsid provided herein and/or known in the art. In one embodiment, the AAV capsid shares at least 95% identity with an AAV capsid. When determining the percent identity of an AAV capsid, the comparison may be made over any of the variable proteins (e.g., vpl, vp2, or vp3). The term “percent (%) identity”, “sequence identity”, “percent sequence identity”, or “percent identical” in the context of nucleic acid sequences or amino acid sequences refers to the residues in the two sequences which are the same when aligned for correspondence. Unless
otherwise specified, it is to be understood that a percentage of identity is a minimum level of identity and encompasses all higher levels of identity up to 100% identity to the reference sequence. For example, “95% identity” and “at least 95% identity” may be used interchangeably and include 95, 96, 97, 98, 99 up to 100% identity to the referenced sequence, and all fractions therebetween. The length of sequence identity comparison may be over the full-length of the genome, the full-length of a gene coding sequence, a fragment of a gene coding sequence, a fragment of at least about 500 to about 5000 nucleotides, the full-length of an amino acid sequence, a fragment of an amino acid sequence, a fragment of at least about 8 to about 200 amino acids, is desired. Generally, when referring to “identity”, “homology”, or “similarity” between two different sequences, “identity”, “homology” or “similarity” is determined in reference to “aligned” sequences. “Aligned” sequences or “alignments” refer to more than one nucleic acid sequences or amino acid sequences, often containing corrections for missing or additional bases or amino acids as compared to a reference sequence. Multiple sequence alignment programs are also available for nucleic acid sequences and amino acid sequences. Examples of such programs include, “Clustal Omega”, “Clustal W”, “CAP Sequence Assembly”, “BLAST”, “MAP”, and “MEME”, which are accessible through Web Servers on the internet. Other sources for such programs are known to those skilled in the art.
Non-viral delivery systems may also be used together with the present invention, for example a liposome, lipid nanoparticle, or other lipid formulations. For example, a nucleic acid for delivery may be associated with a lipid. The nucleic acid associated with a lipid may be encapsulated in the aqueous interior of a liposome, interspersed within the lipid bilayer of a liposome, attached to a liposome via a linking molecule that is associated with both the liposome and the oligonucleotide, entrapped in a liposome, complexed with a liposome, dispersed in a solution containing a lipid, mixed with a lipid, combined with a lipid, contained as a suspension in a lipid, contained or complexed with a micelle, or otherwise associated with a lipid. The nucleic acid for delivery may be encapsulated in a lipid nanoparticle. Lipid nanoparticles can be comprised of a cationic lipid, an anionic lipid, a polyethylene glycol functionalized lipid, and steroids. Lipid, lipid/DNA or lipid/expression vector associated compositions are not limited to any particular structure in solution. For example, they may be present in a bilayer structure, as micelles, or with collapsed structure. They may also simply be interspersed in a solution, possibly forming aggregates that are not uniform in size or shape. Lipids are fatty substances which may be naturally
occurring or synthetic lipids. For example, lipids include the fatty droplets that naturally occur in the cytoplasm as well as the class of compounds which contain long-chain aliphatic hydrocarbons and their derivatives, such as fatty acids, alcohols, amines, amino alcohols, and aldehydes.
Advantageously, the methods of the present invention mediate an immune response to any vector used for the delivery of therapeutics, thereby increasing the efficacy and/or reducing the needed dosage of therapies that use vector deliveries. In certain embodiments, the present invention comprises the use of an effective amount of an immunoglobulin degrading compound described herein, for example and IgG degrading compound, which is to be administered before, concurrently with, or after a vector for the delivery of a therapeutic polypeptide.
Immunoglobulin G
Immunoglobulin G (IgG) is the main type of antibody found in all body fluids (for example, blood and extracellular fluid) and protects against bacterial and viral infections. It represents approximately 75% of serum antibodies in humans and is thus the most common type of antibody found in circulation. IgG antibodies are generated following class switching and maturation of the antibody response, thus they participate predominantly in the secondary immune response.
As a consequence, IgG antibodies frequently mediate a subject's response to therapies, diminishing the effectiveness of those therapies.
IgG can be divided into 4 distinct subclasses: IgGl, IgG2, IgG3, & IgG4. The evolution of IgG subclass switches is regulated by interaction with T cells and follows a I-way direction: IgG3 to IgGl to IgG2 to IgG4. The differences between subclasses are mainly in their size and the configuration of the hinge region, glycosylation sites, and structures, as well as a few key amino acids that impact the ability to interact with complement and FC receptors.
IgGl and IgG3 are monomeric, having 2 heavy chains & 2 light chains, and bivalent, having 2 variable regions. IgG2 has a disulfide bond pattern which allows for two monomeric IgG2 antibodies to form a dimeric and tetravalent structure through unique inter-molecule disulfide bonds. IgG4 has two intrachain disulfide bonds that can be reduced, which generates a monovalent structure. In addition, the monovalent structures can reform the disulfide bonds, but may not be the same IgG4 monovalent chain, meaning the resulting IgG4 will be a bivalent monomer but will have two different variable regions.
Binding of IgG can be accomplished through the use of an IgG-specific ligand. For example, the ligand may bind to the FC region of IgG. For example, the IgG-specific ligand may be a Fc-binding peptide, such as a Fc-BP2. In certain aspects , the IgG-specific ligand may be Fc-111.
or a pharmaceutically acceptable salt thereof.
The Protein Data Bank website provides the crystal structure of IgG searchable by 1H3X (Krapp, S., et al., J. Mol. Biol., 2003, 325: 979); and 5V43 (Lee, C.H., et al., Nat. Immunol., 2017, 18: 889-898); as well as the crystal structure of IgG bound to various compounds searchable by 5YC5 (Kiyoshi M., et al., Sci. Rep., 2018, 8: 3955-3955); 5XJE (Sakae Y., et al., Sci. Rep., 2017, 7: 13780-13780); 5GSQ (Chen, C. L., et al., ACS Chem. Biol., 2017, 12: 1335-1345); and 1HZH (Saphire E. O., et al., Science, 2001, 293: 1155-1159). Additionally, Kiyoshi, M., et al., provides insight into the structural basis for binding of human IgGl to its high-affinity human receptor FcyRI. (Kiyosi M., et al., Nat Commun., 2015, 6, 6866).
Representative IgG Targeting Ligands are provided in Fig. IB.
Additional representative IgG Targeting Ligands include:
wherein XR is O, S, NH, or N-C1-C3 alkyl; and XM is O, S, NH, or N-C1-C3 alkyl. In other embodiments the IgG Targeting Ligand is selected from: ,
In some embodiments, the IgG Targeting Ligand is a group according to the chemical structure:
wherein RN02 is a dinitrophenyl group optionally linked through CH2, S(O), S(O)2, - S(O)2O, - OS(O)2, or OS(O)2O. In certain embodiments the IgG Targeting Ligand is selected from:
ted from O, CH2, NH, N-C1-C3 alkyl, NC(O)C1-C3 alkyl, S(O), S(O)2, -S(O)2O, - OS(O)2, or OS(O)2O. In some embodiments, the IgG Targeting Ligand is a 3-indoleacetic acid group according to the chemical structure: where k”” is 1-4 (preferably 2-3, most often 3) or a
group.
In some embodiments, the IgG Targeting Ligand is a peptide. Nonlimiting examples of IgG Targeting Ligand peptides include:
PAM (RTY)4K2KG (Fassina, et al, J. Mol. Recognit. 1996, 9, 564-569) comprising SEQ ID NO: 1 RTYK and SEQ ID NO:2 RTYKKG
D-PAM, wherein the amino acids of the PAM sequence are all D-amino acids (Verdoliva, et al, J. Immunol. Methods, 2002, 271, 77-88) SEQ ID NO:3 RTYK (D-amino acids) and SEQ ID NO:4 RTYKKG (D-amino acids).
D-RAM-F, wherein the amino acids of the PAM sequence are all D-amino acids with further modifications wherein the four N-terminal arginines are acetylated with phenylacetic acid (Dinon, et al J. Mol. Recognit. 2011, 24, 1087-1094) SEQ ID NO:5 RTYK (D-amino acids, N- terminal arginine acetylated with phenylacetic acid) and SEQ ID NO: 6 RTYKKG (D-amino acids, N-terminal arginine acetylated with phenylacetic acid).
SEQ ID NO:7 TWKTSRISIF (Krook, et al,.J. Immunol. Methods 1998, 221, 151-157)
SEQ ID NO:8 FGRLVSSIRY (Krook, et al, J. Immunol. Methods 1998, 221, 151-157)
SEQ ID NO: 10 FCBP-Ser DSAWHLGELWST (see W02014010813) SEQ ID NO: 11 DCHKRSFWADNCT (see W02014010813) SEQ ID NO: 12 DCRTQFRPNQTCT (see W02014010813) SEQ ID NO: 13 DCQLCDFWRTRCT (see W02014010813) SEQ ID NO: 14 DCFEDFNEQRTCT (see W02014010813) SEQ ID NO: 15 DCLAKFLKGKDCT (see W02014010813) SEQ ID NO: 16 DCWHRRTHKTFCT (see W02014010813) SEQ ID NO: 17 DCRTIQTRSCT (see W02014010813) SEQ ID NO: 18 DCIKLAQLHSVCT (see W02014010813) SEQ ID NO: 19 DCWRHRNATEWCT (see W02014010813) SEQ ID NO:20 DCQNWIKDVHKCT (see W02014010813) SEQ ID NO:21 DC AWHLGEL VWCT (see W02014010813) SEQ ID NO:22 DCAFHLGELVWCT (see W02014010813) SEQ ID NO:23 DCAYHLGELVWCT (see W02014010813)
SEQ ID NO:24 FcBP-1 DPWVLEGLHWALP (Kang, et al, J. Chromatogr. A 2016, 1466, 105-1 12)
SEQ ID NO:26 Fc-lll-4c CTCWVLEGLHWACDC (Gong, et al, Bioconjug. Chem. 2016, 27, 1569-1573)
SEQ ID NO:27 EPIHRSTLTALL (Ehrlich, et al, J. Biochem. Biophys. Method 2001, 49, 443— 454)
SEQ ID NO:28 APAR (Camperi, et al, Biotechnol. Lett. 2003, 25, 1545-1548) FcRM (CFHH)2KG(FC Receptor Mimetic, Verdoliva, etal., ChemBioChem 2005, 6, 1242- 1253) SEQ ID NO:29 CFHH
SEQ ID NO:30 HWRGWV (Yang, et al., J Peptide Res. 2006, 66, 1 1 0-137) SEQ ID NO:31 HYFKFD (Yang, et al, J. Chromatogr. A 2009, 1216, 910-918) SEQ ID NO:32 HFRRHL (Menegatti, et al, J. Chromatogr. A 2016, 1445, 93-104) SEQ ID NO:33 HWCitGWV (Menegatti, et al, J. Chromatogr. A 2016, 1445, 93-
104)
SEQ ID NO:34 HWmetCitGWmetV (US 10,266,566) SEQ ID NO:35 D2AAG (Small Synthetic peptide ligand, Lund, et al, J. Chromatogr. A 2012, 1225, 158- 167)
SEQ ID NO:36 DAAG (Small Synthetic peptide ligand, Lund, et al, J. Chromatogr. A 2012, 1225, 158- 167);
SEQ ID NO:37 cyclo[(Na-Ac) S(A)-RWHYFK-Lact-E] (Menegatti, et al, Anal. Chem. 2013, 85, 9229-9237);
SEQ ID NO:38 cyclo[(Na-Ac)-Dap(A)-RWHYFK-Lact-E] (Menegatti, et al, Anal. Chem. 2013, 85, 9229-9237);
SEQ ID NO:39 cyclo[Link M-WFRHYK] (Menegatti, et al, Biotechnol. Bioeng. 2013, 110, 857-870);
SEQ ID NO:40 NKFRGKYK (Sugita, et al, Biochem. Eng. J. 2013, 79, 33-40); SEQ ID NO:41 NARKFYKG (Sugita, et al, Biochem. Eng. J. 2013, 79, 33-40);
SEQ ID NO:42 FYWHCLDE (Zhao, et al, Biochem. Eng. J. 2014, 88, 1-11); SEQ ID NO:43 FYCHWALE (Zhao, et al, J Chromatogr. A 2014, 1355, 107-114); SEQ ID NO:44 FYCHTIDE (Zhao, et al., Z Chromatogr. A 2014, 1359, 100-111); SEQ ID NO:45 Dual 1/3 (F YWHCLDE-F Y CHTIDE) (Zhao, et al, J. Chromatogr. A 2014, 1369, 64-72); SEQ ID NO:46 RRGW (Tsai, et al, Anal. Chem. 2014, 86, 293 1-2938); SEQ ID NO:47 KHRFNKD (Yoo and Choi, BioChip J. 2015, 10, 88-94); SEQ ID NO:48 CPSTHWK (Sun et al. Polymers 2018, 10, 778); SEQ ID NO:49 NVQYFAV (Sun et al. Polymers 2018, 10, 778); SEQ ID NO:50 ASHTQKS (Sun et al. Polymers 2018, 10, 778); SEQ ID NO:51 QPQMSHM (Sun et al. Polymers 2018, 10, 778); SEQ ID NO: 52 TNIESLK (Sun et al. Polymers 2018, 10, 778); SEQ ID NO:53 NCHKCWN (Sun et al. Polymers 2018, 10, 778); SEQ ID NO: 54 SHLSKNF (Sun et al. Polymers 2018, 10, 778).
In some embodiments the IgG Targeting Ligand is specific for IgG4.
In some embodiments the IgG4 specific Targeting Ligand is described in Gunnarsson et al. Biomolecular Engineering 2006, 23, 111-117.
In some embodiments the IgG4 specific targeting ligand is selected from SEQ ID NO : 55 FDLLEHFY and SEQ ID NO:56 DLLHHFDYF.
In certain embodiments the immunoglobulin degrading compound is selected from:
or a pharmaceutically acceptable salt thereof;
or a pharmaceutically acceptable salt thereof;
or a pharmaceutically acceptable salt thereof;
or a pharmaceutically acceptable salt thereof.
Non-limiting examples of IgG degrading compounds include:
or a pharmaceutically acceptable salt thereof.
In alternative embodiments a hydroxyl, amine, amide, or carboxylic acid group in an Immunoglobulin Targeting Ligand drawn herein is capped with a protecting group. For example in this embodiment:
In alternative embodiments a hydroxyl, amine, amide, or carboxylic acid group in an Immunoglobulin Targeting Ligand drawn herein is used as the attachment point to Linker instead of the drawn attachment point. For example, in this embodiment:
In certain embodiments the immunoglobulin degrading compound is selected from:
or a pharmaceutically acceptable salt thereof.
In certain embodiments the immunoglobulin degrading compound is selected from:
In certain embodiments the Immunoglobulin Targeting Ligand is:
In certain embodiments the Immunoglobulin Targeting Ligand is:
Immunoglobulin E (IgE)
Immunoglobulin E (IgE) is a strong mediator of allergic disease, including but not limited to, atopic asthma, allergic rhinitis, atopic dermatitis, cutaneous contact hypersensitivity, IgE- mediated food allergy, IgE-mediated animal allergies, allergic conjunctivitis, allergic urticaria, anaphylactic shock, nasal polyposis, keratoconjunctivitis, mastocytosis, eosinophilic gastrointestinal disease, bullous pemphigoid, chemotherapy induced hypersensitivity reaction, seasonal allergic rhinitis, interstitial cystitis, eosinophilic esophagitis, angioedema, acute interstitial nephritis, atopic eczema, eosinophilic bronchitis, chronic obstructive pulmonary disease, gastroenteritis, hyper-IgE syndrome (Job's Syndrome), IgE monoclonal gammopathy, monoclonal gammopathy of undetermined significance (MGUS), pemphigus vulgaris, mucus membrane pemphigoid, chronic urticaria, autoimmune uveitis, rheumatoid arthritis, autoimmune pancreatitis, and allergic rhinoconjunctivitis among others.
In certain embodiments the immunoglobulin degrading compound is:
or a pharmaceutically acceptable salt thereof.
In certain embodiments the immunoglobulin degrading compound is:
or a pharmaceutically acceptable salt thereof.
In certain embodiments the immunoglobulin degrading compound is:
or a pharmaceutically acceptable salt thereof.
In certain embodiments the immunoglobulin degrading compound is:
or a pharmaceutically acceptable salt thereof.
In certain embodiments the immunoglobulin degrading compound is:
or a pharmaceutically acceptable salt thereof.
In certain embodiments the immunoglobulin degrading compound is:
or a pharmaceutically acceptable salt thereof.
In certain embodiments the Immunoglobulin Targeting Ligand is:
Immunoglobulin A (IgA)
Aberrant expression of immunoglobulin A (IgA) mediates a range of autoimmune and immune-mediated disorders, including IgA nephropathy (also known as Berger’s disease), celiac disease, Crohn’s disease, Henoch-Schonlein purpura (HSP) (also known as IgA vasculitis), IgA
pemphigus, dermatitis herpetiformis, inflammatory bowel disease (IBD), Sjogren's syndrome, ankylosing spondylitis, alcoholic liver cirrhosis, acquired immunodeficiency syndrome, IgA multiple myeloma, a-chain disease, IgA monoclonal gammopathy, monoclonal gammopathy of undetermined significance (MGUS), linear IgA bullous dermatosis, rheumatoid arthritis, ulcerative colitis, and primary glomerulonephritis, among others.
Specific degradation of IgA can be accomplished through the use of an IgA-specific Immunoglobulin Targeting Ligand. In certain embodiments, the Immunoglobulin Targeting Ligand used is an Opt peptide. Variations and derivatives of the IgA-specific Opt peptide suitable for use as IgA-specific Immunoglobulin Targeting Ligands are described in Hatanaka et al. Journal of Biological Chemistry , 287(57) 43126-43136. In certain embodiments, the IgA-specific Immunoglobulin Targeting Ligand is Opt-1. In certain embodiments, the IgA-specific
Immunoglobulin Targeting Ligand is Opt-2. In certain embodiments, the IgA-specific
Immunoglobulin Targeting Ligand is Opt-3.
In certain embodiments the immunoglobulin degrading compound is:
or a pharmaceutically acceptable salt thereof.
In certain embodiments the immunoglobulin degrading compound is:
or a pharmaceutically acceptable salt thereof.
In certain embodiments the immunoglobulin degrading compound is:
or a pharmaceutically acceptable salt thereof.
In certain embodiments the Immunoglobulin Targeting Ligand is: .
Linkers In non-limiting embodiments, LinkerA and LinkerB are independently selected from: ; wherein:
R11, R12, R13, R14, R15, R16, R17, R18, R19, and R20 are independently at each occurrence selected from the group consisting of a bond, alkyl, -C(O)-, -C(O)O-, -OC(O)-, -SO2-, -S(O)-, -C(S)-, -C(O)NR6-, -NR6C(O)-, -O-, -S-, -NR6-, -C(R21R21)-, -P(O)(R3)O-, -P(O)(R3)-, a divalent residue of a natural or unnatural amino acid, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, heterocycle, heteroaryl, -CH2CH2-[O-(CH2)2]n-O-, -CH2CH2-[O-(CH2)2]n-NR6-, -CH2CH2-[O- (CH2)2]n-, -[-(CH2)2-O-]n-, -[O-(CH2)2]n-, -[O-CH(CH3)C(O)]n-, -[C(O)-CH(CH3)-O]n-, -[O-CH2C(O)]n-, -[C(O)-CH2-O]n-, a divalent residue of a fatty acid, a divalent residue of an unsaturated or saturated mono- or di-carboxylic acid; each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21; n is independently selected at each instance from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
R21 is independently at each occurrence selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, F, Cl, Br, I, hydroxyl, alkoxy, azide, amino, cyano, -NR6R7, -NR8S02R3, -NR8S(0)R3, haloalkyl, heteroalkyl, aryl, heteroaryl, and heterocycle; and the remaining variables are as defined herein.
wherein the amino acid can be oriented in either direction and wherein the amino acid can be in the L- or D-form.
In one embodiment, a divalent residue of a dicarboxylic acid is generated from a nucleophilic addition reaction:
Non-limiting embodiments of a divalent residue of a dicarboxylic acid generated from a nucleophilic addition reaction include:
As used in the embodiments herein, xx is independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, and 25.
As used in the embodiments herein, yy is independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, and 25.
In one embodiment, a divalent residue of a dicarboxylic acid is generated from a condensation reaction:
Non-limiting embodiments of a divalent residue of a dicarboxylic acid generated from a condensation include:
Non-limiting embodiments of a divalent residue of a saturated monocarboxylic acid is selected from butyric acid (-0C(0)(CH2)2CH2-), caproic acid (-0C(0)(CH2)4CH2-), caprylic acid (-0C(0)(CH2)5CH2-), capric acid (-0C(0)(CH2)8CH2-), lauric acid (-OC(0)(CH2)IOCH2-), myristic acid (-0C(0)(CH2)i2CH2-), pentadecanoic acid
(-OC(O)(CH2)13CH2-), palmitic acid (-OC(O)(CH2)14CH2-), stearic acid (-OC(O)(CH2)16CH2-), behenic acid (-OC(O)(CH2)20CH2-), and lignoceric acid (-OC(O)(CH2)22CH2-); Non-limiting embodiments of a divalent residue of a fatty acid include residues selected from linoleic acid, palmitoleic acid, vaccenic acid, paullinic acid, oleic acid, elaidic acid, gondoic acid, gadoleic acid, nervonic acid, myristoleic acid, and erucic acid:
Non-limiting embodiments of a divalent residue of a fatty acid is selected from linoleic acid (-C(O)(CH2)7(CH)2CH2(CH)2(CH2)4CH2-), docosahexaenoic acid (–C(O)(CH2)2(CHCHCH2)6CH2-), eicosapentaenoic acid (-C(O)(CH2)3(CHCHCH2)5CH2-), alpha-linolenic acid (–C(O)(CH2)7(CHCHCH2)3CH2-) stearidonic acid
(-C(O)(CH2)4(CHCHCH2)4CH2-), y-linolenic acid (-C(O)(CH2)4(CHCHCH2)3(CH2)3CH2-), arachidonic acid (-C(O)(CH2)3,(CHCHCH2)4(CH2)4CH2-), docosatetraenoic acid (-C(O)(CH2)5(CHCHCH2)4(CH2)4CH2-), palmitoleic acid (-C(O)(CH2)7CHCH(CH2)5CH2-), vaccenic acid (-C(O)(CH2)9CHCH(CH2)5CH2-), paullinic acid (-C(O)(CH2)11CHCH(CH2)5CH2-), oleic acid (-C(O)(CH2)7CHCH(CH2)7CH2-), elaidic acid (-C(O)(CH2)7CHCH(CH2)7CH2-), gondoic acid (-C(O)(CH2)9CHCH(CH2)7CH2-), gadoleic acid (- C(O)(CH2)7CHCH(CH2)9CH2-), nervonic acid (-C(O)(CH2)13CHCH(CH2)7CH2-), mead acid (- C(O)(CH2)3(CHCHCH2)3(CH2)6CH2-), myristoleic acid (-C(O)(CH2)7CHCH(CH2)3CH2-), and erucic acid (-C(O)(CH2)11CHCH(CH2)7CH2-). In certain embodiments LinkerC is selected from: . wherein:
R22 is independently at each occurrence selected from the group consisting of alkyl, -C(O)N-, -NC(O)-, -N-, -C(R21)-, -P(O)O-, -P(O)-, -P(O)(NR6R7)N-, alkenyl, haloalkyl, aryl, heterocycle, and heteroaryl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21; and the remaining variables are as defined herein. In certain embodiments LinkerD is selected from: ; wherein:
R32 is independently at each occurrence selected from the group consisting of alkyl, N+X", -C-, alkenyl, haloalkyl, aryl, heterocycle, and heteroaryl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21;
X- is an anionic group, for example Br- or Cl-; and all other variables are as defined herein.
In certain embodiments LinkerA is selected from:
each of which is optionally substituted with 1, 2, 3, or 4 optional substituents as defined herein.
In certain embodiments LinkerA is selected from:
each of which is optionally substituted with 1, 2, 3, or 4 optional substituents as defined herein.
In certain embodiments LinkerA is selected from:
each of which is optionally substituted with 1, 2, 3, or 4 optional substituents as defined herein.
In certain embodiments LinkerA is selected from:
each of which is optionally substituted with 1, 2, 3, or 4 optional substituents as defined herein.
In certain embodiments LinkerA is selected from:
each of which is optionally substituted with 1, 2, 3, or 4 optional substituents as defined herein.
In certain embodiments LinkerA is selected from:
each of which is optionally substituted with 1, 2, 3, or 4 optional substituents as defined herein.
In certain embodiments LinkerA is selected from:
wherein each heteroaryl, heterocycle, cycloalkyl, and aryl can optionally be substituted with 1, 2, 3, or 4 of any combination of halogen, alkyl, haloalkyl, aryl, heteroaryl, heterocycle, or cycloalkyl, as allowed by valence.
In certain embodiments LinkerA is selected from:
wherein each heteroaryl, heterocycle, cycloalkyl, and aryl can optionally be substituted with 1, 2, 3, or 4 of any combination of halogen, alkyl, haloalkyl, aryl, heteroaryl, heterocycle, or cycloalkyl, as allowed by valence.
In certain embodiments LinkerA is selected from:
wherein each heteroaryl, heterocycle, cycloalkyl, and aryl can optionally be substituted with 1, 2, 3, or 4 of any combination of halogen, alkyl, haloalkyl, aryl, heteroaryl, heterocycle, or cycloalkyl, as allowed by valence.
In certain embodiments LinkerB, LinkerC, or LinkerD is selected from:
wherein tt is independently selected from 1, 2, or 3 and ss is 3 minus tt. In certain embodiments LinkerB, LinkerC, or LinkerB is selected from:
wherein tt and ss are as defined herein.
wherein each heteroaryl, heterocycle, cycloalkyl, and aryl can optionally be substituted with 1, 2, 3, or 4 of any combination of halogen, alkyl, haloalkyl, aryl, heteroaryl, heterocycle, or cycloalkyl, as allowed by valence; and tt and ss are as defined herein.
wherein each heteroaryl, heterocycle, cycloalkyl, and aryl can optionally be substituted with 1, 2, 3, or 4 of any combination of halogen, alkyl, haloalkyl, aryl, heteroaryl, heterocycle, or cycloalkyl, as allowed by valence; and tt and ss are as defined herein.
In certain embodiments LinkerB, LinkerC, or LinkerD is selected from:
wherein each heteroaryl and aryl can optionally be substituted with 1, 2, 3, or 4 of any combination of halogen, alkyl, haloalkyl, aryl, heteroaryl, heterocycle, or cycloalkyl, as allowed by valence; and tt and ss are as defined herein.
In certain embodiments, the LinkerA is selected from
wherein each is optionally substituted with 1, 2, 3, or 4 substituents substituent selected from R21. In certain embodiments LinkerA is selected from:
In certain embodiments, the LinkerB is selected from
wherein each is optionally substituted with 1, 2, 3, or 4 substituents substituent selected from R21.
In certain embodiments LinkerB -LinkerA is selected from:
In certain embodiments LinkerB -LinkerA is selected from:
In certain embodiments, the LinkerC is selected from
In certain embodiments, the LinkerC is selected from
In certain embodiments Linkerc-(LinkerA)2 is selected from:
In certain embodiments Linkerc-(LinkerA)2 is selected from:
In certain embodiments Linkerc-(LinkerA)2 is selected from:
In certain embodiments, the LinkerD is selected from
In certain embodiments, the LinkerD is selected from
wherein each is optionally substituted with 1, 2, 3, or 4 substituents are selected from R21. In certain embodiments, LinkerB -(LinkerA) is selected from
In certain embodiments, Linker°-(LinkerA) is selected from
In certain embodiments LinkerB is selected from:
wherein each heteroaryl, heterocycle, cycloalkyl, and aryl can optionally be substituted with 1, 2, 3, or 4 of any combination of halogen, alkyl, haloalkyl, aryl, heteroaryl, heterocycle, or cycloalkyl, as allowed by valence.
In certain embodiments LinkerB is selected from:
wherein each heteroaryl, heterocycle, cycloalkyl, and aryl can optionally be substituted with 1, 2, 3, or 4 of any combination of halogen, alkyl, haloalkyl, aryl, heteroaryl, heterocycle, or cycloalkyl, as allowed by valence.
In certain embodiments LinkerB is selected from:
wherein each heteroaryl, heterocycle, cycloalkyl, and aryl can optionally be substituted with 1, 2, 3, or 4 of any combination of halogen, alkyl, haloalkyl, aryl, heteroaryl, heterocycle, or cycloalkyl, as allowed by valence.
wherein each heteroaryl, heterocycle, cycloalkyl, and aryl can optionally be substituted with 1, 2, 3, or 4 of any combination of halogen, alkyl, haloalkyl, aryl, heteroaryl, heterocycle, or cycloalkyl, as allowed by valence.
In certain embodiments LinkerA is selected from:
each of which is substituted with 1 or 2 optional substituents
.
In certain embodiments LinkerA is bond.
In certain embodiments the left side of LinkerA is attached to the ASGPR Binding Ligand and the right side is attached to LinkerB, LinkerC, or LinkerD.
In certain embodiments the right side of LinkerA is attached to the ASGPR Binding Ligand and the right side is attached to LinkerB, LinkerC, or LinkerD.
In certain embodiments the left side of LinkerB is attached to the Extracellular Targeting Ligand and the right side is attached to LinkerA.
In certain embodiments the right side of LinkerB is attached to the Extracellular Targeting Ligand and the left side is attached to LinkerA.
In certain embodiments LinkerB is bond.
In alternative embodiments a linker is provided as described above wherein a
, replaced with a
for example where LinkerB is drawn as it is
in this embodiment.
In alternative embodiments a linker is provided as described above wherein a is
replaced with a , for example where LinkerB is drawn as
this embodiment.
Asialoglycoprotein Receptor
The asialoglycoprotein receptor (ASGPR) is a Ca2+-dependent receptor. The primary endogenous role of ASGPRs is to help regulate serum glycoprotein levels by mediating endocytosis of glycoproteins. The receptor binds ligands with a terminal galactose or N- acetylgalactosamine. The C3- and C4- hydroxyl groups bind to Ca2+, with the N-acetyl position also been considered important to binding activity.
N-acetyl galactosamine
Asialoglycoproteins bind to ASGPRs and are then cleared by receptor-mediated endocytosis. The receptor and the protein are dissociated in the acidic endosomal compartment and the protein is eventually degraded by lysosomes. The receptor is endocytosed and recycled constitutively from the endosome back to the plasma membrane about every 1 5 minutes regardless of whether or not a glycoprotein is bound. Internalization rate of the receptor may be altered by presence of a bound ligand.
Accordingly, in aspects of the invention, the ligand of the immunoglobulin degrading compound that binds to ASGPR may be an asialoglycoprotein or a derivative thereof.
The ASGPR is comprised of two homologous subunits known as HI and H2. Various ratios of HI and H2 form functional homo- and hetero-oligomers with different conformations, but the most abundant conformation is a trimer composed of two HI and one H2 subunits. The ASGPR is
composed of a cytoplasmic domain, a transmembrane domain, a stalk region, and a carbohydrate recognition domain (CRD). Both the HI and H2 subunit form the CRD, and expression of both subunits mediates endocytosis of asialoglycoproteins. ASGPRs are primarily expressed on hepatocytes, and hepatocytes exhibit a high exposition of ASGPR binding cites (approximately 100,000 — 500,000 binding sites per cell).
It is understood that any ligand of ASGPR may be used in immunoglobulin degrading compounds of the invention. For example, ligands that may be used with the invention are described in Stokmaier, Bioorg. Med. Chem., 2009, 17, 7254, which describes the synthesis of a series of D-GalNAc derivatives where the anomeric OH group is removed and the acetamido group is replaced with a 4-substituted 1,2, 3 -triazole moiety, and Mamidyala, JACS, 2012, 134, 1978, which describes compounds derived from 2-azidogalactosyl analogs where the anomeric position is occupied by either a B-methyl or a B-4-methoxy-phenyl group and the azide group is replaced with an amide or a triazole, the entirety of the contest of each of which are incorporated by reference herein.
ASGPR ligands that may be used with the invention are described in PCT Application No. PCT/US21/15939, filed January 29, 2021, and U.S. Provisional Application No. 63/183,450, filed May 3, 2021, the entirety of the contents of each of which are incorporated by reference herein.
For example, the ASGPR ligand may include derivatives of six-carbon pyranose moieties, specifically galactose and talose. These two sugars differ in the stereochemistry of the C 2 substituent. The "down" C 2 configuration corresponds to the stereochemistry of galactose, while the C2 substituent in the "up" configuration corresponds to the stereochemistry oftalose. In aspects of the invention, substituents may be at the C 2 position of the two sugars.
In aspects of the invention the immunoglobulin degrading compounds may utilize a 2:1 ratio of ASGPR ligands to antibody binding ligands. Multiple ASGPR ligands may bind ASGPR more tightly and have increased degradation efficacy. In aspects of the present invention the immunoglobulin degrading compounds may have a 1:1 ratio of ASGPR binding ligands to antibody binding ligands. For example, the compounds may utilize a heteroaryl amine substituents at the C 2 position. The substituents may increase efficacy of the ligand, preferable in compounds with a 1:1 ratio of ASGPR ligand to antibody ligand. For example, in certain embodiments the immunoglobulin degrading molecule is:
In aspects of the present invention, the immunoglobulin degrading molecule is:
or a pharmaceutically acceptable salt thereof.
It is understood that any ligand configured to bind to an antibody may be used with the present invention. For example, immunoglobulin degrading compounds may comprise a ligand that binds to IgG, for example an FC binding peptide, for example Fc-111, Fc-BP2, or derivatives thereof that bind the FC portion of the antibody and thus facilitate the selective recruitment of antibody to hepatocytes for degradation, immunoglobulin degrading compounds may comprise a ligand that binds to IgA, for example an FC binding peptide, for example an Opt class of peptides.
Opt class peptides are advantageous in that they are highly selective for IgA and thus facilitate the selective recruitment of IgA to hepatocytes for degradation.
For example, in aspects of the invention the immunoglobulin degrading molecule may be.
or a pharmaceutically acceptable salt thereof.
In aspects of the invention, the immunoglobulin degrading molecule of the present invention may be provided as an isotopically enriched immunoglobulin degrading molecule with at least one desired isotopic substitution of an atom, at an amount above the natural abundance of the isotope. For example, deuterium can replace one or more hydrogens in the bispecific compound and 13 c can replace one or more carbon atoms. In aspects of the invention, the isotopic substitution is in one or more positions of the ASGPR ligand. In another aspect, the isotopic substitution is in one or more positions of a linker portion of the molecule. In another embodiment, the isotopic substitution is in the antibody ligand portion of the molecule.
The ASGPR ligand may be a molecule according to the Formula IV, Formula V, Formula
or a ph
armaceutically acceptable salt thereof; wherein: R1 and R5 are independently selected from hydrogen, heteroalkyl, C0-C6alkyl-cyano, alkyl, alkenyl, alkynyl, haloalkyl, F, Cl, Br, I, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, heterocycloalkyl, haloalkoxy, C0-C6alkyl-OR6, C0-C6alkyl-SR6, C0-C6alkyl-NR6R7, C0-C6alkyl-C(O)R3, C0-C6alkyl-S(O)R3, C0-C6alkyl-C(S)R3, C0-C6alkyl- S(O)2R3, C0-C6alkyl-N(R8)-C(O)R3, C0-C6alkyl-N(R8)-S(O)R3, C0-C6alkyl-N(R8)-C(S)R3, C0-C6alkyl-N(R8)-S(O)2R3 C0-C6alkyl-O-C(O)R3, C0-C6alkyl-O-S(O)R3, C0-C6alkyl-O-C(S)R3, -N=S(O)(R3)2, C0-C6alkylN3, and C0-C6alkyl-O-S(O)2R3, each of which is optionally substituted with 1, 2, 3, or 4 substituents; R3 at each occurrence is independently selected from hydrogen, alkyl, heteroalkyl, haloalkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle, -OR8, and -NR8R9;
R6 and R7 are independently selected at each occurrence from hydrogen, heteroalkyl, alkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, haloalkyl, heteroaryl, heterocycle, -alkyl-OR8, -alkyl-NR8R9, C(O)R3, S(O)R3, C(S)R3, and S(O)2R3; R8 and R9 are independently selected at each occurrence from hydrogen, heteroalkyl, alkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocycle; R10 is selected from hydrogen, alkyl, heteroalkyl, haloalkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle, C(O)R3, S(O)R3, C(S)R3, and S(O)2R3; R25 is selected from the group consisting of heteroalkyl, C0-C6alkyl-cyano, alkyl, alkenyl, alkynyl, haloalkyl, F, Cl, Br, I, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, heterocycloalkyl, haloalkoxy, C0-C6alkyl-OR6, C0-C6alkyl-SR6, C0-C6alkyl-NR6R7, C0-C6alkyl-C(O)R3, C0-C6alkyl-S(O)R3, C0-C6alkyl-C(S)R3, C0-C6alkyl-S(O)2R3, C0-C6alkyl-N(R8)-C(O)R3, C0-C6alkyl-N(R8)-S(O)R3, C0-C6alkyl-N(R8)-C(S)R3, C0-C6alkyl-N(R8)-S(O)2R3 C0-C6alkyl-O-C(O)R3, C0-C6alkyl-O-S(O)R3, C0-C6alkyl-O-C(S)R3, -N=S(O)(R3)2, C0-C6alkylN3, and C0-C6alkyl-O-S(O)2R3, each of which is optionally substituted with 1, 2, 3, or 4 substituents; R65, R66, and R67 are independently selected from hydrogen, heteroalkyl, C0-C6alkyl-cyano, alkyl, alkenyl, alkynyl, haloalkyl, F, Cl, Br, I, heterocycle, heterocycloalkyl, haloalkoxy, C0-C6alkyl-OR6, C0-C6alkyl-SR6, C0-C6alkyl-NR6R7, C0-C6alkyl-C(O)R3, C0-C6alkyl-S(O)R3, C0-C6alkyl-C(S)R3, C0-C6alkyl-S(O)2R3, C0-C6alkyl-N(R8)-C(O)R3, C0-C6alkyl-N(R8)-S(O)R3, C0-C6alkyl-N(R8)-C(S)R3, C0-C6alkyl-N(R8)-S(O)2R3 C0-C6alkyl-O-C(O)R3, C0-C6alkyl-O-S(O)R3, C0-C6alkyl-O-C(S)R3, -N=S(O)(R3)2, C0-C6alkylN3, and C0-C6alkyl-O-S(O)2R3, each of which is optionally substituted with 1, 2, 3, or 4 substituents; R68, R69, and R70 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, F, Cl, Br, I, heterocycle, heterocycloalkyl, haloalkoxy, C0-C6alkyl-OR6, C0-C6alkyl-SR6, C0-C6alkyl-NR6R7, C0-C6alkyl-C(O)R3, C0-C6alkyl-S(O)R3, C0-C6alkyl-C(S)R3, C0-C6alkyl-S(O)2R3, C0-C6alkyl-N(R8)-C(O)R3, C0-C6alkyl-N(R8)-S(O)R3, C0-C6alkyl-N(R8)-C(S)R3, C0-C6alkyl-N(R8)-S(O)2R3 C0-C6alkyl-O-C(O)R3, C0-C6alkyl-O-S(O)R3, C0-C6alkyl-O-C(S)R3, -N=S(O)(R3)2, C0-C6alkylN3, heteroaryl, aryl, and C0-C6alkyl-O-S(O)2R3 each of which is optionally substituted with 1, 2, 3, or 4 substituents; and
when a compound is “optionally substituted” it may be substituted as allowed by valence with one or more groups selected from alkyl (including C1-C4alkyl), alkenyl (including C2- C4alkenyl), alkynyl (including C2-C4alkynyl), haloalkyl (including C1-C4haloalkyl), -OR6, F, Cl, Br, I, -NR6R7, heteroalkyl, heterocycle, heteroaryl, aryl, cyano, nitro, hydroxyl, azide, amide, - SR3, -S(O)(NR6)R3, -NR8C(O)R3, -C(O)NR6R7, -C(O)OR3, -C(O)R3, -SF5, , , , and , wherein the optional substituent is selected such that a stable compound results. In certain embodiments the ASGPR Binding Ligand is selected from: or a pharmaceutically acceptable salt thereof.
In an alternative aspect the ASGPR Binding Ligand is of Formula:
or a pharmaceutically acceptable salt thereof.
These ASGPR ligands and ASGPR ligand-Linkers are typically attached to the Immunoglobulin Targeting Ligand through the C6 position. For example, in certain embodiments the ASGPR ligand or ASGPR ligand-Linker is a compound of Formula:
The heterobifunctional extracellular immunoglobulin degrading compound for use in the present invention or a pharmaceutically acceptable salt, solvate or prodrug thereof as disclosed herein can be administered as a pharmaceutical composition that includes an effective amount for a subject in need of such treatment to mediate the subject’s immune response to a therapy.
In aspects of the invention, the present invention provides a treatment regimen for use in mediating a subject’s immune response to a cell, gene or biologies therapy that includes administration of an effective amount of a pharmaceutical composition comprising an immunoglobulin degrading bifunctional molecule of the present invention or a pharmaceutically acceptable composition, salt, isotopic analog such as a deuterated derivative, or prodrug thereof, and a pharmaceutically acceptable excipient. In aspects of the invention, the cell, gene, or biologies therapy and heterobifunctional immunoglobulin degrading molecule is present in an effective amount, for example a therapeutically effective amount or a prophylactically effective amount. For example, because the heterobifunctional immunoglobulin degrading molecule mediates the subject's immune response, the effective amount of the therapeutic to be delivered may be reduced.
The treatment regimen of the present invention that includes administering an effective amount of therapeutics and/or immunoglobulin degrading molecules can be administered in any manner that allows the immunoglobulin degrading molecule to bind to the immunoglobulin, typically in the blood stream, and carry it to the ASGPR-bearing hepatocyte cells on the liver for endocytosis and degradation. Methods to deliver the therapeutics and immunoglobulin degrading molecules of the present invention may include oral, intravenous, sublingual, subcutaneous, parenteral, buccal, rectal, intra-aortal, intracranial, subdermal or transnasal, or by other means, in dosage unit formulations containing one or more conventional pharmaceutically acceptable carriers, as appropriate.
In aspects of the invention, the treatment regimen of the present invention includes administering an effective amount of therapeutics and/or immunoglobulin degrading molecules which may be administered intravenously. The therapeutics and/or immunoglobulin degrading molecule may be formulated in a liquid dosage form for intravenous injection, such as a buffered solution, for example a phosphate buffered solution and saline buffered solution. The solution may be buffered with multiple salts.
In aspects of the invention, the treatment regimen of the present invention includes administering an effective amount of therapeutics and/or immunoglobulin degrading molecule which may be administered orally. The therapeutics and/or immunoglobulin degrading molecule may be formulated in capsules, tablets, and powders, for example a gel containing capsule.
In aspects of the invention, the treatment regimen of the present invention includes administering an effective amount of therapeutics and/or heterobifunctional immunoglobulin degrading molecule which may be administered subcutaneously. The therapeutics and immunoglobulin degrading molecule may be formulated in a liquid dosage form for subcutaneous injection, such as a buffered solution, for example a phosphate buffered solution and saline buffered solution. The solution may be buffered with multiple salts.
In aspects of the invention, a pharmaceutically acceptable salt means a salt of the described therapeutics and/or heterobifunctional immunoglobulin degrading molecule which is suitable for administration to a subject without undue toxicity, irritation, or allergic response, and commensurate with a reasonable benefit to risk ratio, and effective for its intended use. A pharmaceutically acceptable salt means a relatively nontoxic, inorganic and organic acid addition salts of the presently disclosed therapeutics and/or immunoglobulin degrading molecules. These salts can be prepared during the final isolation and purification of the therapeutics and/or immunoglobulin degrading molecules or by separately reacting the purified therapeutics and/or immunoglobulin degrading molecule in its free form with a suitable organic or inorganic acid and then isolating the salt thus formed. Acid addition salts of the basic therapeutics and/or immunoglobulin degrading molecules are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner. The free base form can be regenerated by contacting the salt form with a base and isolating the free base in the conventional manner. The free base forms may differ from their respective salt forms in certain physical properties such as solubility in polar solvents. Pharmaceutically acceptable base addition salts may be formed with metals or amines, such as alkali and alkaline earth metal hydroxides, or of organic amines. Examples of metals used as cations, include, but are not limited to, sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines include, but are not limited to, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine, and procaine. The base addition salts of acidic therapeutics and/or immunoglobulin degrading molecules are prepared by contacting the free acid form with a
sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form can be regenerated by contacting the salt form with an acid and isolating the free acid in a conventional manner. The free acid forms may differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents.
Salts can be prepared from inorganic acids sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, phosphorus, and the like. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate mesylate, glucoheptonate, lactobionate, laurylsulphonate and isethionate salts, and the like. Salts can also be prepared from organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl -substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. and the like. Representative salts include acetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenyl acetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like. Pharmaceutically acceptable salts can include cations based on the alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium and the like, as well as non-toxic ammonium, quaternary ammonium, and amine cations including, but not limited to, ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. Also contemplated are the salts of amino acids such as arginate, gluconate, galacturonate, and the like. See, for example, Berge et ah, J. Pharm. Sci., 1977, 66, 1-19, which is incorporated herein by reference.
Pharmaceutically acceptable excipients include inert diluents, dispersing and/or granulating agents, surface active agents and/or emulsifiers, disintegrating agents, binding agents, preservatives, buffering agents, lubricating agents, and/or oils. Additional acceptable excipients include cocoa butter and suppository waxes, coloring agents, coating agents, sweetening, flavoring, perfuming agents, etc., and combinations thereof.
Diluents may include calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose,
cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, etc., and combinations thereof.
Granulating and/or dispersing agents may include potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponge, cation — exchange resins, calcium carbonate, silicates, sodium carbonate, cross — linked poly(vinyl — pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross — linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (Veegum), sodium lauryl sulfate, quaternary ammonium compounds, etc., and combinations thereof.
Surface active agents and/or emulsifiers may include natural emulsifiers (e.g. acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g. bentonite [aluminum silicate] and Veegum [magnesium aluminum silicate]), long chain amino acid derivatives, high molecular weight alcohols (e.g. stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g. carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxyvinyl polymer), carrageenan, cellulosic derivatives (e.g. carboxymethylcellulose sodium, powdered cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose), sorbitan fatty acid esters (e.g. polyoxyethylene sorbitan monolaurate [Tween 20], polyoxyethylene sorbitan [Tween 60], polyoxyethylene sorbitan monooleate [Tween 80], sorbitan monopalmitate [Span 40], sorbitan monostearate [Span 60], sorbitan tristearate [Span 65], glyceryl monooleate, sorbitan monooleate [Span 80]), polyoxyethylene esters (e.g. polyoxyethylene monostearate [Myij 45], polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and Solutol), sucrose fatty acid esters, polyethylene glycol fatty acid esters (e.g., Cremophor), polyoxyethylene ethers, (e.g . polyoxyethylene lauryl ether [Brij 30]), poly(vinyl — pyrrolidone), di ethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, Pluronic F 68, Poloxamer 188, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium, etc. and/or combinations thereof.
Binding agents may include starch (e.g. cornstarch and starch paste), gelatin, sugars (e.g. sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol, etc.), natural and synthetic gums (e.g. acacia, sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husks, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, cellulose acetate, poly(vinyl — pyrrolidone), magnesium aluminum silicate (Veegum), and larch arabogalactan), alginates, polyethylene oxide, polyethylene glycol, inorganic calcium salts, silicic acid, polymethacrylates, waxes, water, alcohol, etc., and/or combinations thereof.
Preservatives may include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives, etc., and/or combinations thereof.
Antioxidants may include alpha tocopherol, ascorbic acid, acorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabi sulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabi sulfite, and sodium sulfite.
Any dosage form can be used that achieves the desired results. In aspects of the invention, the pharmaceutical composition is in a dosage form that contains from about 0.1 mg to about 1500 mg, from about 10 mg to about 1000 mg, from about 100 mg to about 800 mg, or from about 200 mg to about 600 mg of the active immunoglobulin degrading molecule and optionally from about 0.1 mg to about 1500 mg, from about 10 mg to about 1000 mg, from about 100 mg to about 800 mg, or from about 200 mg to about 600 mg of an additional active agent in a unit dosage form. Examples are dosage forms with at least about 0.1, 1, 5, 10, 25, 50, 100, 200, 250, 300, 400, 500, 600, 700, 750, 800, 850, 900, 950, or 1,000 mg of active immunoglobulin degrading molecule, or its salt. In certain embodiments the dosage form has at most about 0.1, 1, 5, 10, 25, 50, 100, 200, 250, 300, 400, 500, 600, 700, 750, 800, 850, 900, 950, or 1,000 mg of active immunoglobulin degrading molecule, or its salt.
In aspects of the invention, the dose ranges from about 0.01-100 mg/kg of patient bodyweight, for example about 0.01 mg/kg, about 0.05 mg/kg, about 0. 1 mg/kg, about 0.5 mg/kg, about 1 mg/kg, about 1.5 mg/kg, about 2 mg/kg, about 2.5 mg/kg, about 3 mg/kg, about 3.5 mg/kg, about 4 mg/kg, about 4.5 mg/kg, about 5 mg/kg, about 110 mg/kg, about 115 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about
50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65 mg/kg, about 70 mg/kg, about 75 mg/kg, about 80 mg/kg, about 85 mg/kg, about 90 mg/kg, about 95 mg/kg, or about 100 mg/kg.
In aspects of the invention, heterobifunctional immunoglobulin degrading molecules disclosed herein are used as described are administered once a day (QD), twice a day (BID), or three times a day (TID). In some embodiments, immunoglobulin degrading molecules disclosed herein are used as described are administered at least once a day for at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, at least 14 days, at least
15 days, at least 16 days, at least 17 days, at least 18 days, at least 19 days, at least 20 days, at least
21 days, at least 22 days, at least 23 days, at least 24 days, at least 25 days, at least 26 days, at least
27 days, at least 28 days, at least 29 days, at least 30 days, at least 31 days, at least 35 days, at least
45 days, at least 60 days, at least 75 days, at least 90 days, at least 120 days, at least 150 days, at least 180 days, or longer.
In aspects of the invention, the heterobifunctional immunoglobulin degrading molecule is administered once a day, twice a day, three times a day, or four times a day.
The pharmaceutical composition may be formulated as any pharmaceutically useful form, for example, a pill, capsule, tablet, an injection or infusion solution, a syrup, an inhalation formulation, a suppository, a buccal or sublingual formulation, a parenteral formulation, or in a medical device. Some dosage forms, such as tablets and capsules, can be subdivided into suitably sized unit doses containing appropriate quantities of the active components, e.g., an effective amount to achieve the desired purpose.
Carriers include excipients and diluents and must be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the patient being treated. The carrier can be inert, or it can possess pharmaceutical benefits of its own. The amount of carrier employed in conjunction with the therapeutics and/or immunoglobulin degrading molecule is sufficient to provide a practical quantity of material for administration per unit dose of the therapeutics and/or immunoglobulin degrading molecule. If provided as in a liquid, it can be a solution or a suspension.
Representative carriers include phosphate buffered saline, water, solvent(s), diluents, pH modifying agents, preservatives, antioxidants, suspending agents, wetting agent, viscosity agents, tonicity agents, stabilizing agents, and combinations thereof. In some embodiments, the carrier is
an aqueous carrier. Examples of aqueous carries include, but are not limited to, an aqueous solution or suspension, such as saline, plasma, bone marrow aspirate, buffers, such as Hank's Buffered Salt Solution (HBSS), HEPES (4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid), Ringers buffer, ProVisc@, diluted ProVisc@, Provisc@ diluted with PBS, Krebs buffer, Dulbecco's PBS, normal PBS, sodium hyaluronate solution (HA, 5 mg/mL in PBS), citrate buffer, simulated body fluids, plasma platelet concentrate and tissue culture medium or an aqueous solution or suspension comprising an organic solvent. Acceptable solutions include, for example, water, Ringer' s solution and isotonic sodium chloride solutions. The formulation may also be a sterile solution, suspension, or emulsion in a non-toxic diluent or solvent such as 1,3-butanediol.
Viscosity agents may be added to the pharmaceutical composition to increase the viscosity of the composition as desired. Examples of useful viscosity agents include, but are not limited to, hyaluronic acid, sodium hyaluronate, carbomers, polyacrylic acid, cellulosic derivatives, polycarbophil, polyvinylpyrrolidone, gelatin, dextin, polysaccharides, polyacrylamide, polyvinyl alcohol (including partially hydrolyzed polyvinyl acetate), polyvinyl acetate, derivatives thereof and mixtures thereof.
Solutions, suspensions, or emulsions for administration may be buffered with an effective amount necessary to maintain a pH suitable for the selected administration. Suitable buffers are well known by those skilled in the art. Some examples of useful buffers are acetate, borate, carbonate, citrate, and phosphate buffers. Solutions, suspensions, or emulsions for topical, for example, ocular administration may also contain one or more tonicity agents to adjust the isotonic range of the formulation. Suitable tonicity agents are well known in the art. Some examples include glycerin, mannitol, sorbitol, sodium chloride, and other electrolytes.
Classes of carriers include, but are not limited to binders, buffering agents, coloring agents, diluents, disintegrants, emulsifiers, flavorants, glidants, lubricants, preservatives, stabilizers, surfactants, tableting agents, and wetting agents. Some carriers may be listed in more than one class, for example vegetable oil may be used as a lubricant in some formulations and a diluent in others. Exemplary pharmaceutically acceptable carriers include sugars, starches, celluloses, powdered tragacanth, malt, gelatin, talc, and vegetable oils. Optional active agents may be included in a pharmaceutical composition, which do not substantially interfere with the activity of the therapeutics and/or immunoglobulin degrading molecule of the present invention.
The pharmaceutical compositions/combinations can be formulated for oral administration. These compositions can contain any amount of active therapeutics and/or immunoglobulin degrading molecule that achieves the desired result, for example between 0.1 and 99 weight % (wt.%) of the therapeutics and/or immunoglobulin degrading molecule and usually at least about 5 wt.% of the therapeutics and/or immunoglobulin degrading molecule. Some embodiments contain from about 25 wt. % to about 50 wt. % or from about 5 wt. % to about 75 wt. % of the therapeutics and/or immunoglobulin degrading molecule. Enteric coated oral tablets may also be used to enhance bioavailability of the therapeutics and/or immunoglobulin degrading molecules for an oral route of administration.
Formulations suitable for rectal administration are typically presented as unit dose suppositories. These may be prepared by admixing the active therapeutics and/or immunoglobulin degrading molecule with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.
Therapeutics and/or immunoglobulin degrading molecules and pharmaceutically acceptable composition, salts, isotopic analogs, or prodrugs thereof, may be formulated in dosage unit form for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of the compositions comprising a therapeutics and/or immunoglobulin degrading molecule as described herein will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular subject or organism will depend upon a variety of factors including the disease, disorder, or condition being treated and the severity of the disorder; the activity of the specific therapeutics and/or immunoglobulin degrading molecule employed; the specific composition employed; the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific therapeutics and/or immunoglobulin degrading molecule employed; the duration of the treatment; drugs used in combination or coincidental with the specific therapeutics and/or immunoglobulin degrading molecule employed; and like factors well known in the medical arts.
The therapeutics and/or immunoglobulin degrading molecules and compositions provided herein can be administered by any route, including enteral (e.g., oral), parenteral, intravenous, intramuscular, intra — arterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal, topical (as by powders, ointments,
creams, and/or drops), mucosal, nasal, buccal, sublingual; by intratracheal instillation, bronchial instillation, and/or inhalation; and/or as an oral spray, nasal spray, and/or aerosol. Specifically contemplated routes are oral administration, intravenous administration (e.g., systemic intravenous injection), regional administration via blood and/or lymph supply, and/or direct administration to an affected site. In general, the most appropriate route of administration will depend upon a variety of factors including the nature of the agent (e.g., its stability in the environment of the gastrointestinal tract), the condition of the subject (e.g., whether the subject is able to tolerate oral administration).
The exact amount of the therapeutic and/or immunoglobulin degrading molecule required to achieve an effective amount will vary from subject to subject, depending, for example, on species, age, and general condition of a subject, severity of the side effects or disorder, identity of the particular therapeutics and/or immunoglobulin degrading molecule(s), mode of administration, and the like. The desired dosage can be delivered using any frequency determined to be useful by the health care provider, including three times a day, two times a day, once a day, every other day, every third day, every week, every two weeks, every three weeks, or every four weeks. In certain embodiments, the desired dosage can be delivered using multiple administrations (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more administrations).
It will be also appreciated that therapeutics and/or immunoglobulin degrading molecules or compositions, as described herein, can be administered in combination with one or more additional therapeutically active agents. The therapeutics and/or immunoglobulin degrading molecules or compositions can be administered in combination with additional therapeutically active agents that improve their bioavailability, reduce and/or modify their metabolism, inhibit their excretion, and/or modify their distribution within the body. It will also be appreciated that the therapy employed may achieve a desired effect for the same disorder (for example, a therapeutic and/or immunoglobulin degrading molecule can be administered in combination with an anti — inflammatory agent, anti — cancer agent, immunosuppressant, etc.), and/or it may achieve different effects (e.g., control of adverse side — effects, e.g., emesis controlled by an antiemetic).
The therapeutics and/or immunoglobulin degrading molecule or composition can be administered concurrently with, prior to, or subsequent to, one or more additional therapeutically active agents. In general, each agent will be administered at a dose and/or on a time schedule determined for that agent. It will further be appreciated that the additional therapeutically active
agent utilized in this combination can be administered together in a single composition or administered separately in different compositions. The particular combination to employ in a regimen will take into account compatibility of the inventive therapeutics and/or immunoglobulin degrading molecule with the additional therapeutically active agent and/or the desired therapeutic effect to be achieved. In general, it is expected that additional therapeutically active agents utilized in combination be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination will be lower than those utilized individually.
Additional therapeutically active agents may include, but are not limited to, small organic molecules such as drug compounds (e.g., compounds approved by the Food and Drugs Administration as provided in the Code of Federal Regulations (CFR)), peptides, proteins, carbohydrates, monosaccharides, oligosaccharides, polysaccharides, nucleoproteins, mucoproteins, lipoproteins, synthetic polypeptides or proteins, small molecules linked to proteins, glycoproteins, steroids, nucleic acids, DNAs, RNAs, nucleotides, nucleosides, oligonucleotides, antisense oligonucleotides, lipids, hormones, vitamins and cells. In certain embodiments, the additional therapeutically active agent is an anti -cancer agent, e.g., radiation therapy and/or one or more chemotherapeutic agents.
In certain aspects, a treatment regimen is provided comprising the administration of a therapeutic and/or immunoglobulin degrading molecule of the present invention or a pharmaceutically acceptable composition, salt, isotopic analog (such as a deuterated derivative), or prodrug thereof in combination or in alternation with at least one additional therapeutic agent. The combinations and/or alternations can be administered for beneficial, additive, or synergistic effect in the treatment of immunoglobulin-mediated disorders.
Advantageously, the methods of the present invention mediate an immune response to any additional excipient or combinations used for the delivery of the therapeutics or the immunoglobulin degrading molecule by the action of the immunoglobulin degrading molecule itself.
Additional Embodiments
1. In certain embodiments a method for administering a therapy is provided, the method comprising:
sequestering immunoglobulin G (IgG) in a subject so that a therapy can be initiated and readministered to the subject and produce a therapeutic effect in the subject that would not otherwise be achieved due to IgG interacting with the therapy.
2. The method of embodiment 1, wherein sequestering is accomplishing by providing to the subject an immunoglobulin degrading compound comprising: a first ligand configured to bind IgG; and a second ligand configured to bind an asialoglycoprotein receptor (ASGPR).
3. The method of embodiment 1, wherein the therapy is a gene therapy.
4. The method of embodiment 3, wherein the gene therapy comprises use of a vector.
5. The method of embodiment 4, wherein the vector is a viral vector.
6. The method of embodiment 5, wherein the viral vector is an adenovirus-associated virus (AAV) vector.
7. The method of embodiment 2, wherein the immunoglobulin degrading compound sequesters the IgG in the liver for degradation.
8. The method of embodiment 1, wherein the method is conducted prior to the therapy being administered to the subject.
9. A method for administering a therapy, the method comprising: providing to a subject an immunoglobulin degrading compound comprising a first ligand configured to bind IgG, and a second ligand configured to bind an asialoglycoprotein receptor (ASGPR), to thereby sequester and degrade immunoglobulin G (IgG) in the subject so that a therapy can be re-administered to the subject and produce a therapeutic effect in the subject that would not otherwise be achieved due to IgG interacting with the therapy.
10. The method of embodiment 9, wherein the first and second ligand are coupled via one or more linker molecules.
11 . The method of embodiment 9, wherein the therapy is a gene therapy.
12. The method of embodiment 11, wherein the gene therapy comprises use of a vector.
13. The method of embodiment 12, wherein the vector is a viral vector.
14. The method of embodiment 13, wherein the viral vector is an adenovirus-associated virus (AAV) vector.
15. The method of embodiment 9, wherein the immunoglobulin degrading compound sequesters the IgG in the liver for degradation.
16. The method of embodiment 9, wherein sequestering does not provoke an immune response in the subject.
17. The method of embodiment 9, wherein the method is conducted prior to the therapy being readministered to the subject.
18. The method of embodiment 17, wherein the method is conducted after the subject has been administered the therapy at least once.
References and citations to other documents, such as patents, patent applications, patent publications, journals, books, papers, web contents, have been made throughout this disclosure. All such documents are hereby incorporated herein by reference in their entirety for all purposes.
Various modifications of the invention and many further embodiments thereof, in addition to those shown and described herein, will become apparent to those skilled in the art from the full contents of this document, including references to the scientific and patent literature cited herein. The subject matter herein contains important information, exemplification and guidance that can be adapted to the practice of this invention in its various embodiments and equivalents thereof.
Claims
1. A method for treating a disorder in a human comprising administering a compound of Formula I, Formula II, or Formula III or a pharmaceutically acceptable salt thereof before, after, or concurrently with the administration of a gene therapy or an adenovirus-associated virus (AAV) vector, wherein:
one of R1 or R5 is a bond to LinkerA; the other of R1 and R5 are independently selected from hydrogen, heteroalkyl, C0-C6alkyl-cyano, alkyl, alkenyl, alkynyl, haloalkyl, F, Cl, Br, I, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, heterocycloalkyl, haloalkoxy, C0-C6alkyl-OR6, C0-C6alkyl-SR6, C0-C6alkyl-NR6R7, C0-C6alkyl-C(O)R3, C0-C6alkyl-S(O)R3, C0-C6alkyl-C(S)R3, C0-C6alkyl- S(O)2R3, C0-C6alkyl-N(R8)-C(O)R3, C0-C6alkyl-N(R8)-S(O)R3, C0-C6alkyl-N(R8)-C(S)R3, C0-C6alkyl-N(R8)-S(O)2R3 C0-C6alkyl-O-C(O)R3, C0-C6alkyl-O-S(O)R3, C0-C6alkyl-O-C(S)R3, -N=S(O)(R3)2, C0-C6alkylN3, and C0-C6alkyl-O-S(O)2R3, each of which is optionally substituted with 1, 2, 3, or 4 substituents; R3 at each occurrence is independently selected from hydrogen, alkyl, heteroalkyl, haloalkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle, -OR8, and -NR8R9; R6 and R7 are independently selected at each occurrence from hydrogen, heteroalkyl, alkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, haloalkyl, heteroaryl, heterocycle, -alkyl-OR8, -alkyl-NR8R9, C(O)R3, S(O)R3, C(S)R3, and S(O)2R3;
R8 and R9 are independently selected at each occurrence from hydrogen, heteroalkyl, alkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocycle; R10 is selected from hydrogen, alkyl, heteroalkyl, haloalkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle, C(O)R3, S(O)R3, C(S)R3, and S(O)2R3; R65, R66, and R67 are independently selected from hydrogen, heteroalkyl, C0-C6alkyl-cyano, alkyl, alkenyl, alkynyl, haloalkyl, F, Cl, Br, I, heterocycle, heterocycloalkyl, haloalkoxy, C0-C6alkyl-OR6, C0-C6alkyl-SR6, C0-C6alkyl-NR6R7, C0-C6alkyl-C(O)R3, C0-C6alkyl-S(O)R3, C0-C6alkyl-C(S)R3, C0-C6alkyl-S(O)2R3, C0-C6alkyl-N(R8)-C(O)R3, C0-C6alkyl-N(R8)-S(O)R3, C0-C6alkyl-N(R8)-C(S)R3, C0-C6alkyl-N(R8)-S(O)2R3 C0-C6alkyl-O-C(O)R3, C0-C6alkyl-O-S(O)R3, C0-C6alkyl-O-C(S)R3, -N=S(O)(R3)2, C0-C6alkylN3, and C0-C6alkyl-O-S(O)2R3, each of which is optionally substituted with 1,
2, 3, or 4 substituents; LinkerA is a bond or a moiety that covalently links LinkerB, LinkerC, or LinkerD to the ASGPR Binding Ligand; LinkerB is a bond or a moiety that covalently links LinkerA to the Immunoglobulin Targeting Ligand; LinkerC is a chemical group that links each LinkerA to the Immunoglobulin Targeting Ligand; LinkerD is a chemical group that links each LinkerA to the Immunoglobulin Targeting Ligand; Immunoglobulin Targeting Ligand is a Ligand that binds to an immunoglobulin; and when a compound is “optionally substituted” it may be substituted as allowed by valence with one or more groups selected from alkyl, alkenyl, alkynyl, haloalkyl, -OR6, F, Cl, Br, I, -NR6R7, heteroalkyl, heterocycle, heteroaryl, aryl, cyano, nitro, hydroxyl, azide, amide, -SR3, -S(O)(NR6)R3, -NR8C(O)R3, -C(O)NR6R7, -C(O)OR3, -C(O)R3, -SF5 , and
, wherein the optional substituent is selected such that a stable compound results.
2. The method of claim 1, wherein a gene therapy is administered.
3. The method of claim 1 or 2, wherein an AAV is administered.
4. The method of any one of claims 1-3, wherein the immunoglobulin is IgG.
5. The method of any one of claims 1-4, wherein the disorder is a loss of function mutation disorder.
6. The method of any one of claims 1-4, wherein the disorder is a monogenic disorder.
7. The method of any one of claims 1-4, wherein the disorder is a disorder caused by a gain of toxicity mutation.
8. The method of any one of claims 1-4, wherein the disorder is a disorder caused by recessive compound heterozygous mutations.
9. The method of any one of claims 1-8, wherein the disorder is selected from Achondroplasia, Alpha-I Antitrypsin Deficiency, Antiphospholipid Syndrome, Autosomal Dominant Polycystic Kidney Disease, Charcot-Marie-Tooth, cancer, Cri du chat, Crohn's Disease, Cystic fibrosis, Dercum Disease, Duane Syndrome, Duchenne Muscular Dystrophy, Factor V Leiden Thrombophilia, Familial Hypercholesterolemia, Familial Mediterranean Fever, Fragile X Syndrome, Gaucher Disease, Hemochromatosis, Hemophilia, Holoprosencephaly, Huntington's disease, Klinefelter syndrome, Marfan syndrome, Myotonic Dystrophy, Neurofibromatosis, Noonan Syndrome, Osteogenesis Imperfecta, Parkinson's disease, Phenylketonuria, Poland Anomaly, Porphyria, Progeria, Retinitis Pigmentosa, Severe Combined Immunodeficiency (SCID), Sickle cell disease, Spinal Muscular Atrophy, Tay- Sachs disease, Thalassemia, Trimethylaminuria, Turner Syndrome, Velocardiofacial Syndrome, WAGR Syndrome, and Wilson Disease.
10. The method of any one of claims 1-8, wherein the disorder is spinal muscular atrophy.
11. The method of any one of claims 1-8, wherein the disorder is mutation-associated retinal dystrophy.
12. The method of any one of claims 1-11, wherein a compound of Formula I is administered.
13. The method of any one of claims 1-11, wherein a compound of Formula II is administered.
18. The method of any one of claims 1-17, wherein the Immunoglobulin Targeting Ligand is a compound selected from Figure 1.
19. A method for reducing the effects of an immune response in a human subject, wherein the immune response is induced by the administration of a therapeutic agent, the method comprising administering a compound of Formula I, Formula II, or Formula III or a pharmaceutically acceptable salt thereof before, after, or concurrently with the administration of the therapeutic agent, wherein:
ASPGR Binding Ligand is a compound selected from:
one of R1 or R5 is a bond to LinkerA; the other of R1 and R5 are independently selected from hydrogen, heteroalkyl, C0-C6alkyl-cyano, alkyl, alkenyl, alkynyl, haloalkyl, F, Cl, Br, I, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, heterocycloalkyl, haloalkoxy, C0-C6alkyl-OR6, C0-C6alkyl-SR6, C0-C6alkyl-NR6R7, C0-C6alkyl-C(O)R3, C0-C6alkyl-S(O)R3, C0-C6alkyl-C(S)R3, C0-C6alkyl- S(O)2R3, C0-C6alkyl-N(R8)-C(O)R3, C0-C6alkyl-N(R8)-S(O)R3, C0-C6alkyl-N(R8)-C(S)R3, C0-C6alkyl-N(R8)-S(O)2R3 C0-C6alkyl-O-C(O)R3, C0-C6alkyl-O-S(O)R3, C0-C6alkyl-O-C(S)R3, -N=S(O)(R3)2, C0-C6alkylN3, and C0-C6alkyl-O-S(O)2R3, each of which is optionally substituted with 1, 2, 3, or 4 substituents; R3 at each occurrence is independently selected from hydrogen, alkyl, heteroalkyl, haloalkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle, -OR8, and -NR8R9; R6 and R7 are independently selected at each occurrence from hydrogen, heteroalkyl, alkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, haloalkyl, heteroaryl, heterocycle, -alkyl-OR8, -alkyl-NR8R9, C(O)R3, S(O)R3, C(S)R3, and S(O)2R3; R8 and R9 are independently selected at each occurrence from hydrogen, heteroalkyl, alkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocycle; R10 is selected from hydrogen, alkyl, heteroalkyl, haloalkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle, C(O)R3, S(O)R3, C(S)R3, and S(O)2R3; R65, R66, and R67 are independently selected from hydrogen, heteroalkyl, C0-C6alkyl-cyano, alkyl, alkenyl, alkynyl, haloalkyl, F, Cl, Br, I, heterocycle, heterocycloalkyl, haloalkoxy, C0-C6alkyl-OR6, C0-C6alkyl-SR6, C0-C6alkyl-NR6R7, C0-C6alkyl-C(O)R3, C0-C6alkyl-S(O)R3, C0-C6alkyl-C(S)R3, C0-C6alkyl-S(O)2R3, C0-C6alkyl-N(R8)-C(O)R3, C0-C6alkyl-N(R8)-S(O)R3, C0-C6alkyl-N(R8)-C(S)R3, C0-C6alkyl-N(R8)-S(O)2R3 C0-C6alkyl-O-C(O)R3, C0-C6alkyl-O-S(O)R3, C0-C6alkyl-O-C(S)R3, -N=S(O)(R3)2,
C0-C6alkylN3, and C0-C6alkyl-O-S(O)2R3, each of which is optionally substituted with 1, 2, 3, or 4 substituents; LinkerA is a bond or a moiety that covalently links LinkerB, LinkerC, or LinkerD to the ASGPR Binding Ligand; LinkerB is a bond or a moiety that covalently links LinkerA to the Immunoglobulin Targeting Ligand; LinkerC is a chemical group that links each LinkerA to the Immunoglobulin Targeting Ligand; LinkerD is a chemical group that links each LinkerA to the Immunoglobulin Targeting Ligand; Immunoglobulin Targeting Ligand is a Ligand that binds to an immunoglobulin; and when a compound is “optionally substituted” it may be substituted as allowed by valence with one or more groups selected from alkyl, alkenyl, alkynyl, haloalkyl, -OR6, F, Cl, Br, I, -NR6R7, heteroalkyl, heterocycle, heteroaryl, aryl, cyano, nitro, hydroxyl, azide, amide, -SR3, -S(O)(NR6)R3, -NR8C(O)R3, -C(O)NR6R7, -C(O)OR3, -C(O)R3, -SF5, , , , and , wherein the optional substituent is selected such that a stable compound results.
20. The method of claim 19, wherein the therapeutic agent comprises a vector.
21. The method of claim 20, wherein the vector comprises a viral vector.
22. ‘The method of claim 21, wherein the viral vector is selected from the group consisting of an adenovirus-associated virus (AAV) vector, a lentivirus vector, an adenovirus vector, a respiratory syncytial virus (RSV) vector, a herpes simplex virus (HSV) vector, a poxvirus, or a vaccinia virus.
23. The method of claim 22, wherein the viral vector is an AAV vector.
24. The method of claim 19, wherein the therapeutic agent is a cell therapy.
25. The method of claim 24, wherein the cell therapy is a chimeric antigen receptor (CAR) – T cell therapy.
26. The method of claim 19, wherein the therapeutic agent is a gene therapy.
27. The method of claim 26, wherein the gene therapy replaces a defective endogenous protein.
28. The method of claim 19, wherein the therapeutic agent is a recombinant protein.
29. The method of claim 28, wherein the recombinant protein is selected from the group consisting of adalimumab, infliximab, golimumab. etanercept, certolizumab, ustekinumab, secukinumab, tocilizumab, sarilumab, daclizumab, basiliximab, cankinumab, rituximab, tositumomab, ofatumumab, ibritumomab, abatacept, muromanab, efalizumab, alemtuzumab, gemtuzumab, eculizumab, ultomiris, omalizumab, palivizumab, abciximab, nofetumumab. capromab, fanolesomab, arcitumomab, imciromab, trastuzumab, cetuximab, bevacizumab, panitumumab, ranibizumab, cetolizumab pegol, and denosumab.
30. The method of claim 19, wherein the recombinant protein is a recombinant Factor VIII protein.
31. The method of claim 19, wherein the recombinant protein is recombinant insulin.
32. The method of any of claims 19-31, wherein Formula I, Formula II, or Formula III or a pharmaceutically acceptable salt thereof is administered prior to the administration of the therapeutic agent.
33. The method of any of claims 19-31, wherein Formula I, Formula II, or Formula III or a pharmaceutically acceptable salt thereof is administered concurrently with the administration of the therapeutic agent.
34. The method of any of claims 19-31, wherein Formula I, Formula II, or Formula III or a pharmaceutically acceptable salt thereof is administered after the administration of the therapeutic agent.
35. The method of claim 34, wherein Formula I, Formula II, or Formula III or a pharmaceutically acceptable salt thereof is administered two or more times after the administration of the therapeutic agent.
36. The method of any one of claims 19-35, wherein a compound of Formula I is administered.
37. The method of any one of claims 19-35, wherein a compound of Formula II is administered.
42. The method of any one of claims 19-41, wherein the Immunoglobulin Targeting Ligand is a compound selected from Figure 1.
43. Use of a compound of Formula I, Formula II, or Formula III, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for reducing the effects of an immune response in a human subject, wherein the immune response is induced by the administration of a therapeutic agent, wherein the effects of the immune response are reduced by administering the compound of Formula I, Formula II, or Formula III or a pharmaceutically acceptable salt thereof before, after, or concurrently with the administration of the therapeutic agent, wherein:
ASPGR Binding Ligand is a compound selected from:
one of R or R5 is a bond to Linker ; the other of R1 and R5 are independently selected from hydrogen, heteroalkyl, C0-C6alkyl-cyano, alkyl, alkenyl, alkynyl, haloalkyl, F, Cl, Br, I, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, heterocycloalkyl, haloalkoxy, C0-C6alkyl-OR6, C0-C6alkyl-SR6, C0-C6alkyl-NR6R7, C0-C6alkyl-C(O)R3, C0-C6alkyl-S(O)R3, C0-C6alkyl-C(S)R3, C0-C6alkyl- S(O)2R3, C0-C6alkyl-N(R8)-C(O)R3, C0-C6alkyl-N(R8)-S(O)R3, C0-C6alkyl-N(R8)-C(S)R3, C0-C6alkyl-N(R8)-S(O)2R3 C0-C6alkyl-O-C(O)R3, C0-C6alkyl-O-S(O)R3, C0-C6alkyl-O-C(S)R3, -N=S(O)(R3)2, C0-C6alkylN3, and C0-C6alkyl-O-S(O)2R3, each of which is optionally substituted with 1, 2, 3, or 4 substituents; R3 at each occurrence is independently selected from hydrogen, alkyl, heteroalkyl, haloalkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle, -OR8, and -NR8R9; R6 and R7 are independently selected at each occurrence from hydrogen, heteroalkyl, alkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, haloalkyl, heteroaryl, heterocycle, -alkyl-OR8, -alkyl-NR8R9, C(O)R3, S(O)R3, C(S)R3, and S(O)2R3; R8 and R9 are independently selected at each occurrence from hydrogen, heteroalkyl, alkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocycle; R10 is selected from hydrogen, alkyl, heteroalkyl, haloalkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle, C(O)R3, S(O)R3, C(S)R3, and S(O)2R3; R65, R66, and R67 are independently selected from hydrogen, heteroalkyl, C0-C6alkyl-cyano, alkyl, alkenyl, alkynyl, haloalkyl, F, Cl, Br, I, heterocycle, heterocycloalkyl, haloalkoxy, C0-C6alkyl-OR6, C0-C6alkyl-SR6, C0-C6alkyl-NR6R7, C0-C6alkyl-C(O)R3, C0-C6alkyl-S(O)R3, C0-C6alkyl-C(S)R3, C0-C6alkyl-S(O)2R3, C0-C6alkyl-N(R8)-C(O)R3, C0-C6alkyl-N(R8)-S(O)R3, C0-C6alkyl-N(R8)-C(S)R3, C0-C6alkyl-N(R8)-S(O)2R3 C0-C6alkyl-O-C(O)R3, C0-C6alkyl-O-S(O)R3, C0-C6alkyl-O-C(S)R3, -N=S(O)(R3)2,
C0-C6alkylN3, and C0-C6alkyl-O-S(O)2R3, each of which is optionally substituted with 1, 2, 3, or 4 substituents; LinkerA is a bond or a moiety that covalently links LinkerB, LinkerC, or LinkerD to the ASGPR Binding Ligand; LinkerB is a bond or a moiety that covalently links LinkerA to the Immunoglobulin Targeting Ligand; LinkerC is a chemical group that links each LinkerA to the Immunoglobulin Targeting Ligand; LinkerD is a chemical group that links each LinkerA to the Immunoglobulin Targeting Ligand; Immunoglobulin Targeting Ligand is a Ligand that binds to an immunoglobulin; and when a compound is “optionally substituted” it may be substituted as allowed by valence with one or more groups selected from alkyl, alkenyl, alkynyl, haloalkyl, -OR6, F, Cl, Br, I, -NR6R7, heteroalkyl, heterocycle, heteroaryl, aryl, cyano, nitro, hydroxyl, azide, amide, -SR3, -S(O)(NR6)R3, -NR8C(O)R3, -C(O)NR6R7, -C(O)OR3, -C(O)R3, -SF5, , , , and , wherein the optional substituent is selected such that a stable compound results.
44. The use of claim 43, wherein the therapeutic agent comprises a vector.
45. The use of claim 44, wherein the vector comprises a viral vector.
46. ‘The use of claim 45, wherein the viral vector is selected from the group consisting of an adenovirus-associated virus (AAV) vector, a lentivirus vector, an adenovirus vector, a respiratory syncytial virus (RSV) vector, a herpes simplex virus (HSV) vector, a poxvirus, or a vaccinia virus.
47. The use of claim 46, wherein the viral vector is an AAV vector.
48. The use of claim 43, wherein the therapeutic agent is a cell therapy.
49. The use of claim 47, wherein the cell therapy is a chimeric antigen receptor (CAR) – T cell therapy.
50. The use of claim 43, wherein the therapeutic agent is a gene therapy.
51. The use of claim 50, wherein the gene therapy replaces a defective endogenous protein.
52. The use of claim 43, wherein the therapeutic agent is a recombinant protein.
53. The use of claim 52, wherein the recombinant protein is selected from the group consisting of adalimumab, infliximab, golimumab. etanercept, certolizumab, ustekinumab, secukinumab, tocilizumab, sarilumab, daclizumab, basiliximab, cankinumab, rituximab, tositumomab, ofatumumab, ibritumomab, abatacept, muromanab, efalizumab, alemtuzumab, gemtuzumab, eculizumab, ultomiris, omalizumab, palivizumab, abciximab, nofetumumab. capromab, fanolesomab, arcitumomab, imciromab, trastuzumab, cetuximab, bevacizumab, panitumumab, ranibizumab, cetolizumab pegol, and denosumab.
54. The use of claim 43, wherein the recombinant protein is a recombinant Factor VIII protein.
55. The use of claim 43, wherein the recombinant protein is recombinant insulin.
56. The use of any of claims 43-55, wherein Formula I, Formula II, or Formula III or a pharmaceutically acceptable salt thereof is administered prior to the administration of the therapeutic agent.
57. The use of any of claims 43-55, wherein Formula I, Formula II, or Formula III or a pharmaceutically acceptable salt thereof is administered concurrently with the administration of the therapeutic agent.
58. The use of any of claims 43-55, wherein Formula I, Formula II, or Formula III or a pharmaceutically acceptable salt thereof is administered after the administration of the therapeutic agent.
59. The use of claim 58, wherein Formula I, Formula II, or Formula III or a pharmaceutically acceptable salt thereof is administered two or more times after the administration of the therapeutic agent.
60. The use of any one of claims 43-59, wherein a compound of Formula I is administered.
61. The use of any one of claims 43-59, wherein a compound of Formula II is administered.
66. The use of any one of claims 43-65, wherein the Immunoglobulin Targeting Ligand is a compound selected from Figure 1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163225746P | 2021-07-26 | 2021-07-26 | |
US63/225,746 | 2021-07-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023009554A1 true WO2023009554A1 (en) | 2023-02-02 |
Family
ID=85087227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/038397 WO2023009554A1 (en) | 2021-07-26 | 2022-07-26 | Methods to reduce adverse effects of gene or biologics therapy |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023009554A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160207953A1 (en) * | 2014-05-19 | 2016-07-21 | Pfizer Inc. | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of asgpr |
WO2019199621A1 (en) * | 2018-04-09 | 2019-10-17 | Yale University | Bi-functional molecules to degrade circulating proteins |
US20200190515A1 (en) * | 2017-06-02 | 2020-06-18 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
WO2021155317A1 (en) * | 2020-01-31 | 2021-08-05 | Avilar Therapeutics, Inc. | Asgpr-binding compounds for the degradation of extracellular proteins |
-
2022
- 2022-07-26 WO PCT/US2022/038397 patent/WO2023009554A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160207953A1 (en) * | 2014-05-19 | 2016-07-21 | Pfizer Inc. | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of asgpr |
US20200190515A1 (en) * | 2017-06-02 | 2020-06-18 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
WO2019199621A1 (en) * | 2018-04-09 | 2019-10-17 | Yale University | Bi-functional molecules to degrade circulating proteins |
WO2021155317A1 (en) * | 2020-01-31 | 2021-08-05 | Avilar Therapeutics, Inc. | Asgpr-binding compounds for the degradation of extracellular proteins |
Non-Patent Citations (1)
Title |
---|
SREEMAN K. MAMIDYALA: "Glycomimetic Ligands for the Human Asialoglycoprotein Receptor", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 134, no. 4, 24 January 2012 (2012-01-24), pages 1978 - 1981, XP055048572, DOI: 10.1021/ja2104679 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220395544A1 (en) | Compositions for the treatment of disease | |
US20240124889A1 (en) | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation | |
RU2423383C2 (en) | Ox40l antibodies | |
AU2018255293B2 (en) | Regulation of RAN translation by PKR and eIF2a-P pathways | |
CN114144197A (en) | Fully human post-translationally modified antibody therapeutics | |
EP3963055A1 (en) | Vectorized antibodies (vab) and uses thereof | |
Rosenberg et al. | AAVrh. 10-mediated expression of an anti-cocaine antibody mediates persistent passive immunization that suppresses cocaine-induced behavior | |
US8597647B1 (en) | Humanized anti-IL-20 antibody and uses thereof | |
EP3126385B1 (en) | Humanized pertussis antibodies and uses thereof | |
US9682100B2 (en) | Cationic polyamines for treatment of viruses | |
US20230226214A1 (en) | Bifunctional bridging compositions for viral transduction | |
TW202016310A (en) | CODON-OPTIMIZED ACID α-GLUCOSIDASE EXPRESSION CASSETTES AND METHODS OF USING SAME | |
US20220401464A1 (en) | Treatment of cyr61- and vegf-mediated conditions | |
JP2022515570A (en) | Treatment of influenza with substituted polycyclic pyridone derivatives and prodrugs thereof in subjects with influenza and complication risk factors | |
WO2023009554A1 (en) | Methods to reduce adverse effects of gene or biologics therapy | |
JP2020537675A (en) | Treatment of neuropathies with DNA constructs that reduce interference from gabapentinoids and express HGF variants | |
WO2021231575A1 (en) | Immunosuppressive agents and viral delivery re-dosing methods for gene therapy | |
US20240075155A1 (en) | Compositions comprising chemerin and methods of use thereof | |
AU2020216501A1 (en) | One-step gene therapy for duchenne muscular dystrophy via gene replacement and anti-inflammation | |
Wu et al. | Half-Life Extension Enhances Drug Efficacy in Adeno-Associated Virus Delivered Gene Therapy | |
WO2022092326A1 (en) | Gdf15 modulator for use in inhibition of ocular tissue fibrosis | |
JP2024510760A (en) | PEGylated T cell engager with dual specificity for CD3 and CD19 | |
BR112021000772A2 (en) | ANTIBODIES AGAINST CAMPILOBACTER SPECIES | |
WO2024049878A2 (en) | Bioreducible polymer and use thereof | |
Castro | American Society of Gene and Cell Therapy (ASGCT)-19th Annual Meeting. Washington, DC, USA-May 4-7, 2016 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22850208 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |